Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1S,2S)-beta-methylstyrene oxide + H2O
?
enzyme attacks almost exclusively at the benzylic position
-
-
?
(5Z,11Z,14Z)-8,9-epoxyeicosatrienoic acid + H2O
(5Z,11Z,14Z)-8,9-dihydroxyeicosatrienoic acid
(5Z,8Z)-N-((2-methoxy-4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)sulfonyl)-10-(3-((Z)-oct-2-en-1-yl)oxiran-2-yl)deca-5,8-dienamide + H2O
?
-
-
-
?
(5Z,8Z,11Z)-14,15-epoxyeicosa-5,8,11-trienoic acid + H2O
(5Z,8Z,11Z)-14,15-dihydroxyeicosa-5,8,11-trienoic acid
binding structure in the active site, docking analysis and molecular dynamics simulations
-
-
?
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O
(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid
(5Z,8Z,11Z)-N-((2-methoxy-4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl) sulfonyl)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienamide + H2O
?
-
-
-
?
(5Z,8Z,14Z)-11,12-epoxyeicosatrienoic acid + H2O
(5Z,8Z,14Z)-11,12-dihydroxyeicosatrienoic acid
(8Z,11Z,14Z)-5,6-epoxyeicosatrienoic acid + H2O
(8Z,11Z,14Z)-5,6-dihydroxyeicosatrienoic acid
(S)-styrene oxide + H2O
1-phenylethane-1,2-diol
preferred attack at the benzylic position
-
-
?
1-myristoyl-sn-glycerol 3-phosphate + H2O
?
-
-
-
?
11,12-epoxy-eicosatrienoic acid + H2O
11,12-dihydroxy-eicosatrienoic acid
-
-
-
?
12,13-cis-epoxy-octadeca-9E-enoic acid + H2O
?
-
-
-
?
12,13-trans-epoxy-octadeca-9E-enoic acid + H2O
?
-
-
-
?
14,15-epoxy-(5Z,8Z,11Z)-eicosatrienoic acid + H2O
14,15-dihydroxyeicosatrienoic acid
-
-
-
?
14,15-epoxyeicosatrienoic acid + H2O
14,15-dihydroxyeicosatrienoic acid
-
-
-
?
14S,15R-epoxy-eicosatrienoic acid + H2O
14S,15R-dihydroxy-eicosatrienoic acid
-
-
-
?
3-phenyl-cyano(6-methoxy-2-naphthalenyl)methyl ester-2-oxiraneacetic acid + H2O
6-methoxy-2-naphtaldehyde + ?
-
-
-
?
3-phenyl-cyano(6-methoxy-2-naphthalenyl)methyl ester-2-oxiraneacetic acid + H2O
6-methoxy-2-naphthaldehyde + ?
fluorometric activity assay substrate
-
-
?
3-phenyl-cyano(6-methoxy-2-naphthalenyl)methyl ester-2-oxiraneacetic acid + H2O
?
-
-
-
?
3-phenyl-cyano-(6-methoxy-2-naphthalenyl)methylester-2-oxirane-acetic acid + H2O
6-methoxynaphtaldehyde + ?
the non-fluorescent substrate can be hydrolyzed by enzyme sEH to the fluorescent 6-methoxynaphtaldehyde
-
-
?
3-phenylcyano-(6-methoxy-2-naphthalenyl)methyl ester 2-oxiraneacetic acid + H2O
?
-
-
-
?
4-nitrophenyl-trans-2,3-epoxy-3-phenylpropyl carbonate + H2O
?
-
-
-
?
6,8-difluoro-4-methylumbelliferyl trans-2,3-epoxy-3-phenylpropylcarbonate + H2O
?
-
-
-
?
9R,10R-trans-epoxy-13R-hydroxy-11E-octadecenoic acid + H2O
(9R,10S,13R)-trihydroxy-11E-octadecenoic acid
-
-
-
?
9R,10S-cis-epoxy-13R-hydroxy-11E-octadecenoic acid
(9R,10R,13R)-trihydroxy-11E-octadecenoic acid
-
-
-
?
9R,10S-cis-epoxy-13R-hydroxy-11E-octadecenoic acid + H2O
(9R,10R,13R)-trihydroxy-11E-octadecenoic acid
-
-
-
?
cis-14,15-epoxyeicosatrienoic acid + H2O
?
simulation of substrate binding, modeling
-
-
?
cis-14,15-epoxyeicosatrienoic acid + H2O
cis-14,15-dihydroxyeicosatrienoic acid
-
-
-
?
cyano(2-methoxynaphthalen-6-yl)methyl trans-(3-phenyl-oxiran-2-yl)methyl carbonate + H2O
?
a fluorogenic substrate
-
-
?
cyano(2-methoxynaphthalen-6-yl)methyl trans-(3-phenyloxyran-2-yl)methylcarbonate + H2O
6-methoxy-2-naphthaldehyde + ?
fluorometric activity assay substrate
-
-
?
cyano(6-methoxy-naphthalen-2-yl)methyl trans-[(3-phenyloxiran-2-yl)methyl] carbonate + H2O
?
i.e. CMNPC, a fluorescent substrate
-
-
?
cyano-(2-methoxynaphthalen-6-yl)-methyl trans-(3-phenyl-oxiran-2-yl)-methyl carbonate + H2O
?
Epoxy Fluor 7 + H2O
?
i.e. cyano(6-methoxy-2-naphthalenyl)methyl[(2,3)-3-phenyloxiranyl]methyl ester
-
-
?
epoxyeicosatrienoic acid + H2O
dihydroxyeicosatrienoic acid
-
-
-
?
leukotoxin + H2O
leukotoxin-1,2-diol
-
-
-
?
rac trans-1,3-diphenylpropene oxide + H2O
?
-
-
-
?
trans-1,3-diphenylpropene oxide + H2O
?
-
-
-
?
trans-1,3-diphenylpropene oxide + H2O
trans-1,3-diphenylpropane-1,2-diol
-
-
-
?
trans-diphenyl-propene oxide + H2O
trans-diphenyl-propene diol
-
-
-
?
(10R)-hydroxy-(11S,12S)-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid + H2O
(10R,11R,12S)-trihydroxy-(5Z,8Z,14Z)-eicosatrienoic acid
-
i.e. hepoxilin B3
-
-
?
(3-phenyl-oxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester + H2O
6-methoxy-2-naphthaldehyde + ?
-
substrate for high-throughput screen
product is fluorescent
-
?
(3-phenyl-oxiranyl)-acetic acid cyano-(6-methoxynaphthalen-2-yl)-methyl ester + H2O
6-methoxy-2-naphthaldehyde + ?
-
-
-
-
?
(5Z,11Z,14Z)-8,9-epoxyeicosa-5,11,14-trienoic acid + H2O
(5Z,11Z,14Z)-8,9-dihydroxyeicosa-5,11,14-trienoic acid
-
i.e. 8,9-EET
i.e. 8,9-DHET
-
?
(5Z,8Z,11Z)-14,15-epoxyeicosa-5,8,11-trienoic acid + H2O
(5Z,8Z,11Z)-14,15-dihydroxyeicosa-5,8,11-trienoic acid
-
i.e. 14,15-EET
i.e. 14,15-DHET
-
?
(5Z,8Z,14Z)-11,12-epoxyeicosa-5,8,14-trienoic acid + H2O
(5Z,8Z,14Z)-11,12-dihydroxyeicosa-5,8,14-trienoic acid
-
i.e. 11,12-EET
i.e. 11,12-DHET
-
?
(8R)-hydroxy-(11S,12S)-epoxy-(5Z,9E,14Z)-eicosatrienoic acid + H2O
(8R,11R,12S)-trihydroxy-(5Z,9E,14Z)-eicosatrienoic acid
-
i.e. hepoxilin A3, hydrolysis in liver is mainly catalyzed by soluble epoxide hydrolase
-
-
?
(8Z,11Z,14Z)-5,6-epoxyeicosa-8,11,14-trienoic acid + H2O
(8Z,11Z,14Z)-5,6-dihydroxyeicosa-8,11,14-trienoic acid
-
i.e. 5,6-EET
i.e. 5,6-DHET
-
?
1,2,3,4,9,9-hexachloro-6,7-epoxy-1,4,41,5,6,7,8,8a-octahydro-1,4-methanonaphthalene + H2O
?
-
i.e. HEOM
-
-
?
11,12-epoxyeicosatrienoic acid + H2O
11,12-dihydroxyeicosatrienoic acid
-
-
-
-
?
12-phosphonooxyoctadec-9E-enoic acid + H2O
(9E)-octadecenoic acid + phosphate
-
-
-
-
?
12-phosphonooxyoctadec-9Z-enoic acid + H2O
(9Z)-octadecenoic acid + phosphate
-
-
-
-
?
12-phosphonooxyoctadecanoic acid + H2O
octadecanoic acid + phosphate
-
-
-
-
?
14,15-epoxyeicosatrienoic acid + H2O
14,15-dihydroxyeicosatrienoic acid
-
-
-
-
?
2,2-dimethylstyrene oxide + H2O
?
-
-
-
-
?
2,3-epoxy-1,3-diphenyl-propane + H2O
?
-
-
-
-
?
2,3-squalene oxide + H2O
?
-
-
-
-
?
2-acetylaminofluorene + H2O
?
-
-
-
-
?
3-phenyl-cyano(6-methoxy-2-naphthalenyl)methyl ester-2-oxiraneacetic acid + H2O
6-methoxynaphthaldehyde + ?
-
-
-
-
?
4-nitrophenyl (2R,3R)-2,3-epoxy-3-phenylpropyl carbonate + H2O
?
-
14.6% of the activity with 2,3-epoxy-1,3-diphenyl-propane, no activity with the 2S,3S-enantiomer
-
-
?
4-nitrophenyl-trans-2,3-epoxy-3-phenylpropyl carbonate + H2O
?
-
-
-
-
?
4-nitrostyrene 7,8-oxide + H2O
?
-
i.e. PNSO
-
-
?
4-nitrostyrene oxide + H2O
?
-
-
-
-
?
5,6-epoxyeicosatrienoic acid + H2O
5,6-hydroxyeicosatrienoic acid
-
-
-
-
?
8,9-epoxyeicosatrienoic acid + H2O
8,9-hydroxyeicosatrienoic acid
-
-
-
-
?
9R,10R-trans-epoxy-13R-hydroxy-11E-octadecenoic acid + H2O
(9R,10S,13R)-trihydroxy-11E-octadecenoic acid
-
-
-
?
9R,10S-cis-epoxy-13R-hydroxy-11E-octadecenoic acid
(9R,10R,13R)-trihydroxy-11E-octadecenoic acid
-
-
-
?
9R,10S-cis-epoxy-13R-hydroxy-11E-octadecenoic acid + H2O
(9R,10R,13R)-trihydroxy-11E-octadecenoic acid
-
-
-
?
alpha-cyanocarbonate epoxide + H2O
?
-
-
-
-
?
arochlor 1254 + H2O
?
-
-
-
-
?
benzopyrene 4,5-oxide + H2O
(-)benzopyrene 4,5-dihydrodiol
-
-
-
-
?
chalcone oxides + H2O
?
-
-
-
-
?
cis-1,2-dimethylstyrene oxide + H2O
?
-
-
-
-
?
cis-1,3-diphenylpropene oxide + H2O
?
-
18.1% of the activity with 2,3-epoxy-1,3-diphenyl-propane
-
-
?
cis-14,15-epoxyeicosatrienoic acid + H2O
cis-14,15-dihydroxyeicosatrienoic acid
-
-
-
?
cis-2-methylstyrene oxide + H2O
?
-
-
-
-
?
cis-8-ethylstyrene 7,8-oxide + H2O
?
-
-
-
-
?
cis-9,10-epoxy-12-octadecenoate methyl ester + H2O
?
-
5.2% of the activity with 2,3-epoxy-1,3-diphenyl-propane
-
-
?
cis-9,10-epoxystearic acid + H2O
?
-
7.9% of the activity with 2,3-epoxy-1,3-diphenyl-propane
-
-
?
cis-stilbene oxide + H2O
(1R,2R)-1,2-diphenylethane-1,2-diol
-
-
-
-
?
cis-stilbene oxide + H2O
?
-
-
-
-
?
clofibrate + H2O
?
-
-
-
-
?
cyano(2-methoxy-naphthalen-6-yl)methyl trans-2-(3-propyloxiran-2-yl) acetate + H2O
6-methoxy-2-naphthaldehyde + CN- + ?
-
-
-
-
?
cyano(2-methoxynaphthalen-6-yl)methyl trans-(3-phenyloxiran-2-yl)methylcarbonate + H2O
?
-
-
-
-
?
cyano(2-methoxynaphthalen-6-yl)methyl trans-(3-phenyloxyran-2-yl)methyl carbonate + H2O
?
-
-
-
-
?
cyano(6-methoxy-2-naphthyl)methyl (3,3-dimethyloxiran-2-yl)methyl carbonate + H2O
6-methoxy-2-naphthaldehyde + CN- + ?
-
-
-
-
?
cyano(6-methoxy-2-naphthyl)methyl (3-ethyloxiran-2-yl)methyl carbonate + H2O
6-methoxy-2-naphthaldehyde + CN- + ?
-
-
-
-
?
cyano(6-methoxy-2-naphthyl)methyl (3-phenyloxiran-2-yl)acetate + H2O
6-methoxy-2-naphthaldehyde + CN- + ?
-
-
-
-
?
cyano(6-methoxy-2-naphthyl)methyl (3-phenyloxiran-2-yl)methyl carbonate + H2O
6-methoxy-2-naphthaldehyde + CN- + ?
-
preferred fluorogenic substrate
-
-
?
cyano(6-methoxy-2-naphthyl)methyl (3-propyloxiran-2-yl)methyl carbonate + H2O
6-methoxy-2-naphthaldehyde + CN- + ?
-
-
-
-
?
cyano(6-methoxy-2-naphthyl)methyl [3-(4-nitrophenyl)oxiran-2-yl]methyl carbonate + H2O
6-methoxy-2-naphthaldehyde + CN- + ?
-
-
-
-
?
cyano(6-methoxynaphthalen-2-yl)methyl (3-phenyloxiran-2-yl)acetate + H2O
[1,2-dihydroxy-2-(3-phenyloxiran-2-yl)ethoxy](6-methoxynaphthalen-2-yl)acetonitrile
-
-
-
-
?
di(2-ethylhexyl)phthalate + H2O
?
-
-
-
-
?
epoxy stearic acid + H2O
?
-
-
-
-
?
epoxyeicosatrienoic acid + H2O
dihydroxyeicosatrienoic acid
erythro-10-hydroxy-9-phosphonooxy-octadecanoic acid + H2O
10-hydroxy-octadecanoic acid + phosphate
-
-
-
-
?
hepoxilin A3 + H2O
?
-
excellent substrate for sEH
-
-
?
hepoxilin B3 + H2O
?
-
excellent substrate for sEH
-
-
?
juvenile hormone III + H2O
?
-
6.3% of the activity with 2,3-epoxy-1,3-diphenyl-propane
-
-
?
leukotoxin + H2O
leukotoxin diol
-
-
-
-
?
naphthalene 1,2-oxide + H2O
?
-
-
-
-
?
p-nitrophenyl phosphate + H2O
?
-
-
-
-
?
phenanthrene-9,10-oxide + H2O
?
-
-
-
-
?
phenobarbital + H2O
?
-
-
-
-
?
racemic 4-nitrophenyl-trans-2,3-epoxy-3-phenylpropyl carbonate + H2O
?
-
-
-
-
?
racemic trans-1,3-diphenylpropene oxide + H2O
?
-
-
-
-
?
squalene oxide + H2O
?
-
weak substrate
-
-
?
stearic acid epoxide + H2O
?
-
-
-
-
?
styrene 7,8-oxide + H2O
?
-
-
-
-
?
styrene 7,8-oxide + H2O
styrene glycol
-
-
-
-
?
styrene oxide + H2O
styrene glycol
-
-
-
-
?
threo-10-hydroxy-9-phosphonooxy-octadecanoic acid + H2O
10-hydroxy-octadecanoic acid + phosphate
-
-
-
-
?
trans-1,2-dimethylstyrene oxide + H2O
?
-
hydration by microsomal enzyme, no activity with cytosolic enzyme
-
-
?
trans-1,3-diphenylpropene oxide + H2O
1,3-diphenylpropane-1,2-diol
-
-
-
-
?
trans-2-methylstyrene oxide + H2O
?
-
-
-
-
?
trans-8-ethylstyrene 7,8-oxide + H2O
?
-
i.e. TESO
-
-
?
trans-9,10-epoxystearate + H2O
?
-
-
-
-
?
trans-diphenyl propene oxide + H2O
?
-
-
-
-
?
trans-diphenylpropene oxide + H2O
?
-
-
-
-
?
trans-ethyl styrene oxide + H2O
?
-
-
-
-
?
trans-stilbene oxide + H2O
?
[3-(4-chlorophenyl)oxiran-2-yl]methyl cyano(6-methoxy-2-naphthyl)methyl carbonate + H2O
6-methoxy-2-naphthaldehyde + CN- + ?
-
-
-
-
?
additional information
?
-
(5Z,11Z,14Z)-8,9-epoxyeicosatrienoic acid + H2O
(5Z,11Z,14Z)-8,9-dihydroxyeicosatrienoic acid
-
-
-
?
(5Z,11Z,14Z)-8,9-epoxyeicosatrienoic acid + H2O
(5Z,11Z,14Z)-8,9-dihydroxyeicosatrienoic acid
-
-
-
-
?
(5Z,11Z,14Z)-8,9-epoxyeicosatrienoic acid + H2O
(5Z,11Z,14Z)-8,9-dihydroxyeicosatrienoic acid
-
-
-
?
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O
(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid
-
-
-
?
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O
(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid
-
-
-
-
?
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O
(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid
-
-
-
?
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O
(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid
-
-
-
-
?
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O
(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid
-
-
-
?
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O
(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid
-
-
-
-
?
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O
(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid
-
-
-
?
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O
(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid
preferred substrate
-
-
?
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O
(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid
i.e. EETs, showing endothelium-derived hyperpolarizing factor effects dominating in microvessels independent of nitric oxide and prostacyclin. sEH reduces the beneficial effects of EETs
-
-
?
(5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O
(5Z,8Z,11Z)-14,15-dihydroxyeicosatrienoic acid
enzyme-substrate binding, overview
-
-
?
(5Z,8Z,14Z)-11,12-epoxyeicosatrienoic acid + H2O
(5Z,8Z,14Z)-11,12-dihydroxyeicosatrienoic acid
-
-
-
?
(5Z,8Z,14Z)-11,12-epoxyeicosatrienoic acid + H2O
(5Z,8Z,14Z)-11,12-dihydroxyeicosatrienoic acid
-
-
-
-
?
(5Z,8Z,14Z)-11,12-epoxyeicosatrienoic acid + H2O
(5Z,8Z,14Z)-11,12-dihydroxyeicosatrienoic acid
-
-
-
?
(5Z,8Z,14Z)-11,12-epoxyeicosatrienoic acid + H2O
(5Z,8Z,14Z)-11,12-dihydroxyeicosatrienoic acid
preferred substrate
-
-
?
(8Z,11Z,14Z)-5,6-epoxyeicosatrienoic acid + H2O
(8Z,11Z,14Z)-5,6-dihydroxyeicosatrienoic acid
-
-
-
?
(8Z,11Z,14Z)-5,6-epoxyeicosatrienoic acid + H2O
(8Z,11Z,14Z)-5,6-dihydroxyeicosatrienoic acid
-
-
-
-
?
(8Z,11Z,14Z)-5,6-epoxyeicosatrienoic acid + H2O
(8Z,11Z,14Z)-5,6-dihydroxyeicosatrienoic acid
-
-
-
?
cyano-(2-methoxynaphthalen-6-yl)-methyl trans-(3-phenyl-oxiran-2-yl)-methyl carbonate + H2O
?
-
-
-
?
cyano-(2-methoxynaphthalen-6-yl)-methyl trans-(3-phenyl-oxiran-2-yl)-methyl carbonate + H2O
?
CMNPC, a fluorescent substrate with an epoxide group, which releases a strong fluorophore 6-methoxy-2-naphthaldehyde after hydrolysis of the epoxide
-
-
?
epoxyeicosatrienoic acid + H2O
dihydroxyeicosatrienoic acid
-
-
-
-
?
epoxyeicosatrienoic acid + H2O
dihydroxyeicosatrienoic acid
-
elimination of the biological effects of the substrate, involved in regulation of renal eicosanoid levels and blood pressure, mechanism
-
-
?
styrene oxide + H2O
?
-
-
-
-
?
styrene oxide + H2O
?
-
very poor substrate for sEH
-
-
?
trans-stilbene oxide + H2O
?
-
-
-
-
?
trans-stilbene oxide + H2O
?
-
highly selective for the trans-enantiomer. 1.2% of the activity with 2,3-epoxy-1,3-diphenyl-propane
-
-
?
additional information
?
-
activity of the sEH can be regulated by the tyrosine nitration of the protein
-
-
?
additional information
?
-
-
activity of the sEH can be regulated by the tyrosine nitration of the protein
-
-
?
additional information
?
-
contribution of hydrolase and phosphatase domains in soluble epoxide hydrolase to vascular endothelial growth factor expression and cell growth, overview
-
-
?
additional information
?
-
-
contribution of hydrolase and phosphatase domains in soluble epoxide hydrolase to vascular endothelial growth factor expression and cell growth, overview
-
-
?
additional information
?
-
EETs are important regulators of cardiovascular function, of cerebral blood flow, and exhibit a wide array of potentially beneficial actions in stroke, including vasodilation, neuroprotection, promotion of angiogenesis and suppression of platelet aggregation, oxidative stress and postischemic inflammation, detailed overview
-
-
?
additional information
?
-
sEH rapidly hydrolyzes eicosatrienoic acids to their corresponding dihydroxyeicosatrienoic acid, DHET, metabolites, which, in general, are much less biologically active than eicosatrienoic acids. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation, overview. functional impact of CYP epoxygenase-derived eicosatrienoic acids biosynthesis and sEH-mediated xyeicosatrienoic acids hydrolysis on key inflammatory process in the cardiovascular system
-
-
?
additional information
?
-
Vascular actions and antiinflammatory actions of epoxyeicosatrienoic acids, overview
-
-
?
additional information
?
-
development of a high throughput cell-based assay for soluble epoxide hydrolase using BacMam technology, determination of Cy3B-fluorescence labeled product Cy3B-DAE-14,15-DHET, i.e. 14-(2-[(2-([(5Z,8Z,11Z)-14,15-dihydroxy-5,8,11-icosatrienoyl]amino)ethyl)amino]-2-oxoethyl)-16,16,18,18-tetramethyl-6,7,7a,8a,9,10,16,18-octahydrobenzo[2'',3''] indolizino[8'',7'':5',6']pyrano[3',2':3,4]pyrido[1,2-a]indol-5-ium-2-sulfonate, overview
-
-
?
additional information
?
-
sEH has phosphatase activity as well as epoxide hydrolase activity
-
-
?
additional information
?
-
-
sEH has phosphatase activity as well as epoxide hydrolase activity
-
-
?
additional information
?
-
the C-terminal domain of the soluble epoxide hydrolase metabolizes epoxyeicosatrienoic acids, EETs, to their less active diols, while the N-terminal domain demonstrates lipid phosphatase activity
-
-
?
additional information
?
-
-
the C-terminal domain of the soluble epoxide hydrolase metabolizes epoxyeicosatrienoic acids, EETs, to their less active diols, while the N-terminal domain demonstrates lipid phosphatase activity
-
-
?
additional information
?
-
human soluble EH (sEH or EPHX2) and human or murine epoxide hydrolase-3 (EH3 or EPHX3) hydrolyze cis or trans allylic epoxides to single diastereomers, identical to the major isomers detected in epidermis. Microsomal EH (mEH or EPHX1, EC 3.3.2.9) is inactive with these substrates. 12,13-trans-Epoxy-octadeca-9E-enoic acid is completely hydrolyzed by human sEH, human EH3, and N-truncated murine EH3 and mostly hydrolyzed using the N-truncated+7aa-insert murine EH3. 12,13-cis-Epoxy-octadeca-9E-enoic acid is hardly hydrolyzed by human EH3, N-truncated murine EH3, and the N-truncated+7aa-insert murine EH3, and 30% hydrolysis is observed using human sEH. At low substrate concentrations, EPHX2 hydrolyzes 14,15-epoxyeicosatrienoic acid (EET) at twice the rate of the epidermal epoxyalcohol, 9R,10R-trans-epoxy-11E-13R-hydroxy-octadecenoic acid, whereas human or murine EPHX3 hydrolyze the allylic epoxyalcohol at 31fold and 39fold higher rates, respectively
-
-
?
additional information
?
-
human soluble EH (sEH or EPHX2) and human or murine epoxide hydrolase-3 (EH3 or EPHX3) hydrolyze cis or trans allylic epoxides to single diastereomers, identical to the major isomers detected in epidermis. Microsomal EH (mEH or EPHX1, EC 3.3.2.9) is inactive with these substrates. 12,13-trans-Epoxy-octadeca-9E-enoic acid is completely hydrolyzed by human sEH, human EH3, and N-truncated murine EH3 and mostly hydrolyzed using the N-truncated+7aa-insert murine EH3. 12,13-cis-Epoxy-octadeca-9E-enoic acid is hardly hydrolyzed by human EH3, N-truncated murine EH3, and the N-truncated+7aa-insert murine EH3, and 30% hydrolysis is observed using human sEH. At low substrate concentrations, EPHX2 hydrolyzes 14,15-epoxyeicosatrienoic acid (EET) at twice the rate of the epidermal epoxyalcohol, 9R,10R-trans-epoxy-11E-13R-hydroxy-octadecenoic acid, whereas human or murine EPHX3 hydrolyze the allylic epoxyalcohol at 31fold and 39fold higher rates, respectively
-
-
?
additional information
?
-
-
human soluble EH (sEH or EPHX2) and human or murine epoxide hydrolase-3 (EH3 or EPHX3) hydrolyze cis or trans allylic epoxides to single diastereomers, identical to the major isomers detected in epidermis. Microsomal EH (mEH or EPHX1, EC 3.3.2.9) is inactive with these substrates. 12,13-trans-Epoxy-octadeca-9E-enoic acid is completely hydrolyzed by human sEH, human EH3, and N-truncated murine EH3 and mostly hydrolyzed using the N-truncated+7aa-insert murine EH3. 12,13-cis-Epoxy-octadeca-9E-enoic acid is hardly hydrolyzed by human EH3, N-truncated murine EH3, and the N-truncated+7aa-insert murine EH3, and 30% hydrolysis is observed using human sEH. At low substrate concentrations, EPHX2 hydrolyzes 14,15-epoxyeicosatrienoic acid (EET) at twice the rate of the epidermal epoxyalcohol, 9R,10R-trans-epoxy-11E-13R-hydroxy-octadecenoic acid, whereas human or murine EPHX3 hydrolyze the allylic epoxyalcohol at 31fold and 39fold higher rates, respectively
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
microsomal enzyme shows highest activity with trans-2-methylstyrane oxide, followed by styrene 7,8-oxide, cis-2-methylstyrene oxide, cis-1,2-dimethylstyrene oxide, trans-1,2-dimethylstyrene oxide and 2,2-dimethylstyrene oxide. With the cytosolic enzyme the same order is obtained for the first three substrates, whereas activity with 2,2-dimethylstyrene oxide is higher than with cis-1,2-dimethylstyrene oxide and no hydration occurs with trans-1,2-dimethylstyrene oxide
-
-
?
additional information
?
-
-
the N-terminal domain of the enzyme is a functional phosphatase unaffected by a number of classic phosphatase inhibitors. The phosphatase domain has high specificity for lipophilic phosphates
-
-
?
additional information
?
-
-
enzyme regulation, overview
-
-
?
additional information
?
-
-
the enzyme is involved in regulation of blood pressure and inflammation
-
-
?
additional information
?
-
-
reaction mechanism with flurogenic substrates
-
-
?
additional information
?
-
-
substrate specificity, 2 enzymes with different specificities termed cytosolic TESO hydrolase and cytosolic PNSO hydrolase, no activity with benz[a]pyrene 4,5-oxide
-
-
?
additional information
?
-
-
substrate specificity, the microsomal enzyme rapidly hydrolyzes epoxides on cyclic systems as well as mono, 1,1-di and cis-1,2-disubstituted epoxides
-
-
?
additional information
?
-
-
the enzyme also shows phosphatase activity, EC 3.1.3.76, sEH prefers gem-di-, trans-di-, cis-di-, tri-, and tetra-substituted epoxides
-
-
?
additional information
?
-
-
the enzyme prefers trans- over cis-epoxides of sterically hindered substrates like stilbene oxides, the C-terminal domain catalyzes epoxy fatty acid hydrolysis, the N-terminal catalytic domain has also phosphatase activity with specificity for fatty acid diol phosphates, overview
-
-
?
additional information
?
-
-
differential localization of the enzyme in the brain indicates an essential role in the central nervous system
-
-
?
additional information
?
-
-
kinetic analysis of the effects of human enzyme polymorphisms on the N-terminal phosphatase activity of soluble epoxide hydrolase activity
-
-
?
additional information
?
-
-
epoxyeicosatrienoic acids are substrates of sEH, enzyme regulation, overview
-
-
?
additional information
?
-
-
soluble epoxide hydrolase is an enzyme that catalyzes the hydrolysis of epoxyeicosatrienoic acids, EETs, which are lipid mediators derived from arachidonic acid through the cytochrome P450 epoxygenase pathway. EETs can activate multiple antiapoptotic targets through PI3K/Akt survival signaling and protect cardiomyocytes from hypoxia/anoxia
-
-
?
additional information
?
-
-
each monomer is comprised of two distinct structural domains, linked by a proline-rich segment, the 35 kDa C-terminal domain displays epoxide hydrolase activity, while the N-terminal domain exhibits phosphatase activity
-
-
?
additional information
?
-
the enzyme converts epoxyalcohols into linoleate triols
-
-
?
additional information
?
-
the enzyme converts epoxyalcohols into linoleate triols
-
-
?
additional information
?
-
-
the enzyme converts epoxyalcohols into linoleate triols
-
-
?
additional information
?
-
human soluble EH (sEH or EPHX2) and human or murine epoxide hydrolase-3 (EH3 or EPHX3) hydrolyze cis or trans allylic epoxides to single diastereomers, identical to the major isomers detected in epidermis. Microsomal EH (mEH or EPHX1, EC 3.3.2.9) is inactive with these substrates. 12,13-trans-Epoxy-octadeca-9E-enoic acid is completely hydrolyzed by human sEH, human EH3, and N-truncated murine EH3 and mostly hydrolyzed using the N-truncated+7aa-insert murine EH3. 12,13-cis-Epoxy-octadeca-9E-enoic acid is hardly hydrolyzed by human EH3, N-truncated murine EH3, and the N-truncated+7aa-insert murine EH3, and 30% hydrolysis is observed using human sEH. At low substrate concentrations, EPHX2 hydrolyzes 14,15-epoxyeicosatrienoic acid (EET) at twice the rate of the epidermal epoxyalcohol, 9R,10R-trans-epoxy-11E-13R-hydroxy-octadecenoic acid, whereas human or murine EPHX3 hydrolyze the allylic epoxyalcohol at 31fold and 39fold higher rates, respectively
-
-
?
additional information
?
-
human soluble EH (sEH or EPHX2) and human or murine epoxide hydrolase-3 (EH3 or EPHX3) hydrolyze cis or trans allylic epoxides to single diastereomers, identical to the major isomers detected in epidermis. Microsomal EH (mEH or EPHX1, EC 3.3.2.9) is inactive with these substrates. 12,13-trans-Epoxy-octadeca-9E-enoic acid is completely hydrolyzed by human sEH, human EH3, and N-truncated murine EH3 and mostly hydrolyzed using the N-truncated+7aa-insert murine EH3. 12,13-cis-Epoxy-octadeca-9E-enoic acid is hardly hydrolyzed by human EH3, N-truncated murine EH3, and the N-truncated+7aa-insert murine EH3, and 30% hydrolysis is observed using human sEH. At low substrate concentrations, EPHX2 hydrolyzes 14,15-epoxyeicosatrienoic acid (EET) at twice the rate of the epidermal epoxyalcohol, 9R,10R-trans-epoxy-11E-13R-hydroxy-octadecenoic acid, whereas human or murine EPHX3 hydrolyze the allylic epoxyalcohol at 31fold and 39fold higher rates, respectively
-
-
?
additional information
?
-
-
human soluble EH (sEH or EPHX2) and human or murine epoxide hydrolase-3 (EH3 or EPHX3) hydrolyze cis or trans allylic epoxides to single diastereomers, identical to the major isomers detected in epidermis. Microsomal EH (mEH or EPHX1, EC 3.3.2.9) is inactive with these substrates. 12,13-trans-Epoxy-octadeca-9E-enoic acid is completely hydrolyzed by human sEH, human EH3, and N-truncated murine EH3 and mostly hydrolyzed using the N-truncated+7aa-insert murine EH3. 12,13-cis-Epoxy-octadeca-9E-enoic acid is hardly hydrolyzed by human EH3, N-truncated murine EH3, and the N-truncated+7aa-insert murine EH3, and 30% hydrolysis is observed using human sEH. At low substrate concentrations, EPHX2 hydrolyzes 14,15-epoxyeicosatrienoic acid (EET) at twice the rate of the epidermal epoxyalcohol, 9R,10R-trans-epoxy-11E-13R-hydroxy-octadecenoic acid, whereas human or murine EPHX3 hydrolyze the allylic epoxyalcohol at 31fold and 39fold higher rates, respectively
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R,2R,4R,5S,6R,7S)-4-[(benzyloxy)methyl]-3,8-dioxatricyclo[5.1.0.02,4]octane-5,6-diyl diacetate
5.87% inhibition
(1R,3S)-N-(4-cyano-2-(trifluoromethyl)benzyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide
GSK2256294
(1S,3R)-N-[[4-cyano-2-(trifluoromethyl)phenyl]methyl]-3-[[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino]cyclohexane-1-carboxamide
GSK2256294
(1S,6S,9R)-1-(4-hydroxy-3-methoxyphenyl)-6-methoxy-9-methyl-4-(prop-2-en-1-yl)-7-oxabicyclo[4.2.1]non-4-ene-3,8-dione
75.56% inhibition
(1Z)-1-[(4aS,8aR)-2-(3-[[(2S)-2-(5-methylfuran-2-yl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl]phenyl)-4-oxooctahydrophthalazin-1(2H)-ylidene]dioxidan-1-ium
-
(2E)-4-[(2-methylpropyl)amino]-4-oxobut-2-enoic acid
25.86% inhibition
(2E)-5-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)pent-2-enamide
93.12% inhibition, uncompetitive inhibition
(2E,4E)-5-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)penta-2,4-dienamide
86.54% inhibition, uncompetitive inhibition
(2E,4E)-N-(2-methylpropyl)deca-2,4-dienamide
52.12% inhibition
(2E,6E)-7-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)hepta-2,6-dienamide
88.58% inhibition, uncompetitive inhibition
(2R,3R)-2-(2,6-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydro-4H-1-benzopyran-4-one
15.47% inhibition
(2R,3R,3aS)-2-(4-hydroperoxy-3-methoxyphenyl)-3a-methoxy-3-methyl-5-(prop-2-en-1-yl)-3,3a-dihydro-1-benzofuran-6(2H)-one
86.57% inhibition
(2R,3R,4S,5S)-2,5-bis(3,4-dimethoxyphenyl)-3,4-dimethyloxolane
15.21% inhibition
(2R,3S,4S,5S)-2,5-bis(3,4-dimethoxyphenyl)-3,4-dimethyloxolane
7.12% inhibition
(2S)-5,7-dihydroxy-6-methoxy-2-phenyl-2,3-dihydro-4H-1-benzopyran-4-one
68.98% inhibition
(2S,3R,3aR)-2-(4-hydroperoxy-3-methoxyphenyl)-3a-methoxy-3-methyl-5-(prop-2-en-1-yl)-3,3a-dihydro-1-benzofuran-6(2H)-one
76.89% inhibition
(3R)-N-[(1s,2R,3S)-2,3-diphenylcyclopropyl]-3-[(4-fluorobenzene-1-sulfonyl)amino]piperidine-1-carboxamide
-
(3R)-N-[(1s,2R,3S)-2,3-diphenylcyclopropyl]-3-[(methanesulfonyl)amino]piperidine-1-carboxamide
-
(4-bromo-3-cyclopropyl-1H-pyrazol-1-yl)acetic acid
-
(4Z)-9-[(pentylcarbamoyl)amino]non-4-enoic acid
-
(5Z)-13-[(pentylcarbamoyl)amino]tridec-5-enoic acid
-
(8E)-13-[(pentylcarbamoyl)amino]tridec-8-enoic acid
-
(8Z)-12-[(hexylcarbamoyl)amino]dodec-8-enoic acid
-
(8Z)-12-[[(pentylcarbamoyl)amino]oxy]dodec-8-enoic acid
-
(8Z)-13-(4-pentyl-1H-1,2,3-triazol-1-yl)tridec-8-enoic acid
-
(8Z)-13-(5-pentyl-4,5-dihydro-1,3-oxazol-2-yl)tridec-8-enoic acid
-
(8Z)-13-(5-pentylfuran-2-yl)tridec-8-enoic acid
-
(8Z)-13-(heptanoylamino)tridec-8-enoic acid
-
(8Z)-13-[(pentylcarbamothioyl)amino]tridec-8-enoic acid
-
(8Z)-13-[(pentylcarbamoyl)amino]tridec-8-enoic acid
-
(8Z)-13-[(pentylcarbamoyl)oxy]tridec-8-enoic acid
-
(8Z)-13-[heptanoyl(methyl)amino]tridec-8-enoic acid
-
(8Z)-13-[heptanoyl(propan-2-yl)amino]tridec-8-enoic acid
-
(8Z)-13-[methyl(pentylcarbamoyl)amino]tridec-8-enoic acid
-
(8Z)-13-[methyl[methyl(pentyl)carbamoyl]amino]tridec-8-enoic acid
-
(8Z)-13-[[(butylamino)(oxo)acetyl]amino]tridec-8-enoic acid
-
(8Z)-13-[[(pentyloxy)carbonyl]amino]tridec-8-enoic acid
-
(8Z)-13-[[methyl(pentyl)carbamoyl]amino]tridec-8-enoic acid
-
(8Z)-13-[[[butyl(methyl)amino](oxo)acetyl](methyl)amino]tridec-8-enoic acid
-
(8Z)-14-(hexylamino)-14-oxotetradec-8-enoic acid
-
(8Z)-14-[(butylcarbamoyl)amino]tetradec-8-enoic acid
-
(8Z)-14-[hexyl(methyl)amino]-14-oxotetradec-8-enoic acid
-
(8Z,11Z)-16-[(ethylcarbamoyl)amino]hexadeca-8,11-dienoic acid
-
(E)-4-[N-((2-trifluoromethyl)benzyl)benzamide]-alpha-ethylcinnamic acid
-
(E)-N-methoxy-N-methyl 3-[4-(N-((2-trifluoromethyl)benzyl)-benzamide)]but-2-enamide
-
(R)-1-((3,5-difluoropyridin-2-yl)methyl)-2-methyl-N-(1-phenylpropyl)-1H-benzo[d]imidazole-5-carboxamide
GSK1997132B
(R)-4-cyano-N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-benzamide
-
(R)-N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-6-hydroxy-nicotinamide
-
(S)-4-cyano-N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-benzamide
-
(S)-N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-6-hydroxy-nicotinamide
-
1,1'-(butane-1,4-diyl)bis(3-[1-(adamantan-1-yl) butane-2-yl]urea)
-
1,1'-(butane-1,4-diyl)bis(3-[1-(adamantan-1-yl)ethyl]urea)
-
1,1'-(hexane-1,6-diyl)bis(3-[1-(adamantan-1-yl) butane 2 yl]urea)
-
1,1'-(hexane-1,6-diyl)bis(3-[1-(adamantan-1-yl)ethyl]urea)
-
1,1'-(octane-1,8-diyl)bis(3-[1-(adamantan-1-yl)butan 2 yl]urea)
-
1,1'-(octane-1,8-diyl)bis(3-[1-(adamantan-1-yl)ethyl]urea)
-
1,1'-(phenylene 1,4)bis(3-[3,5-dimethyl(adamantan-1-yl)]urea)
-
1,1'-(phenylene-1,4)bis(3-[1-(adamantan-1-yl)butan-2-yl]urea)
-
1,1'-(phenylene-1,4)bis(3-[1-(adamantan-1-yl)ethyl]urea)
-
1,1'-(phenylene-1,4)bis[3-([adamantan-1-yl)urea]
-
1-(1-acetylpiperidin-4-yl)-3-adamantan-1-yl-urea
AR9281
1-(1-acetylpiperidin-4-yl)-3-cycloheptylurea
-
1-(1-acetylpiperidin-4-yl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
-
1-(1-acetylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea
-
1-(1-acetylpiperidin-4-yl)-3-[4-(trifluoromethyl)phenyl]urea
-
1-(1-acetypiperidin-4-yl)-3-adamantanylurea
1-(1-adamantyl)-3-(1-propionyl-piperidin-4-yl)urea
-
1-(1-butanoylpiperidin-4-yl)-3-[4-(trifluoromethyl)phenyl]urea
-
1-(1-cyclopropylethyl)-3-phenylurea
-
1-(1-isobutyrylpiperidin-4-yl)-3-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)urea
binding structure at the enzyme's active site, docking analysis and molecular dynamics simulations using the PDB ID 4JNC structure as template
-
1-(1-methanesulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxy-phenyl)-urea
-
1-(1-methylsulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxyphenyl)-urea
-
1-(1-nicotinoylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)-urea
-
1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethyl)phenyl]urea
-
1-(2-hydroxyphenyl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
-
1-(3,4-dihydro-1'H-spiro[chromene-2,4'-piperidin]-1'-yl)-3-phenylpropan-1-one
-
1-(3,5-dimethyladamant-1-yl)-3-(1-propionylpiperidin-4-yl)urea
-
1-(3-(5-(hydroxyureido)methyl-2-methoxyphenoxy)propyl)-3-[4-(trifluoromethoxy)phenyl]urea
i.e. KM55, a dual inhibitor of 5-lipoxygenase (5-LO) and soluble epoxide hydrolase (sEH), synthesis and evaluation, overview. Applied to leukocytes, it strongly inhibits the lipopolysaccharide (LPS)-induced adhesion of the leukocytes to endothelial cells. KM55 is a designed multi-target ligand which inhibits the enzymatic activity of 5-LO and sEH
1-(3-ethyladamant-1-yl)-3-(1-propionylpiperidin-4-yl)urea
-
1-(3-ethyladamant-1-ylmethyl)-3-(1-propionylpiperidin-4-yl)urea
-
1-(3-hydroxypropyl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
-
1-(4-(N1-methyl-N2-methyl-N2-(methyloxy)oxalamido)-benzyl)-3-adamantylurea
-
1-(4-(N2-(tetrahydro-2H-pyran-2-yloxy)oxalamido)benzyl)-3-adamantylurea
-
1-(4-(N2-methyl-N2-(methyloxy)oxalamido)benzyl)-3-adamantylurea
-
1-(4-(N2-methyloxyoxalamido)benzyl)-3-adamantylurea
-
1-(4-(N2-tert-butyloxyoxalamido)benzyl)-3-adamantylurea
-
1-(4-acetylphenyl)-N-(5-chloro-1,3-benzoxazol-2-yl)piperidine-4-carboxamide
IC50 value in COS-7 cell assay 4.7 nM, 45% remiaining stability in human microsomes
1-(4-acetylphenyl)-N-(5-methyl-1,3-benzoxazol-2-yl)piperidine-4-carboxamide
IC50 value in COS-7 cell assay 5.8 nM, 53% remiaining stability in human microsomes
1-(4-chlorophenyl)-3-(3,4-dichlorophenyl)urea
-
1-(4-tert-butylphenyl)-3-[1-(2-methylbutanoyl)piperidin-4-yl]urea
-
1-(4-trifluoro-methoxy-phenyl)-3-(1-propionylpiperidin-4-yl)urea
TPPU, a tight binding inhibitor of enzyme sEH
1-(5-hydroxypentyl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
-
1-(adamant-1-ylmethyl)-3-(1-propionylpiperidin-4-yl)urea
-
1-(adamantan-1-yl)-3-(1-propionylpiperidin-4-yl)urea
-
1-(cis-4-ethylcyclohexyl)-3-[1-(2-methylbutanoyl)piperidin-4-yl]urea
-
1-adamantan-1-yl-3-(5-[2-(2-ethoxyethoxy)ethoxy]pentyl)urea
i.e. 1-adamantan-1-yl-3-(5-[2-(2-ethoxyethoxy)ethoxy]pentyl)urea
1-adamantanyl-3-(5-(2-(2-ethoxyethoxy)ethoxy)pentyl)urea
-
1-adamantyl-3-cyclohexylurea
-
1-benzyl-3-tricyclo[3.3.1.13,7]dec-1-ylurea
-
1-cycloheptyl-3-[1-(2-methylbutanoyl)piperidin-4-yl]urea
-
1-cyclohexyl-3-dodecyl urea
-
1-cyclohexyl-3-ethyl urea
i.e. CEU
1-cyclohexyl-3-[1-(2-methylbutanoyl)piperidin-4-yl]urea
-
1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl)-urea
-
1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)-urea
-
1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea
-
1-[1-(2-methylbutanoyl)piperidin-4-yl]-3-[4-(propan-2-yl)phenyl]urea
-
1-[1-(2-methylbutanoyl)piperidin-4-yl]-3-[4-(trifluoromethoxy)phenyl]urea
-
1-[1-(2-methylbutanoyl)piperidin-4-yl]-3-[4-(trifluoromethyl)phenyl]urea
-
1-[1-(2-methylpropanoyl)piperidin-4-yl]-3-[4-(trifluoromethoxy)phenyl]urea
-
1-[1-(2-methylpropanoyl)piperidin-4-yl]-3-[4-(trifluoromethyl)phenyl]urea
-
1-[1-(3-methylbutanoyl)piperidin-4-yl]-3-[4-(trifluoromethyl)phenyl]urea
-
1-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]-3-[4-(trifluoromethyl)phenyl]urea
-
1-[1-(butylsulfonyl)piperidin-4-yl]-3-[4-(trifluoromethoxy)phenyl]urea
-
1-[1-(butylsulfonyl)piperidin-4-yl]-3-[4-(trifluoromethyl)phenyl]urea
-
1-[1-(cyclopropylcarbonyl)piperidin-4-yl]-3-[4-(trifluoromethyl)phenyl]urea
-
1-[1-(cyclopropylsulfonyl)piperidin-4-yl]-3-[4-(trifluoromethyl)phenyl]urea
-
1-[1-(ethylsulfonyl)piperidin-4-yl]-3-[4-(trifluoromethyl)phenyl]urea
-
1-[1-(methylsulfonyl)piperidin-4-yl]-3-[4-(trifluoromethoxy)phenyl]urea
-
1-[1-(methylsulfonyl)piperidin-4-yl]-3-[4-(trifluoromethyl)phenyl]urea
-
1-[1-(propan-2-ylsulfonyl)piperidin-4-yl]-3-[4-(trifluoromethyl)phenyl]urea
-
1-[1-(propylsulfonyl)piperidin-4-yl]-3-[4-(trifluoromethyl)phenyl]urea
-
1-[1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl]-3-[4-(trifluoromethyl)phenyl]urea
-
1-[1-[(2S)-2-methylbutanoyl]piperidin-4-yl]-3-[4-(trifluoromethoxy)phenyl]urea
-
1-[1-[(2S)-2-methylbutanoyl]piperidin-4-yl]-3-[4-(trifluoromethyl)phenyl]urea
-
1-[3-(trifluoromethyl)pyridin-2-yl]piperazine
-
1-[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)phenyl]-3-[1-(2-methylbutanoyl)piperidin-4-yl]urea
-
1-[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)phenyl]-3-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]urea
-
1-[4-(trifluoromethyl)phenyl]-3-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]urea
-
1-[4-(trifluoromethyl)pyridin-2-yl]-1H-pyrazol-4-ol
-
1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-[2-(trifluoromethyl)benzyl]piperidine-4-carboxamide
analysis of the crystal structure of enzyme-inhibitor complex
1-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]-3-tricyclo[3.3.1.13,7]dec-1-ylurea
12-(3-adamantan-1-yl-ureido)-dodecanoic acid
12-(3-adamantan-1-yl-ureido)-dodecanoic acid butylester
-
12-(3-adamantan-1-yl-ureido)dodecanoic acid
12-(3-adamantan-1-yl-ureido)dodecanoic acid butyl ester
AUDA-BE, displays improved bioavailability compared to AUDA
12-(3-adamantyl-ureido)-dodecanoic acid
AUDA, a tight binding inhibitor of enzyme sEH
12-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]dodecanoic acid
12-[[(cyclohexylamino)carbonyl]amino]-dodecanoic acid
i.e. CUDA
12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid
13-(heptanoylamino)tridec-5-ynoic acid
-
13-[(pentylcarbamoyl)amino]tridec-8-ynoic acid
-
13-[methyl[methyl(pentyl)carbamoyl]amino]tridec-5-ynoic acid
-
2-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazole
-
2-(2,4-dichlorophenyl)-1-[6-(methylsulfonyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidin]-1'-yl]ethanone
-
2-(2,6-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one
12.34% inhibition
2-(2-fluorophenyl)-N-[(5-methylthiophen-2-yl)methyl]ethan-1-amine
-
2-(3,4-dihydroxy-5-methoxyphenyl)-5,7-dihydroxy-1-benzopyran-1-ium-3-yl beta-D-glucopyranoside
mixed-type inhibition
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-1-benzopyran-1-ium
noncompetitive inhibition
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-1-benzopyran-1-ium-3-yl beta-D-glucopyranoside
noncompetitive inhibition
2-(piperazin-1-yl)pyridine-3-carbonitrile
-
2-(tricyclo[3.3.1.13,7]dec-1-yl)-N-[1-(trifluoroacetyl)piperidin-4-yl]acetamide
-
2-([[2-(adamantan-1-yl)ethyl]amino]methyl)phenol
-
2-cyclopentyl-N-(1,3-thiazol-2-yl)acetamide
-
2-ethyl 3-[4-(N-(4-fluoro(2-trifluoromethyl)benzyl)-benzamide)]propionic acid
-
2-ethyl-3-[3-(N-((2-trifluoromethyl)benzyl)benzamide)]-propionic acid
-
2-ethyl-3-[4-(N-((2-bromo)benzyl)benzamide)]propionic acid
34% inhibition at 0.01 mM, pH 7.0, 22°C
2-ethyl-3-[4-(N-((2-chloro)benzyl)benzamide)]propionic acid
20% inhibition at 0.01 mM, pH 7.0, 22°C
2-ethyl-3-[4-(N-((2-methyl)benzyl)benzamide)]propionic acid
25% inhibition at 0.01 mM, pH 7.0, 22°C
2-ethyl-3-[4-(N-((2-trifluoromethoxy)benzyl)benzamide)]-propionic acid
23% inhibition at 0.01 mM, pH 7.0, 22°C
2-ethyl-3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propionic acid
-
2-ethyl-3-[4-(N-((4-chloro)benzyl)benzamide)]propionic acid
-
2-ethyl-3-[4-(N-((4-fluoro)benzyl)benzamide)]propionic acid
28% inhibition at 0.01 mM, pH 7.0, 22°C
2-ethyl-3-[4-(N-((4-methoxy)benzyl)benzamide)]propionic acid
34% inhibition at 0.01 mM, pH 7.0, 22°C
2-ethyl-3-[4-(N-((4-phenoxy)benzyl)benzamide)]propionic acid
-
2-ethyl-3-[4-(N-((4-trifluoromethoxy)benzyl)benzamide)]-propionic acid
-
2-ethyl-3-[4-(N-((4-trifluoromethyl)benzyl)benzamide)]-propionic acid
-
2-ethyl-3-[4-(N-(4-methoxy(2-trifluoromethyl)benzyl)-benzamide)]propionic acid
-
2-ethyl-3-[4-(N-benzylbenzamide)]propionic acid
4% inhibition at 0.01 mM, pH 7.0, 22°C
2-methoxy-4-[7-methoxy-3-methyl-5-[(1E)-prop-1-en-1-yl]-1-benzofuran-2-yl]phenol
82.46% inhibition
2-methyl 3-[4-(N-((2-Trifluoromethyl)benzyl)benzamide)]-propionic acid
-
2-phenyl-3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propionic acid
-
2-propyl-3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propionic acid
-
2-[(4-[3-[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]propanoyl]piperazin-1-yl)methyl]-4H-pyrido[1,2-a]pyrimidin-4-one
-
2-[1-[(2S)-2-methylbutanoyl]piperidin-4-yl]-N-[4-(trifluoromethoxy)phenyl]acetamide
-
2-[2-(adamantan-1-yl)ethyl]-N-(3,5-dimethyladamantan-1-yl)hydrazine-1-carboxamide
-
2-[2-(adamantan-1-yl)ethyl]-N-[(adamantan-1-yl)methyl]hydrazine-1-carboxamide
-
2-[3-(adamantan-1-yl)propyl]-N-(3,5-dimethyladamantan-1-yl)hydrazine-1-carboxamide
-
2-[4-(N-((2-trifluoromethyl)benzyl )benzamide)]-cyclopropanecarboxylic acid
-
3,4-dihydro-1'H-spiro[chromene-2,4'-piperidin]-1'-yl[4-(trifluoromethyl)phenyl]methanone
-
3-(2-amino-1,3-thiazol-4-yl)-5-methyl-1-(tetrahydrofuran-2-ylmethyl)-1H-pyrrol-2-ol
-
3-(3-amino-3-oxopropyl)-N-(4-chlorophenyl)-3-phenylpiperidine-1-carboxamide
-
3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propylamine
-
3-([cis-4-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]cyclohexyl]oxy)benzoic acid
-
3-([[(adamantan-1-yl)methyl]carbamoyl]amino)adamantan-1-yl trifluoroacetate
-
3-methyl-3-phenyl-N-(4-(pyridin-3-yl)benzyl)piperidine-1-carboxamide
-
3-methyl-3-phenyl-N-(pyridin-4-yl)piperidine-1-carboxamide
-
3-methyl-3-phenyl-N-[3-(pyridin-3-yl)propyl]piperidine-1-carboxamide
-
3-methyl-3-phenyl-N-[3-[(1S,2S)-2-phenylcyclopropyl]benzyl]piperidine-1-carboxamide
-
3-methyl-3-phenyl-N-[3-[2-(quinoxalin-6-yl)ethyl]benzyl]piperidine-1-carboxamide
-
3-methyl-3-phenyl-N-[[2'-(trifluoromethyl)biphenyl-4-yl]methyl]piperidine-1-carboxamide
-
3-morpholinosydnonimine
i.e. SIN-1, a peroxonitrite generator, causes nitration on several tyrosine residues including Tyr383 and Tyr466. 1-adamantyl-3-cyclohexylurea in vitro decreases sensitivity to SIN-1
3-[1-[(4-chlorophenyl)carbamoyl]-3-(pyridin-2-yl)piperidin-3-yl]propanoic acid
-
3-[1-[(4-chlorophenyl)carbamoyl]-3-(pyridin-3-yl)piperidin-3-yl]propanoic acid
-
3-[1-[(4-chlorophenyl)carbamoyl]-3-(pyridin-4-yl)piperidin-3-yl]propanoic acid
-
3-[1-[(4-chlorophenyl)carbamoyl]-3-phenylpiperidin-3-yl]propanoic acid
-
3-[1-[(4-chlorophenyl)carbamoyl]-3-[3-(trifluoromethyl)phenyl]piperidin-3-yl]propanoic acid
-
3-[1-[(4-chlorophenyl)carbamoyl]-3-[4-(trifluoromethyl)phenyl]piperidin-3-yl]propanoic acid
-
3-[3-(biphenyl-4-yl)-1-[(4-chlorophenyl)carbamoyl]piperidin-3-yl]propanoic acid
-
3-[4-(benzyloxy)phenyl]propan-1-ol
-
3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]propionic acid
-
3-[4-[(1-[[(1R,3S)-2,2-dimethyl-3-phenylcyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid
-
3-[4-[(1-[[(1S,2R)-2-phenylcyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid
-
3-[4-[(1-[[(1S,2R,3R)-2-methyl-3-phenylcyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid
-
3-[4-[(1-[[(1s,2R,3S)-2,3-bis(4-fluorophenyl)cyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid
-
3-[4-[(1-[[(1s,2R,3S)-2,3-diphenylcyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid
-
3-[4-[(1-[[(1S,2S,3R)-2-methyl-3-phenylcyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid
-
4'-hydroxy-N-(2-phenylcyclopropyl)-3',4'-dihydro-1H-spiro[piperidine-4,2'-pyrano[3,2-b]pyridine]-1-carboxamide
-
4'-[([2-(trifluoromethyl)phenyl]methyl)carbamoyl][1,1'-biphenyl]-3-carboxylic acid
-
4'-[([2-(trifluoromethyl)phenyl]methyl)carbamoyl][1,1'-biphenyl]-4-carboxylic acid
-
4,4-diphenyl-N-(pyridin-3-yl)-butyramide
-
4-((4-(3-(adamantan-1-yl)ureido)trans-cyclohexyl)oxy)benzoic acid
-
4-((4-[3-(2-oxo-1-adamantyl)-ureido]cyclohexyl)oxy)benzoic acid
-
4-((4-[3-(2-oxoadamant-1-yl)ureido]cyclohexyl)oxy)benzoic acid
-
4-((4-[3-(3,5,7-trimethyladamant-1-yl)ureido]cyclohexyl)oxy)benzoic acid
-
4-((4-[3-(3,5-dimethyladamant-1-yl)ureido]cyclohexyl)oxy)benzoic acid
-
4-((4-[3-(3-chloroadamant-1-yl)ureido]cyclohexyl)oxy)benzoic acid
-
4-((4-[3-(3-ethyladamant-1-yl)ureido]cyclohexyl)oxy)benzoic acid
-
4-((4-[3-(3-ethyladamant-1-ylmethyl)ureido]cyclohexyl)oxy)benzoic acid
-
4-((4-[3-(3-methyladamant-1-yl)ureido]cyclohexyl)oxy)benzoic acid
-
4-((4-[3-(adamant-!-ylmethyl)ureido]cyclohexyl)oxy)benzoic acid
-
4-(1,2,4-oxadiazol-3-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
-
4-(1,3,4-oxadiazol-2-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
-
4-(1,3-benzoxazol-2-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
-
4-(1-methyl-1H-1,2,3-triazol-4-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
-
4-(2,3-dihydro-1H-1,2,3-triazol-1-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
-
4-(3-adamantan-1-yl-ureido) butyric acid
-
4-(3-adamantan-1-yl-ureido) butyric acid methyl ester
-
4-(3-cyclohexylureido)-butyric acid
binding structure analysis
4-(3-cyclohexylureido)-butyric acid methyl ester
-
4-(3-cyclohexylureido)-heptanoic acid
binding structure analysis
4-(3-cyclohexylureido)-hexanoic acid
binding structure analysis
4-(3-cyclohexylureido)-hexanoic acid methyl ester
-
4-(3-hydroxy-4-methyl-1,2-oxazol-5-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
-
4-(3-methyl-1,2,4-oxadiazol-5-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
-
4-(4-methyl-4H-1,2,4-triazol-3-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
-
4-(5-phenyl-3-[3-[3-(3-trifluoromethyl-phenyl)-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonamide
dual inhibitor of cyclooxygenase-2 and soluble epoxide hydrolase
4-(5-phenyl-3-[3-[3-(4-trifluoromethoxy-phenyl)-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonamide
dual inhibitor of cyclooxygenase-2 and soluble epoxide hydrolase
4-(5-phenyl-3-[3-[3-(4-trifluoromethyl-phenyl)-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonamide
dual inhibitor of cyclooxygenase-2 and soluble epoxide hydrolase
4-(5-[1-[(2-phenylcyclopropyl)carbamoyl]piperidin-4-yl]-1,2,4-oxadiazol-3-yl)benzoic acid
-
4-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
-
4-([trans-4-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]cyclohexyl]oxy)benzoic acid
-
4-benzyl-3,4-dihydroquinoxalin-2(1H)-one
-
4-cyano-N-(2-(trifluoromethyl)benzyl)benzamide
-
4-cyano-N-[(3S)-3-(4-fluorophenyl)-3-[4-(methanesulfonyl)phenyl]propyl]benzamide
-
4-cyano-N-[3,3-bis-(4-fluorophenyl)-propyl]-benzamide
-
4-hydroxy-3,5-dimethoxybenzaldehyde
13.48% inhibition
4-hydroxy-3-methoxybenzaldehyde
19.25% inhibition
4-iodo-N-(2-(trifluoromethyl)-benzyl)benzamide
-
4-oxo-N-(1,2,3,4-tetrahydronaphthalen-2-yl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
-
4-oxo-N-(2-phenylcyclopropyl)-6-(pyridin-4-yl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
-
4-oxo-N-(3-phenylcyclopentyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
-
4-oxo-N-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-yl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
-
4-oxo-N-[(1S,2R)-2-phenylcyclopropyl]-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
-
4-[(4-[[(3-methyladamantan-1-yl)carbamoyl]amino]cyclohexyl)oxy]benzoic acid
-
4-[1-[(4-chlorophenyl)carbamoyl]-3-phenylpiperidin-3-yl]butanoic acid
-
4-[3-(isoquinolin-1-yl)-1,2,4-oxadiazol-5-yl]-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
-
4-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]-N-(1,2,3,4-tetrahydronaphthalen-2-yl)piperidine-1-carboxamide
-
4-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]-N-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-yl)piperidine-1-carboxamide
-
4-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]-N-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide
-
4-[3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl]-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
-
4-[5-(cyclohexylamino)-2-(4-ethylpiperazin-1-yl)imidazo[2,1-b][1,3,4]thiadiazol-6-yl]-2,6-dimethoxyphenol
-
4-[[(1r,4r)-4-([[(adamantan-1-yl)methyl]carbamoyl]amino)cyclohexyl]oxy]benzoic acid
-
4-[[(1r,4r)-4-[[(3,5,7-trimethyladamantan-1-yl)carbamoyl]amino]cyclohexyl]oxy]benzoic acid
-
4-[[(1r,4r)-4-[[(3,5-dimethyladamantan-1-yl)carbamoyl]amino]cyclohexyl]oxy]benzoic acid
-
4-[[(1r,4r)-4-[[(3-chloroadamantan-1-yl)carbamoyl]amino]cyclohexyl]oxy]benzoic acid
-
4-[[(1r,4r)-4-[[(3-ethyladamantan-1-yl)carbamoyl]amino]cyclohexyl]oxy]benzoic acid
-
4-[[(1r,4r)-4-[[(3-methyladamantan-1-yl)carbamoyl]amino]cyclohexyl]oxy]benzoic acid
-
4-[[(2R,5R)-5-[[(2-oxoadamantan-1-yl)carbamoyl]amino]piperidin-2-yl]oxy]benzoic acid
-
4-[[cis-4-([[4-(trifluoromethoxy)phenyl]carbamoyl]amino)cyclohexyl]oxy]benzoic acid
-
5,6,7-trihydroxy-2-phenyl-4H-1-benzopyran-4-one
36.86% inhibition
5,6,7-trihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one
35.58% inhibition
5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl D-threo-hexopyranosiduronic acid
75.86% inhibition
5,7,8-trihydroxy-2-phenyl-4H-1-benzopyran-4-one
15.96% inhibition
5,7-dihydroxy-2-(2-hydroxy-6-methoxyphenyl)-4H-1-benzopyran-4-one
5,7-dihydroxy-2-(2-hydroxyphenyl)-4H-1-benzopyran-4-one
34.96% inhibition
5,7-dihydroxy-2-(2-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-one
34.82% inhibition
5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyran-1-ium-3-yl beta-D-galactopyranoside
mixed-type inhibition
5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyran-1-ium-3-yl beta-D-glucopyranoside
noncompetitive inhibition
5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one
24.33% inhibition
5,7-dihydroxy-6-methoxy-2-phenyl-4H-1-benzopyran-4-one
75.88% inhibition
5,7-dihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one
20.88% inhibition
5-(4-bromobenzyl)-1,3-thiazol-2-amine
-
5-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
-
5-benzyl-N-phenyl-1,3,4-oxadiazol-2-amine
-
5-hydroxy-2-(2-hydroxy-6-methoxyphenyl)-6,7,8-trimethoxy-4H-1-benzopyran-4-one
20.83% inhibition
5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-methoxy-4H-1-benzopyran-4-one
25.64% inhibition
5-methyl-N-(2-phenylethyl)-4,5-dihydro-1,3-thiazol-2-amine
-
5-phenyl-N-[4-(trifluoromethyl)benzyl]-1,2-oxazol-3-amine
-
5-phenyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazol-3-amine
-
5-[1-[(4-chlorophenyl)carbamoyl]-3-phenylpiperidin-3-yl]pentanoic acid
-
5-[[(adamantan-1-yl)carbamoyl]amino]pentanoic acid
-
6'-(methylsulfonyl)-N-(2-phenylcyclopropyl)-1H,4'H-spiro[azepane-4,3'-chromene]-1-carboxamide
-
6-(1-methyl-1H-pyrazol-5-yl)-4-oxo-N-(2-phenylcyclopropyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
-
6-(1H-indol-5-yl)-N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
-
6-(2-fluorophenyl)-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
-
6-(3-methylpyridin-2-yl)-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
-
6-(isoquinolin-5-yl)-N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
-
6-(methylsulfonyl)-4-oxo-N-(2-phenylcyclopropyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
-
6-(pyridin-3-yl)-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
-
6-(pyridin-4-yl)-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
-
6-(trifluoromethyl)-1,3-benzothiazol-2-amine
-
6-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
-
6-amino-1-methyl-5-(piperidin-1-yl)pyrimidine-2,4(1H,3H)-dione
-
6-amino-N-(2,4-dichlorobenzyl)pyridine-3-carboxamide
-
6-amino-N-(3,3-diphenylpropyl)pyridine-3-carboxamide
-
6-fluoro-N-(2-phenylcyclopropyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
-
6-phenyl-N-[3-(trifluoromethyl)benzyl]pyrimidin-4-amine
-
6-[(1-methyl-1H-pyrazol-5-yl)amino]-4-oxo-N-(2-phenylcyclopropyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
-
6-[3-(trifluoromethyl)phenyl]-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
-
7-(1H-indol-5-yl)-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
-
7-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
-
7-(trifluoromethyl)-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
-
7-(trifluoromethyl)-N-[5-(trifluoromethyl)pyridin-2-yl][1,2]oxazolo[5,4-c]pyridin-3-amine
-
7-(trifluoromethyl)-N-[6-(trifluoromethyl)pyridin-3-yl]-1,2-benzoxazol-3-amine
-
7-[2-(trifluoromethyl)phenyl]-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
-
7-[3-(trifluoromethyl)phenyl]-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
-
9-[(pentylcarbamoyl)amino]non-4-ynoic acid
-
APAU
i.e. N-(1-acetylpiperidin-4-yl)-N'-(adamant-1-yl)urea
butyl 12-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]dodecanoate
-
butyl 12-[[(adamantan-1-yl)carbamoyl]amino]dodecanoate
-
cis-1-adamantan-1-yl-3-(4-benzyloxycyclohexyl)urea
-
cis-1-adamantan-1-yl-3-[4-(2,6-dichlorobenzyloxy)cyclohexyl]-urea
-
cis-1-adamantan-1-yl-3-[4-(2,6-difluorobenzyloxy)cyclohexyl]-urea
-
cis-1-adamantan-1-yl-3-[4-(4-bromophenoxy)cyclohexyl]urea
-
cis-1-adamantan-1-yl-3-[4-(4-fluorophenoxy)cyclohexyl]-urea
-
cis-1-adamantan-1-yl-3-[4-(4-methoxyphenoxy)cyclohexyl]-urea
-
cis-1-adamantan-1-yl-3-[4-(4-nitrophenoxy)cyclohexyl]urea
-
cis-3-[4-(3-adamantan-1-ylureido)cyclohexyloxy]benzoic acid
-
cis-4-(4-[3-(4-trifluoromethoxyphenyl)ureido]cyclohexyloxy)-benzoic acid
-
cis-4-[4-(3-adamantan-1-ylureido)cyclohexyloxy]-benzoic acid
-
ethyl (E)-3-[N-((2-trifluoromethyl)benzyl)benzamide]-alpha-ethylcinnamate
-
ethyl (E)-3-[N-((2-trifluoromethyl)benzyl)benzamide]-alpha-ethylcinnamic acid
-
ethyl (E)-4-[N-((2-(trifluoromethyl)-benzyl)benzamide]-alpha-ethylcinnamate
-
ethyl 2-ethyl 3-[3-(N-((2-trifluoromethyl)benzyl)benzamide)]-propanoate
-
ethyl 2-ethyl 3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]propanoate
-
ethyl 2-ethyl 3-[4-(N-((4-chloro)benzyl)benzamide)]-propanoate
-
ethyl 2-ethyl 3-[4-(N-((4-fluoro)benzyl)benzamide)]-propanoate
-
ethyl 2-ethyl 3-[4-(N-((4-methoxy)benzyl)benzamide)]-propanoate
-
ethyl 2-ethyl 3-[4-(N-((4-phenoxy)benzyl)benzamide)]-propanoate
-
ethyl 2-ethyl 3-[4-(N-((4-trifluoromethoxy)benzyl)-benzamide)]propanoate
-
ethyl 2-ethyl 3-[4-(N-((4-trifluoromethyl)benzyl)benzamide)]-propanoate
-
ethyl 2-ethyl 3-[4-(N-(4-fluoro(2-trifluoromethyl)benzyl)-benzamide)]propanoate
-
ethyl 2-ethyl 3-[4-(N-(4-methoxy(2-trifluoromethyl)benzyl)-benzamide)]propanoate
-
ethyl 2-ethyl-3-[4-(N-((2-bromo)benzyl)benzamide)]-propanoate
-
ethyl 2-ethyl-3-[4-(N-((2-chloro)benzyl)benzamide)]-propanoate
-
ethyl 2-ethyl-3-[4-(N-((2-methyl)benzyl)benzamide)]-propanoate
-
ethyl 2-ethyl-3-[4-(N-((2-trifluoromethoxy)benzyl)-benzamide)]prop
-
ethyl 2-ethyl-3-[4-(N-benzylbenzamide)]propanoate
-
ethyl 2-methyl 3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propanoate
-
ethyl 2-phenyl 3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propanoate
-
ethyl 2-propyl 3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propanoate
-
ethyl 3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propanoate
-
methyl 2-([4-[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]piperidin-1-yl]carbonyl)benzoate
-
methyl 2-hydroxy-4-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]benzoate
-
methyl 2-[(4-[[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]methyl]piperidin-1-yl)carbonyl]benzoate
-
methyl 3-([4-[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]piperidin-1-yl]carbonyl)benzoate
-
methyl 3-[(4-[[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]methyl]piperidin-1-yl)carbonyl]benzoate
-
methyl 3-[1-[(4-chlorophenyl)carbamoyl]-3-phenylpiperidin-3-yl]propanoate
-
methyl 4-([4-[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]piperidin-1-yl]carbonyl)benzoate
-
methyl 4-[(4-[[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]methyl]piperidin-1-yl)carbonyl]benzoate
-
methyl 4-[(6R,12aS)-2-[3-(1H-imidazol-1-yl)propyl]-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-6-yl]benzoate
-
methyl 4-[[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]methyl]benzoate
-
methyl 5-oxo-5-(4-[[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]methyl]piperidin-1-yl)pentanoate
-
methyl 5-oxo-5-[4-[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]piperidin-1-yl]pentanoate
-
methyl N-(cyclohexylcarbamoyl)glycinate
-
N,5-dibenzyl-1,3,4-oxadiazol-2-amine
-
N,N'-(butane-1,4-diyl)bis[4-(adamantan-2-yl)piperazine-1-carboxamide]
-
N,N'-1,2-phenylenebis[N'-(3-chloroadamantan-1-yl)urea]
-
N,N'-1,2-phenylenebis[N'-[(adamantan-1-yl)methyl]urea]
-
N,N'-1,4-phenylenebis[N'-[(adamantan-1-yl)methyl]urea]
-
N,N'-bis(3,5,7-trimethyladamantan-1-yl)urea
-
N,N'-bis(3,5-dimethyladamantan-1-yl)urea
-
N,N'-bis(3-chloroadamantan-1-yl)urea
-
N,N'-bis(3-ethyladamantan-1-yl)urea
-
N,N'-bis(3-methyladamantan-1-yl)urea
-
N,N'-bis[(adamantan-1-yl)methyl]urea
-
N,N'-butane-1,4-diylbis[N'-(3,5-dimethyladamantan-1-yl)urea]
-
N,N'-butane-1,4-diylbis[N'-(3-chloroadamantan-1-yl)urea]
-
N,N'-butane-1,4-diylbis[N'-(3-ethyladamantan-1-yl)urea]
-
N,N'-butane-1,4-diylbis[N'-[(3,5-dimethyladamantan-1-yl)methyl]urea]
-
N,N'-butane-1,4-diylbis[N'-[(adamantan-1-yl)methyl]urea]
-
N,N'-butane-1,4-diylbis[N'-[1-(adamantan-1-yl)-2-methylpropan-2-yl]urea]
-
N,N'-butane-1,4-diylbis[N'-[2-(adamantan-1-yl)-2-phenylethyl]urea]
-
N,N'-butane-1,4-diylbis[N'-[2-(adamantan-1-yl)ethyl]urea]
-
N,N'-butane-1,4-diylbis[N'-[2-(adamantan-1-yl)pentyl]urea]
-
N,N'-butane-1,4-diylbis[N'-[4-(adamantan-1-yl)phenyl]urea]
-
N,N'-decane-1,10-diylbis[N'-(3-chloroadamantan-1-yl)urea]
-
N,N'-dicyclohexyl urea
i.e. DCU
N,N'-ethane-1,2-diylbis[N'-(3-chloroadamantan-1-yl)urea]
-
N,N'-ethane-1,2-diylbis[N'-[(adamantan-1-yl)methyl]urea]
-
N,N'-heptane-1,7-diylbis[N'-(3-chloroadamantan-1-yl)urea]
-
N,N'-heptane-1,7-diylbis[N'-[(adamantan-1-yl)methyl]urea]
-
N,N'-hexane-1,6-diylbis(N'-[3-[(adamantan-1-yl)oxy]propyl]urea)
-
N,N'-hexane-1,6-diylbis[N'-(3-chloroadamantan-1-yl)urea]
-
N,N'-hexane-1,6-diylbis[N'-(3-ethyladamantan-1-yl)urea]
-
N,N'-hexane-1,6-diylbis[N'-[(3,5-dimethyladamantan-1-yl)methyl]urea]
-
N,N'-hexane-1,6-diylbis[N'-[1-(adamantan-1-yl)ethyl]urea]
-
N,N'-hexane-1,6-diylbis[N'-[2-(adamantan-1-yl)-2-methylpropyl]urea]
-
N,N'-hexane-1,6-diylbis[N'-[2-(adamantan-1-yl)-2-phenylethyl]urea]
-
N,N'-hexane-1,6-diylbis[N'-[2-(adamantan-1-yl)butyl]urea]
-
N,N'-hexane-1,6-diylbis[N'-[2-(adamantan-1-yl)ethyl]urea]
-
N,N'-hexane-1,6-diylbis[N'-[2-(adamantan-1-yl)pentyl]urea]
-
N,N'-hexane-1,6-diylbis[N'-[4-(adamantan-1-yl)phenyl]urea]
-
N,N'-octane-1,8-diylbis(N'-[3-[(adamantan-1-yl)oxy]propyl]urea)
-
N,N'-octane-1,8-diylbis[N'-(3,5-dimethyladamantan-1-yl)urea]
-
N,N'-octane-1,8-diylbis[N'-(3-chloroadamantan-1-yl)urea]
-
N,N'-octane-1,8-diylbis[N'-[(3,5-dimethyladamantan-1-yl)methyl]urea]
-
N,N'-octane-1,8-diylbis[N'-[(adamantan-1-yl)methyl]urea]
-
N,N'-octane-1,8-diylbis[N'-[2-(adamantan-1-yl)-2-methylpropyl]urea]
-
N,N'-octane-1,8-diylbis[N'-[2-(adamantan-1-yl)-2-phenylethyl]urea]
-
N,N'-octane-1,8-diylbis[N'-[2-(adamantan-1-yl)ethyl]urea]
-
N,N'-octane-1,8-diylbis[N'-[2-(adamantan-1-yl)pentyl]urea]
-
N,N'-octane-1,8-diylbis[N'-[4-(adamantan-1-yl)phenyl]urea]
-
N,N'-pentane-1,5-diylbis[N'-(3-chloroadamantan-1-yl)urea]
-
N,N'-pentane-1,5-diylbis[N'-(3-ethyladamantan-1-yl)urea]
-
N,N'-pentane-1,5-diylbis[N'-[(adamantan-1-yl)methyl]urea]
-
N,N'-propane-1,3-diylbis[N'-(3-chloroadamantan-1-yl)urea]
-
N,N'-propane-1,3-diylbis[N'-(3-ethyladamantan-1-yl)urea]
-
N,N'-propane-1,3-diylbis[N'-[(adamantan-1-yl)methyl]urea]
-
N,N'-undecane-1,11-diylbis[N'-[(adamantan-1-yl)methyl]urea]
-
N,N'-[1,4-phenylenebis(methylene)]bis[N'-(3,5-dimethyladamantan-1-yl)urea]
-
N-((4-bromo-2-[(trifluoromethyl)oxy]phenyl)-methyl)-1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-4-piperidinecarboxamide
GSK2188931B
N-(1,2-benzoxazol-3-yl)-3-methyl-3-phenylpiperidine-1-carboxamide
-
N-(1-acetylpiperidin-4-yl)-2-(tricyclo[3.3.1.13,7]dec-1-yl)acetamide
-
N-(1-acetylpiperidin-4-yl)-N'-(adamant-1-yl) urea
-
N-(1-acetylpiperidin-4-yl)-N'-adamantan-1-ylurea
-
N-(1-tert-butoxyethenyl)-1,2,3,4-tetrahydroquinolin-3-amine
-
N-(1-trifluoroacetylpiperidin-4-yl)-N'-(adamant-1-yl) urea
-
N-(2,2-diphenyl-ethyl)-nicotinamide
-
N-(2,3-dihydro-1H-inden-1-yl)-4-oxo-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
-
N-(2,3-dihydro-1H-inden-1-yl)-4-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
-
N-(2,4-dichlorobenzyl)-1-(2-ethoxyethyl)-6-oxo-1,6-dihydropyridine-3-carboxamide
-
N-(2,4-dichlorobenzyl)-3-methyl-3-phenylpiperidine-1-carboxamide
-
N-(2,4-dichlorobenzyl)-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide
-
N-(2,4-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxamide
-
N-(2,4-dichlorobenzyl)-6-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-carboxamide
-
N-(2-chloro-4-cyanobenzyl)-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
-
N-(2-chlorobenzyl)-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
-
N-(2-oxoadamantan-1-yl)-N'-1,3,5-triazatricyclo[3.3.1.13,7]decan-7-ylurea
-
N-(2-phenylcyclopropyl)-3',4'-dihydro-1H-spiro[piperidine-4,2'-pyrano[3,2-b]pyridine]-1-carboxamide
-
N-(2-phenylcyclopropyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
-
N-(2-phenylcyclopropyl)-4-(1H-1,2,4-triazol-1-yl)piperidine-1-carboxamide
-
N-(2-phenylcyclopropyl)-4-(1H-pyrazol-1-yl)piperidine-1-carboxamide
-
N-(2-phenylcyclopropyl)-4-[3-(pyrazin-2-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
-
N-(2-phenylcyclopropyl)-4-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
-
N-(2-phenylcyclopropyl)-4-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
-
N-(2-phenylcyclopropyl)-4-[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
-
N-(2-phenylcyclopropyl)-4-[3-(pyrimidin-2-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
-
N-(2-phenylcyclopropyl)-4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
-
N-(2-phenylcyclopropyl)-4-[3-[2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
-
N-(3,3-diphenyl-propyl)-2-pyridine-3-ylacetamide
-
N-(3,3-diphenyl-propyl)-isonicotinamide
-
N-(3,3-diphenyl-propyl)-nicotinamide
-
N-(3,3-diphenylpropyl)-1-(2-ethoxyethyl)-6-oxo-1,6-dihydropyridine-3-carboxamide
-
N-(3,3-diphenylpropyl)-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide
-
N-(3,3-diphenylpropyl)-6-oxo-1,6-dihydropyridine-3-carboxamide
-
N-(3,3-diphenylpropyl)-6-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-carboxamide
-
N-(3,5,7-trimethyladamantan-1-yl)-4-([[(3,5,7-trimethyladamantan-1-yl)carbamoyl]amino]methyl)piperidine-1-carboxamide
-
N-(3,5-dimethyladamantan-1-yl)-N'-(1-propanoylpiperidin-4-yl)urea
-
N-(3,5-dimethyladamantan-1-yl)-N'-(3,5,7-trimethyladamantan-1-yl)urea
-
N-(3,5-dimethyladamantan-1-yl)-N'-1,3,5-triazatricyclo[3.3.1.13,7]decan-7-ylurea
-
N-(3,5-dimethyladamantan-1-yl)-N'-[(3-ethyladamantan-1-yl)methyl]urea
-
N-(3,5-dimethyladamantan-1-yl)-N'-[4-([[(3,5-dimethyladamantan-1-yl)carbamoyl]amino]methyl)phenyl]urea
-
N-(3-ethyladamantan-1-yl)-N'-(1-propanoylpiperidin-4-yl)urea
-
N-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-2-(tricyclo[3.3.1.13,7]dec-1-yl)acetamide
-
N-(3-methylphenyl)-4-[[1-methyl-5-(pyrrolidine-1-carbonyl)-1H-benzimidazol-2-yl]methyl]piperazine-1-carboxamide
-
N-(3-phenyl-propyl)-nicotinamide
-
N-(4,4-diphenyl-butyl)-nicotinamide
-
N-(4-(N1-methyl-N2-methyl-N2-(methyloxy)oxalamido)-benzyl)adamantanecarboxamide
-
N-(4-(N2-(tetrahydro-2H-pyran-2-yloxy)oxalamido)benzyl)adamantanecarboxamide
-
N-(4-(N2-methyl-N2-(methyloxy)oxalamido)benzyl)adamantanecarboxamide
-
N-(4-(N2-methyloxyoxalamido)benzyl)adamantanecarboxamide
-
N-(4-(N2-tert-butyloxyoxalamido)benzyl)adamantanecarboxamide
-
N-(4-bromo-2-cyanobenzyl)-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
-
N-(4-chlorobenzyl)-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
-
N-(4-chlorophenyl)-3-(2-cyanoethyl)-3-phenylpiperidine-1-carboxamide
-
N-(4-chlorophenyl)-3-(2-hydroxyethyl)-3-phenylpiperidine-1-carboxamide
-
N-(4-chlorophenyl)-3-(3-hydroxypropyl)-3-phenylpiperidine-1-carboxamide
-
N-(4-chlorophenyl)-3-methyl-3-phenylpiperidine-1-carboxamide
-
N-(4-chlorophenyl)-3-phenyl-3-[2-(1H-tetrazol-5-yl)ethyl]piperidine-1-carboxamide
-
N-(4-chlorophenyl)-3-[2-(dimethylamino)ethyl]-3-phenylpiperidine-1-carboxamide
-
N-(4-chlorophenyl)-3-[2-oxo-2-(1H-tetrazol-5-ylamino)ethyl]-3-phenylpiperidine-1-carboxamide
-
N-(4-chlorophenyl)-3-[3-(diethylamino)-3-oxopropyl]-3-phenylpiperidine-1-carboxamide
-
N-(4-chlorophenyl)-3-[3-(methylamino)-3-oxopropyl]-3-phenylpiperidine-1-carboxamide
-
N-(4-chlorophenyl)-3-[3-(morpholin-4-yl)-3-oxopropyl]-3-phenylpiperidine-1-carboxamide
-
N-(4-chlorophenyl)-3-[3-oxo-3-(1H-tetrazol-5-ylamino)propyl]-3-phenylpiperidine-1-carboxamide
-
N-(4-[[(adamantan-1-yl)carbamoyl]amino]butyl)-N'-(3,5-dimethyladamantan-1-yl)urea
-
N-(5-chloro-1,3-benzoxazol-2-yl)-2-cyclopentylacetamide
-
N-(6-[[(adamantan-1-yl)carbamoyl]amino]hexyl)-N'-(3,5-dimethyladamantan-1-yl)urea
-
N-(8-[[(adamantan-1-yl)carbamoyl]amino]octyl)-N'-(3,5-dimethyladamantan-1-yl)urea
-
N-(benzyloxy)-2-(adamant-2-ylamino)acetamide
-
N-(biphenyl-3-yl)-1,2-benzoxazol-3-amine
-
N-(biphenyl-3-yl)-3-methyl-3-phenylpiperidine-1-carboxamide
-
N-(biphenyl-4-yl)-1,2-benzoxazol-3-amine
-
N-(cyclohexylcarbamoyl)glycine
binding structure analysis
N-(naphthalen-1-yl)-1,2-benzoxazol-3-amine
-
N-(naphthalen-2-yl)-1,2-benzoxazol-3-amine
-
N-([1-(phenylcarbonyl)piperidin-4-yl]methyl)-N'-(adamant-1-yl) urea
-
N-([1-(trifluoroacetyl)piperidin-4-yl]methyl)-N'-(adamant-1-yl) urea
-
N-adamantan-1-yl-N'-(3,5,7-trimethyladamantan-1-yl)urea
-
N-adamantan-1-yl-N'-(3,5-dimethyladamantan-1-yl)urea
-
N-adamantan-1-yl-N'-(5-hydroxypentyl)urea
-
N-adamantan-1-yl-N'-(5-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]pentyl)urea
-
N-adamantan-1-yl-N'-[(3-ethyladamantan-1-yl)methyl]urea
-
N-adamantan-1-yl-N'-[5-(2-hydroxyethoxy)pentyl]urea
-
N-adamantan-1-yl-N'-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]urea
N-adamantan-1-yl-N'-[5-[2-(2-hydroxyethoxy)ethoxy]pentyl]urea
-
N-adamantyl-N'-cyclohexylurea
-
N-benzyl-1,3-benzothiazol-2-amine
-
N-benzyl-1,3-benzoxazol-2-amine
-
N-benzyl-4-phenylpyridin-2-amine
-
N-benzyl-5-phenyl-1,3,4-oxadiazol-2-amine
-
N-benzyl-5-phenylpyrazin-2-amine
-
N-benzyl-5-phenylpyridin-2-amine
-
N-benzyl-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
-
N-benzylquinoxalin-2-amine
-
N-benzyltricyclo[3.3.1.13,7]decane-1-carboxamide
-
N-cyclohexyl-N'-(3-phenyl)propyl urea
-
N-cyclohexyl-N'-(4-iodophenyl)urea
CIU
N-cyclohexyl-N'-(iodophenyl)urea
N-cyclohexyl-N'-iodophenyl urea
binding structure analysis
N-methoxy-N-methyl 3-[4-(N-((2-trifluoromethyl)benzyl)-benzamide)]cyclopropanecarboxamide
-
N-methyl-1-[3-(pyridin-3-yl)phenyl]methanamine
-
N-phenyl-5-(trifluoromethyl)-1,3,4-oxadiazol-2-amine
-
N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-phenylethan-1-amine
-
N-[(1s,2R,3S)-2,3-diphenylcyclopropyl]-4-methylpiperazine-1-carboxamide
-
N-[(1s,2R,3S)-2,3-diphenylcyclopropyl]piperidine-1-carboxamide
-
N-[(3'-chlorobiphenyl-4-yl)methyl]-3-methyl-3-phenylpiperidine-1-carboxamide
-
N-[(3,5-dimethyladamantan-1-yl)methyl]-N'-(3,5,7-trimethyladamantan-1-yl)urea
-
N-[(3-ethyladamantan-1-yl)methyl]-N'-(1-propanoylpiperidin-4-yl)urea
-
N-[(3-ethyladamantan-1-yl)methyl]-N'-1,3,5-triazatricyclo[3.3.1.13,7]decan-7-ylurea
-
N-[(adamantan-1-yl)carbamoyl]-beta-alanine
-
N-[(adamantan-1-yl)methyl]-2-[3-(adamantan-1-yl)propyl]hydrazine-1-carboxamide
-
N-[(adamantan-1-yl)methyl]-4-[([[(adamantan-1-yl)methyl]carbamoyl]amino)methyl]piperidine-1-carboxamide
-
N-[(adamantan-1-yl)methyl]-N'-(1-propanoylpiperidin-4-yl)urea
-
N-[(adamantan-1-yl)methyl]-N'-[2-(adamantan-1-yl)pentyl]urea
-
N-[(adamantan-1-yl)methyl]-N'-[4-(adamantan-1-yl)phenyl]urea
-
N-[1-(1-oxopropyl)-4-piperidinyl]-N'-[4-(trifluoromethoxy)phenyl]urea
-
N-[1-(adamantan-1-yl)ethyl]-N'-(3,5,7-trimethyladamantan-1-yl)urea
-
N-[1-(adamantan-1-yl)ethyl]-N'-[(3-ethyladamantan-1-yl)methyl]urea
-
N-[1-(phenylcarbonyl)piperidin-4-yl]-N'-(adamant-1-yl) urea
-
N-[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]-N'-(adamant-1-yl) urea
-
N-[1-[(2S)-2-methylbutanoyl]piperidin-4-yl]-2-[4-(trifluoromethoxy)phenyl]acetamide
-
N-[2-(adamantan-1-yl)butyl]-N'-(3,5,7-trimethyladamantan-1-yl)urea
-
N-[2-(adamantan-1-yl)butyl]-N'-(3,5-dimethyladamantan-1-yl)urea
-
N-[2-(adamantan-1-yl)ethyl]-N'-[(adamantan-1-yl)methyl]urea
-
N-[2-(adamantan-1-yl)pentyl]-N'-(3-chloroadamantan-1-yl)urea
-
N-[2-(methylsulfonyl)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
-
N-[2-(morpholin-4-yl)phenyl]thiophene-3-carboxamide
-
N-[2-(trifluoromethoxy)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
-
N-[2-(trifluoromethoxy)phenyl]-1,2-benzoxazol-3-amine
-
N-[2-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
-
N-[2-chloro-4-(1H-tetrazol-5-yl)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
-
N-[2-chloro-4-(methylsulfamoyl)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
-
N-[2-chloro-4-(methylsulfonyl)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
-
N-[3,3-bis-(4-fluorophenyl)-propyl]-2-(2,2,2-trifluoro-ethoxy)-isonicotinamide
-
N-[3,3-bis-(4-fluorophenyl)-propyl]-4-methanesulfonyl-benzamide
-
N-[3,3-bis-(4-fluorophenyl)-propyl]-6-(2,2,2-trifluoro-ethoxy)-nicotinamide
-
N-[3,3-bis-(4-fluorophenyl)-propyl]-6-hydroxy-nicotinamide
-
N-[3,3-bis-(4-fluorophenyl)-propyl]-benzamide
-
N-[3,3-bis-(4-fluorophenyl)-propyl]-nicotinamide
-
N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-4-methanesulfonyl-benzamide
-
N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-6-(2,2,2-trifluoro-ethoxy)-nicotinamide
-
N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-nicotinamide
-
N-[3-(trifluoromethoxy)phenyl]-1,2-benzoxazol-3-amine
-
N-[3-[(2',4'-difluorobiphenyl-4-yl)methoxy]phenyl]piperidine-4-carboxamide
-
N-[3-[2-(4-chlorophenyl)ethyl]benzyl]-3-methyl-3-phenylpiperidine-1-carboxamide
-
N-[4-(1H-indol-5-yl)benzyl]-3-methyl-3-phenylpiperidine-1-carboxamide
-
N-[4-(2-methylpropanoyl)cyclohexyl]-N'-[4-(trifluoromethyl)phenyl]urea
i.e. UC2389
N-[4-(methylsulfonyl)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
-
N-[4-(trifluoromethoxy)phenyl]-1,2-benzoxazol-3-amine
-
N-[4-(trifluoromethyl)benzyl]-1,2-benzoxazol-3-amine
-
N-[4-(trifluoromethyl)phenyl]-1,2-benzothiazol-3-amine
-
N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
-
N-[4-(trifluoromethyl)phenyl]-1H-indazol-3-amine
-
N-[4-(trifluoromethyl)phenyl][1,2]oxazolo[4,5-b]pyridin-3-amine
-
N-[4-(trifluoromethyl)phenyl][1,2]oxazolo[5,4-b]pyridin-3-amine
-
N-[4-(trifluoromethyl)phenyl][1,2]oxazolo[5,4-c]pyridin-3-amine
-
N-[4-([[(adamantan-1-yl)methyl]carbamoyl]amino)butyl]-N'-[(3,5-dimethyladamantan-1-yl)methyl]urea
-
N-[4-([[(adamantan-1-yl)methyl]carbamoyl]amino)phenyl]-N'-[(3,5-dimethyladamantan-1-yl)methyl]urea
-
N-[4-chloro-2-(methylsulfonyl)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
-
N-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]-N'-(4-hydroxyadamantan-1-yl)urea
-
N-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]-N'-(4-oxoadamantan-1-yl)urea
-
N-[6-([[(adamantan-1-yl)methyl]carbamoyl]amino)hexyl]-N'-[(3,5-dimethyladamantan-1-yl)methyl]urea
-
N-[8-([[(adamantan-1-yl)methyl]carbamoyl]amino)octyl]-N'-[(3,5-dimethyladamantan-1-yl)methyl]urea
-
N-[[4'-(methylsulfonyl)biphenyl-4-yl]methyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
-
N1,N4-bis[(adamantan-1-yl)methyl]piperazine-1,4-dicarboxamide
-
N1-(4-((2-adamantylacetamido)methyl)phenyl)-N1-methyl-N2-methyl-N2-methyloxyoxalamide
-
N1-(4-((2-adamantylacetamido)methyl)phenyl)-N2-methyl-N2-methyloxyoxalamide
-
N1-(4-(2-adamantylacetamido)phenyl)-N1-methyl-N2-methyl-N2-(methyloxy)oxalamide
-
N1-(4-(2-adamantylacetamido)phenyl)-N2-methyl-N2-(methyloxy)oxalamide
-
N1-(adamant-1-yl)-N2-(benzyloxy)oxalamide
-
N1-(adamant-1-ylmethyl)-N2-(benzyloxy)oxalamide
-
N1-(adamant-2-yl)-N2-(2-phenylethyloxy)oxalamide
-
N1-(adamant-2-yl)-N2-(3-phenylpropyloxy)oxalamide
-
N1-(adamant-2-yl)-N2-(4-chlorobenzyloxy)oxalamide
-
N1-(adamant-2-yl)-N2-(4-methoxycarbonylbenzyloxy)oxalamide
-
N1-(adamant-2-yl)-N2-(4-nitrobenzyloxy)oxalamide
-
N1-(adamant-2-yl)-N2-(benzyloxy)-N2-methyloxalamide
-
N1-(adamant-2-yl)-N2-(benzyloxy)oxalamide
-
N1-(adamant-2-yl)-N2-(phenyloxy)oxalamide
-
N1-(adamant-2-yl)-N2-(tetrahydro-2H-pyran-2-yloxy)oxalamide
-
N1-(adamant-2-yl)-N2-methyl-N2-(methyloxy)oxalamide
-
N1-(benzyloxy)-N2-(3-phenylpropyl)oxalamide
-
peroxynitrite
causes nitration on several tyrosine residues including Tyr383 and Tyr466
pyridine-2-carboxylic acid (3,3-diphenyl-propyl)-amide
-
pyridine-3-sulfonic acid 3,3-(diphenylpropyl)-amide
-
t-butyl 4-[2-[(5-chloro-1,3-benzoxazol-2-yl)amino]-2-oxoethyl]piperidine-1-carboxylate
IC50 value in COS-7 cell assay 1.5 nM, 43% remiaining stability in human microsomes
trans-1-adamantan-1-yl-3-(4-benzyloxycyclohexyl)urea
-
trans-1-adamantan-1-yl-3-[4-(2,6-dichlorobenzyloxy)cyclohexyl]-urea
-
trans-1-adamantan-1-yl-3-[4-(2,6-difluorobenzyloxy)cyclohexyl]-urea
-
trans-1-adamantan-1-yl-3-[4-(2-methylbenzyloxy)cyclohexyl]-urea
-
trans-1-adamantan-1-yl-3-[4-(3,5-difluorophenoxy)cyclohexyl]-urea
-
trans-1-adamantan-1-yl-3-[4-(4-bromobenzyloxy)cyclohexyl]-urea
-
trans-4-(4-(3-adamantan-1-yl-ureido)-cyclohexyloxy)-benzoic acid
-
trans-4-(4-[3-(4-trifluoromethoxyphenyl)ureido]cyclohexyloxy)benzoic acid
-
trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid
trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid
trans-4-[4-(3-adamantan-1-ylureido)cyclohexyloxy]-benzoic acid
-
trans-4-[4-(3-adamantan-1-ylureido)cyclohexyloxy]benzoic acid
-
trans-4-[4-[3-(4-trifluoromethoxyphenyl)-ureido]-cyclohexyloxy]benzoic acid
-
[(5-[[(adamantan-1-yl)carbamoyl]amino]pentyl)oxy]acetic acid
-
[1-[(4-chlorophenyl)carbamoyl]-3-phenylpiperidin-3-yl]acetic acid
-
[2-[(5-[[(adamantan-1-yl)carbamoyl]amino]pentyl)oxy]ethoxy]acetic acid
-
[6-(methylsulfonyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidin]-1'-yl][4-(trifluoromethyl)phenyl]methanone
-
[N-(2-(trifluoromethyl)benzyl)benzamide]-4-(1H-tetrazole)
-
(3-[4-(allyloxy)phenyl]oxiran-2-yl)(phenyl)methanone
-
IC50 is 0.00029 mM
(3-[4-(benzyloxy)phenyl]oxiran-2-yl)(phenyl)methanone
-
IC50 is 0.00023 mM
(4-bromophenyl)(3-phenyloxiran-2-yl)methanone
-
IC50 is 0.00022 mM
(4-bromophenyl)[3-(2-naphthyl)oxiran-2-yl]methanone
-
IC50 is 0.00018 mM
(4-fluorophenyl)(3-phenyloxiran-2-yl)methanone
-
IC50 is 0.00039 mM
(4-iodophenyl)(3-phenyloxiran-2-yl)methanone
-
IC50 is 0.00042 mM
(4-methoxyphenyl)(3-phenyloxiran-2-yl)methanone
-
IC50 is 0.00020 mM
(4-methylphenyl)(3-phenyloxiran-2-yl)methanone
-
IC50 is 0.00023 mM
(4-methylphenyl)[3-(2-naphthyl)oxiran-2-yl]methanol
-
IC50 is 0.00015 mM
(4-methylphenyl)[3-(2-naphthyl)oxiran-2-yl]methanone
-
IC50 is 0.00019 mM
(4-nitrophenyl)(3-phenyloxiran-2-yl)methanone
-
IC50 is 0.00025 mM
(E)-phenyl(3-phenyloxiran-2-yl)methanone oxime
-
IC50 is 0.00029 mM
(E)-[3-(2-naphthyl)oxiran-2-yl](phenyl)methanone oxime
-
IC50 is 0.035 mM
(R)-N-(2-(diphenylamino)ethyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide
-
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
(R)-N-(3,3-bis(4-fluorophenyl)propyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide
-
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
1,1'-(benzene-1,3-diyldicarbonyl)bis[N-(2,4-dichlorobenzyl)piperidine-4-carboxamide]
-
55% inhibition at 200 nM
1,1'-(benzene-1,3-diyldisulfonyl)bis[N-(2,4-dichlorobenzyl)piperidine-4-carboxamide]
-
45% inhibition at 200 nM
1,1,1-Trichloropropene 2,3-oxide
-
-
1,2-(ethylene)bis[[(adamant-1-yl)methyl]urea]
-
-
1,3-disubstituted amides
-
potent and stable inhibition, Ki in the nanomolar range, mechanism
1,3-disubstituted carbamate derivatives
-
potent and stable inhibition, Ki in the nanomolar range, mechanism
1,3-disubstituted urea derivatives
-
potent and stable inhibition, Ki in the nanomolar range, mechanism
1,4-(phenylene)bis[(adamant-2-yl)urea]
-
-
1,4-(phenylene)bis[[(adamant-1-yl)ethyl-1]urea]
-
-
1,4-(phenylene)bis[[(adamant-1-yl)methyl]urea]
-
-
1,4-(tetramethylene)bis[(adamant-1-yl)methyl]urea
-
-
1,4-(tetramethylene)bis[(adamant-1-yl)urea]
-
-
1,4-(tetramethylene)bis[[(adamant-1-yl)ethyl-1]urea]
-
-
1,4-(tetramethylene)bis[[(adamant-1-yl)sec-butyl-1]urea]
-
-
1,4-(tetramthylene)bis[(adamant-2-yl)urea]
-
-
1,6-(hexamethylene)bis[[(adamant-1-yl)methyl]urea]
-
-
1,8-(octamethylene)bis[(adamant-1-yl)urea]
-
-
1,8-(octamethylene)bis[(adamant-1-ylethyl)urea]
-
potent inhibitor
1,8-(octamethylene)bis[(adamant-2-yl)urea]
-
-
1,8-(octamethylene)bis[[(adamant-1-yl)ethyl-1]urea]
-
-
1,8-(octamethylene)bis[[(adamant-1-yl)methyl]urea]
-
-
1,8-(octamethylene)bis[[(adamant-1-yl)sec-butyl-1]urea]
-
-
1-(1-methanesulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxy-phenyl)-urea
-
i.e. TUPS
1-(1-methylsulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxy-phenyl)-urea
-
potent inhibitor of sEH
1-(1-nicotinoylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)-urea
-
i.e. AR9276
1-(2-((3-((3s,5s,7s)-adamantan-1-yl)ureido)methyl)benzyl)-1H-pyrrole-2-carboxylic acid
-
-
1-(3,4-dichlorophenyl)-3-(4-phenoxyphenyl)urea
-
-
1-(3-((3-((3s,5s,7s)-adamantan-1-yl)ureido)methyl)benzyl)-1H-pyrrole-2-carboxylic acid
-
-
1-(4-((3-((3s,5s,7s)-adamantan-1-yl)ureido)methyl)benzyl)-1H-pyrrole-2-carboxylic acid
-
-
1-(cyclohexylsulfonyl)-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
-
27% inhibition at 200 nM
1-(trifluoromethoxyphenyl-3-(1-methylsulfonyl)piperidin-4-yl)urea
-
-
1-adamantan-1-yl-3-(5-(2-[2-(2,2,2-trifluoroethoxy)ethoxy]-ethoxy)pentyl)urea
-
-
1-adamantan-1-yl-3-(5-(2-[2-(4-ethylphenoxy)ethoxy]-ethoxy)pentyl)urea
-
-
1-adamantan-1-yl-3-(5-butoxypentyl)urea
-
-
1-adamantan-1-yl-3-(5-hexoxypropyl)urea
-
-
1-adamantan-1-yl-3-(5-pentoxybutyl)urea
-
-
1-adamantan-1-yl-3-(5-propyloxyhexyl)urea
-
-
1-adamantan-1-yl-3-(5-[4-propyloxy]butyl)-urea
-
-
1-adamantan-1-yl-3-(5-[4-propyloxy]propyl)-urea
-
-
1-adamantan-3-(5-(2-(2-ethylethoxy)ethoxy)pentyl)urea
-
highly potent and selective sEH inhibitor
1-adamantanyl-3-(5-(2-(2-ethoxyethoxy)ethoxy)pentyl)urea
-
i.e. AEPU
1-adamantyl-3-(1-acetylpiperidin-4-yl)-urea
-
-
1-Benzylimidazole
-
microsomal activity with cis-stilbene oxide as substrate
1-cyclohexyl-3-dodecyl urea
1-cyclohexyl-3-dodecylurea
-
i.e. 1-cyclohexyl-3-dodecyl-urea
1-cyclohexyl-3-ethyl urea
1-cyclohexyl-3-ethylurea
-
i.e. N-cyclohexyl-N'-ethylurea
1-cyclohexyl-3-hexyl urea
1-cyclohexyl-3-hexylurea
-
i.e. N-cyclohexyl-N'-hexylurea
1-cyclohexyl-3-[3-(3-morpholin-4-ylpropoxy)phenyl]urea
-
-
1-trichloropropene oxide
-
-
1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl) urea
-
i.e. TPAU
1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl)urea
-
-
1-[(1-chloroisoquinolin-5-yl)sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
-
30% inhibition at 200 nM
1-[(2,4-dimethylphenyl)sulfonyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(2-fluorophenyl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(2-hydroxyphenyl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(2-methylphenyl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(2-methylpropyl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(4-fluorophenyl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(4-hydroxyphenyl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(4-methoxyphenyl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(4-nitrophenyl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(4-phenoxyphenyl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(6-methoxy-1,3-benzodioxol-5-yl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(isoquinolin-5-yl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(naphthalen-2-yl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(quinolin-3-yl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(quinolin-6-yl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(quinolin-8-yl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-(tricyclo[3.3.1.13,7]dec-1-yl)piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-phenylpiperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-[(1R,2S)-2-phenylcyclopropyl]piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-[4-(morpholin-4-yl)phenyl]piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-[4-(piperidin-1-yl)phenyl]piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-[4-(propan-2-yl)phenyl]piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-[4-(trifluoromethoxy)phenyl]piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-[4-(trifluoromethyl)phenyl]piperidine-4-carboxamide
-
-
1-[(2,4-dimethylphenyl)sulfonyl]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]piperidine-4-carboxamide
-
-
1-[(2-bromophenyl)sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
-
63% inhibition at 200 nM
1-[(2-chloroethyl)sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
-
31% inhibition at 200 nM
1-[(4-bromoisoquinolin-5-yl)sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
-
37% inhibition at 200 nM
1-[(4-bromophenyl)sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
-
32% inhibition at 200 nM
1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
-
97% inhibition at 200 nM
1-[(4-tert-butylphenyl)sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
-
85% inhibition at 200 nM
1-[(5-bromothiophen-2-yl)sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
-
43% inhibition at 200 nM
1-[(5-chlorothiophen-2-yl)sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
-
52% inhibition at 200 nM
1-[2-[(cyclohexylcarbamoyl)amino]benzyl]-1H-pyrrole-2-carboxylic acid
-
-
1-[3-(3-morpholin-4-ylpropoxy)phenyl]-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]thiourea
-
-
1-[3-(3-morpholin-4-ylpropoxy)phenyl]-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]urea
-
-
1-[3-(3-morpholin-4-ylpropoxy)phenyl]-3-[4-(trifluoromethoxy)phenyl]urea
-
-
1-[3-(3-morpholin-4-ylpropoxy)phenyl]-3-[4-(trifluoromethyl)phenyl]urea
-
-
1-[3-(4-nitrophenyl)oxiran-2-yl]ethanol
-
IC50 is 0.0187 mM
1-[3-(4-nitrophenyl)oxiran-2-yl]ethanone
-
IC50 is 0.269 mM
1-[3-([[4-(trifluoromethoxy)phenyl]carbamoyl]amino)benzyl]-1H-pyrrole-2-carboxylic acid
-
-
1-[3-[(cyclohexylcarbamoyl)amino]benzyl]-1H-pyrrole-2-carboxylic acid
-
-
1-[4-([[4-(trifluoromethoxy)phenyl]carbamoyl]amino)benzyl]-1H-pyrrole-2-carboxylic acid
-
-
1-[4-[(cyclohexylcarbamoyl)amino]benzyl]-1H-pyrrole-2-carboxylic acid
-
-
1-[[1-((adamant-1-yl)methylcarbamoyl)piperidin-4-yl]methyl]-3-[(adamant-1-yl)methyl]urea
-
-
1-[[4-(acetylamino)phenyl]sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
-
53% inhibition at 200 nM
10-(sulfooxy)octadecanoic acid
-
IC50 is 0.028 mM
12-(3-adamantan-1-yl-ureido) 2-chlorobenzyl dodecanoate
-
-
12-(3-adamantan-1-yl-ureido) 2-methylpropyl dodecanoate
-
-
12-(3-adamantan-1-yl-ureido) butan-2-yl dodecanoate
-
-
12-(3-adamantan-1-yl-ureido) butyl dodecanoate
-
-
12-(3-adamantan-1-yl-ureido) ethyl dodecanoate
-
-
12-(3-adamantan-1-yl-ureido) N-(methylsulfonyl)dodecanylamide
-
-
12-(3-adamantan-1-yl-ureido) N-(phenylsulfonyl)dodecanylamide
-
-
12-(3-adamantan-1-yl-ureido) prop-2-en-1-yl dodecanoate
-
-
12-(3-adamantan-1-yl-ureido) prop-2-yn-1-yl dodecanoate
-
-
12-(3-adamantan-1-yl-ureido) propan-2-yl dodecanoate
-
-
12-(3-adamantan-1-yl-ureido) propyl dodecanoate
-
-
12-(3-adamantan-1-yl-ureido) tert-butyl dodecanoate
-
-
12-(3-adamantan-1-yl-ureido)-dodecanoic acid
12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester
-
i.e. AUDA-BE
12-(3-adamantan-1-yl-ureido)dodecanoic acid
12-(3-adamantan-1-ylureido)dodecanoic acid
-
-
12-(3-adamantan-1-ylureido)dodecanoic acid butyl ester
-
-
12-(3-adamantane-1-yl-ureido)-dodecanoic acid
-
-
12-(3-adamantane-1-yl-ureido)dodecanoic acid
-
shows an IC50 of 0.00013 mg/ml
12-(3-adamantylureido)-dodecanoic acid
-
-
12-sulfonoxy-cis-9-octadecenoic acid
-
IC50 is above 0.1 mM
12-sulfonoxy-trans-9-octadecenoic acid
-
IC50 is 0.016 mM
2,2'-Dithiopyridine
-
73% inhibition at 1 mM at pH 7.4
2-(2-naphthyl)-3-(phenylsulfinyl)oxirane
-
IC50 is 0.070 mM
2-Bromo-4'-nitroacetophenone
2-cyclohexa-1,5-dien-1-yl-3-(phenylsulfinyl)oxirane
-
IC50 is 0.00031 mM
2-cyclohexa-1,5-dien-1-yl-3-[methoxy(phenyl)methyl]oxirane
-
IC50 is 0.034 mM
2-cyclohexyl-N-[3-(3-morpholin-4-ylpropoxy)phenyl]acetamide
-
-
2-hydroxy-N-[3-(3-morpholin-4-ylpropoxy)phenyl]-2-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]acetamide
-
-
2-hydroxy-N-[3-(3-morpholin-4-ylpropoxy)phenyl]-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]propanamide
-
-
2-hydroxy-N-[3-(3-morpholin-4-ylpropoxy)phenyl]-4-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]butanamide
-
-
2-naphthyl(3-phenyloxiran-2-yl)methanone
-
IC50 is 0.00028 mM
2-[methoxy(phenyl)methyl]-3-(2-naphthyl)oxirane
-
IC50 is 0.00134 mM
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
-
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(3-phenyl-3-(4-(trifluoromethoxy)phenyl)propyl)benzamide
-
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(4-methoxy-2-(trifluoromethyl)benzyl)-benzamide
-
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
3-(3-(1-hydroxyureido)hex-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
-
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
4,5-dimethoxy-2-nitrophenyl 4-[(2,4-dichlorobenzyl)carbamoyl]piperidine-1-carboxylate
-
71% inhibition at 200 nM
4-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
-
dual 5-LOX/soluble epoxide hydrolase inhibitor, displays cellular activity in human polymorphonuclear leukocytes, oral bioavailability, and target engagement in vivo and demonstrates anti-inflammatory and anti-fibrotic efficiency in a kidney injury model caused by unilateral ureteral obstruction in mice
-
4-(3-benzoyloxiran-2-yl)benzoic acid
-
IC50 is above 0.5 mM
4-([3-(2-naphthyl)oxiran-2-yl]carbonyl)benzoic acid
-
IC50 is 0.00016 mM
4-([3-(4-fluorophenyl)oxiran-2-yl]carbonyl)benzoic acid
-
IC50 is 0.113 mM
4-fluoro-chalcone oxide
-
0.1 mM, 87% inhibition of epoxide hydrolase activity, 8% inhibition of phosphatase activity
4-fluorochalcone oxide
-
87% inhibition at 0.1 mM, competitive substrate
4-nitrobenzenesulfonyl fluoride
-
94% inhibition at 1 mM at pH 7.4
4-nitrophenyl 4-[(2,4-dichlorobenzyl)carbamoyl]piperidine-1-carboxylate
-
41% inhibition at 200 nM
4-nitrophenyl sulfate
-
IC50 is above 0.1 mM
4-phenyl-chalcone oxide
-
0.1 mM, complete inhibition of epoxide hydrolase activity, 11% inhibition of phosphatase activity
4-[(3-phenyloxiran-2-yl)carbonyl]benzoic acid
-
IC50 is 0.144 mM
4-[([1-[(2,4-dimethylphenyl)sulfonyl]piperidin-4-yl]carbonyl)amino]benzoic acid
-
-
4-[3-(4-fluorobenzoyl)oxiran-2-yl]benzoic acid
-
IC50 is above 0.5 mM
6-[([1-[(2,4-dimethylphenyl)sulfonyl]piperidin-4-yl]carbonyl)amino]naphthalene-2-carboxylic acid
-
-
9-hydroxy-10-(sulfooxy)octadecanoic acid
-
IC50 is 0.09 mM
Al3+
-
20% inhibition at 1 mM
alpha-hydroxyfarnesyl phosphonic acid
-
IC50 is 0.073 mM
alpha-sulfostearic acid
-
IC50 is above 0.1 mM
AUDA
-
i.e. 12-(3-adamantan-1-yl-ureido) dodecanoic acid
Ba2+
-
20% inhibition at 1 mM
benzil
-
inhibition of microsomal enzyme with cis-stilbene oxide, and of cytosolic enzyme forms cEHTSO and cEHCSO
benzyl phenylmetanethiosulfonate
-
complete inhibition at 1 mM at pH 7.4
carbodiimide/glycine methyl ester
-
48% inhibition at 1 mM at pH 5.2, no inhibition at pH 7.4
Ce3+
-
inhibition of Mg2+-dependent acrtivity
chalcone
-
microsomal activity with cis-stilbene oxide as substrate, cytosolic enzyme form cEHCSO and cEHTSO
cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid
-
-
Cu+
-
inhibition of phosphatase activity and epoxide hydrolase activity
cyclohexane 1,2-oxide
-
-
D-galactose 6-sulfate
-
IC50 is above 0.1 mM
dibenzyl phosphonate
-
IC50 is above 0.1 mM
diethyl 2,2,2-trifluoro-1-hydroxyethyl phosphonate
-
IC50 is above 0.1 mM
diethyl 4-methylbenzyl phosphonate
-
IC50 is above 0.1 mM
diethyl allyl phosphonate
-
IC50 is above 0.1 mM
diethyl benzoylphosphonate
-
IC50 is above 0.1 mM
diethyl cyclopropyl methylphosphonate
-
IC50 is above 0.1 mM
diethyl ethylthiomethyl phosphonate
-
IC50 is above 0.1 mM
diethyl trans-cinnamyl phosphonate
-
IC50 is above 0.1 mM
diethyl vinylphosphonate
-
IC50 is above 0.1 mM
diethyldicarbonate
-
72% inhibition at 1 mM at pH 7.4
dimethyl 2-oxoheptyl phosphonate
-
IC50 is above 0.1 mM
dioctyl phenyl phosphonate
-
IC50 is 0.092 mM
dodecyl phosphonic acid
-
IC50 is 0.040 mM
DTNB
-
86% inhibition at 1 mM at pH 7.4
Estrone 3-sulfate
-
IC50 is above 0.1 mM
ethyl 1-(2-((3-((3s,5s,7s)-adamantan-1-yl)ureido)methyl)benzyl)-1H-pyrrole-2-carboxylate
-
-
ethyl 1-(3-((3-((3s,5s,7s)-adamantan-1-yl)ureido)methyl)benzyl)-1H-pyrrole-2-carboxylate
-
-
ethyl 1-(4-((3-((3s,5s,7s)-adamantan-1-yl)ureido)methyl)benzyl)-1H-pyrrole-2-carboxylate
-
-
ethyl 1-[2-([[4-(trifluoromethoxy)phenyl]carbamoyl]amino)benzyl]-1H-pyrrole-2-carboxylate
-
-
ethyl 1-[2-[(cyclohexylcarbamoyl)amino]benzyl]-1H-pyrrole-2-carboxylate
-
-
ethyl 1-[3-[(cyclohexylcarbamoyl)amino]benzyl]-1H-pyrrole-2-carboxylate
-
-
ethyl 1-[4-([[4-(trifluoromethoxy)phenyl]carbamoyl]amino)benzyl]-1H-pyrrole-2-carboxylate
-
-
ethyl 1-[4-[(cyclohexylcarbamoyl)amino]benzyl]-1H-pyrrole-2-carboxylate
-
-
L-ascorbic acid 2-sulfate
-
IC50 is above 0.1 mM
methyl 4-((1,2,3,4-tetrahydronaphthalene-2-carboxamido)methyl)benzoic acid
-
-
methyl 4-([[(6-hydroxynaphthalen-2-yl)carbonyl]amino]methyl)benzoate
-
-
methyl 4-([[(6-methoxynaphthalen-2-yl)carbonyl]amino]methyl)benzoate
-
-
methyl 4-[([1-[(2,4-dimethylphenyl)sulfonyl]piperidin-4-yl]carbonyl)amino]benzoate
-
-
methyl 6-[([1-[(2,4-dimethylphenyl)sulfonyl]piperidin-4-yl]carbonyl)amino]naphthalene-2-carboxylate
-
-
methyl methanethiosulfonate
-
89% inhibition at 1 mM at pH 7.4
Mg2+
-
20% inhibition at 1 mM
N'-(2-chlorophenyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carbohydrazide
-
62% inhibition at 200 nM
N'-(4-fluorophenyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carbohydrazide
-
9% inhibition at 200 nM
N'-phenyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carbohydrazide
-
16% inhibition at 200 nM
N'-[2-(3-chlorophenyl)ethyl]-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carbohydrazide
-
65% inhibition at 200 nM
N,N'-bis-(3,4-dichlorophenyl)urea
-
-
N,N-dicyclohexylurea
-
i.e. N,N-dicyclohexylurea
N-((1-acetylpiperidin-4-yl)methyl)-N'-(adamant-1-yl)urea
-
-
N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
79% inhibition at 200 nM
N-(1,3-benzodioxol-5-yl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-(1-(2,2,2-trifluoroethanoyl)piperidin-4-yl)-N'-(adamant-1-yl)urea
-
-
N-(1-acetylpiperidin-4-yl)-N'-(adamant-1-yl)urea
-
-
N-(1-tert-butoxypiperidin-4-yl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
88% inhibition at 200 nM
N-(2,3-dihydro-1H-inden-2-yl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
62% inhibition at 200 nM
N-(2,4-dichloro-6-methylbenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
95% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-(diphenylphosphanyl)piperidine-4-carboxamide
-
3% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-(methylsulfonyl)piperidine-4-carboxamide
-
45% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-(quinolin-5-ylsulfonyl)piperidine-4-carboxamide
-
34% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-(thiophen-2-ylcarbonyl)piperidine-4-carboxamide
-
16% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-([1-[(2,4,6-trimethylphenyl)sulfonyl]piperidin-4-yl]carbonyl)piperidine-4-carboxamide
-
31% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(1-methylethyl)sulfonyl]piperidine-4-carboxamide
-
13% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(2,4,6-tri-tert-butylphenyl)sulfonyl]piperidine-4-carboxamide
-
88% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(2,4,6-trimethylphenyl)carbonyl]piperidine-4-carboxamide
-
34% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
97% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
97% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(2-fluorophenyl)sulfonyl]piperidine-4-carboxamide
-
66% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(2-nitrophenyl)carbonyl]piperidine-4-carboxamide
-
44% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(2-nitrophenyl)sulfonyl]piperidine-4-carboxamide
-
47% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(3-nitrophenyl)carbonyl]piperidine-4-carboxamide
-
18% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(3-nitrophenyl)sulfonyl]piperidine-4-carboxamide
-
21% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(4-fluoro-2-nitrophenyl)sulfonyl]piperidine-4-carboxamide
-
63% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
98% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(4-methyl-2-nitrophenyl)sulfonyl]piperidine-4-carboxamide
-
28% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[(4-methylphenyl)sulfonyl]piperidine-4-carboxamide
-
15% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[[2-(trifluoromethyl)phenyl]sulfonyl]piperidine-4-carboxamide
-
39% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[[2-nitro-4-(trifluoromethyl)phenyl]sulfonyl]piperidine-4-carboxamide
-
37% inhibition at 200 nM
N-(2,4-dichlorobenzyl)-1-[[3-([4-[(2,4-dichlorobenzyl)carbamoyl]piperidin-1-yl]carbonyl)phenyl]sulfonyl]piperidine-4-carboxamide
-
45% inhibition at 200 nM
N-(2,4-difluorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
97% inhibition at 200 nM
N-(2,5-dichlorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
98% inhibition at 200 nM
N-(2-bromophenyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-(2-chloro-4-fluorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
98% inhibition at 200 nM
N-(2-chloro-6-fluorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
97% inhibition at 200 nM
N-(2-chlorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
90% inhibition at 200 nM
N-(2-chlorophenyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-(2-methylcyclohexyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
77% inhibition at 200 nM
N-(2-phenylethyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
67% inhibition at 200 nM
N-(3,3-diphenylpropyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
78% inhibition at 200 nM
N-(3,4-dichlorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
97% inhibition at 200 nM
N-(3,4-dichlorophenyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-(3,5-dichlorophenyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-(3-(4-chlorophenyl)-3-phenylpropyl)-3-(3-(1-hydroxyureido)-but-1-yn-1-yl)benzamide
-
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
N-(3-methylbutyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
87% inhibition at 200 nM
N-(4-bromophenyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-(4-chlorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
97% inhibition at 200 nM
N-(4-chloronaphthalen-1-yl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
44% inhibition at 200 nM
N-(4-chlorophenyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-(4-methylcyclohexyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
86% inhibition at 200 nM
N-(4-[(3-phenyloxiran-2-yl)carbonyl]phenyl)acetamide
-
IC50 is 0.00014 mM
N-(cyclohexylmethyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
92% inhibition at 200 nM
N-(cyclohexylmethyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-(naphthalen-1-ylmethyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
55% inhibition at 200 nM
N-(pyridin-3-ylmethyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
23% inhibition at 200 nM
N-(pyridin-4-ylmethyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
49% inhibition at 200 nM
N-acetyl-D-galactosamine 4-sulfate
-
IC50 is above 0.1 mM
N-benzyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
65% inhibition at 200 nM
N-cyclobutyl-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-cycloheptyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
N-cycloheptyl-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-cyclohexyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
87% inhibition at 200 nM
N-cyclohexyl-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-cyclohexyl-N'-4-chlorophenylurea
-
-
N-cyclooctyl-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-cyclopentyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
75% inhibition at 200 nM
N-cyclopentyl-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-cyclopentyl-N'-dodecylurea
-
-
N-cyclopropyl-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-ethylmaleimide
-
98% inhibition at 1 mM at pH 7.4
N-morpholin-4-yl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
14% inhibition at 200 nM
N-naphthalen-1-yl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
50% inhibition at 200 nM
N-phenyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
48% inhibition at 200 nM
N-Phenylmaleimide
-
97% inhibition at 1 mM at pH 7.4
N-piperidin-1-yl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
55% inhibition at 200 nM
N-piperidin-4-yl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
15% inhibition at 200 nM
N-tert-butyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
3% inhibition at 200 nM
N-[(4-chlorophenyl)(phenyl)methyl]-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
7% inhibition at 200 nM
N-[1-(4-chlorophenyl)ethyl]-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
94% inhibition at 200 nM
N-[2-(4-methoxyphenyl)ethyl]-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
44% inhibition at 200 nM
N-[2-chloro-5-(trifluoromethyl)benzyl]-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
94% inhibition at 200 nM
N-[2-[4-(benzyloxy)phenyl]ethyl]-2-hydroxy-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]propanamide
-
-
N-[2-[4-(benzyloxy)phenyl]ethyl]-2-hydroxy-4-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]butanamide
-
-
N-[2-[4-(benzyloxy)phenyl]ethyl]-2-oxo-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]propanamide
-
-
N-[2-[4-(benzyloxy)phenyl]ethyl]-2-oxo-4-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]butanamide
-
-
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-2-oxo-2-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]acetamide
-
-
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-2-oxo-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]propanamide
-
-
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-2-oxo-4-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]butanamide
-
-
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-2-[4-(trifluoromethyl)phenyl]acetamide
-
-
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-4-(trifluoromethyl)benzamide
-
-
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-4-(trifluoromethyl)benzenesulfonamide
-
-
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-N'-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]sulfamide
-
-
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-N-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-ylmethyl]formamide
-
-
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-N-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]formamide
-
-
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-N2-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]glycinamide
-
-
N-[3-(3-morpholin-4-ylpropoxy)phenyl]cyclohexanecarboxamide
-
-
N-[3-carbamoyl-4-(piperidin-1-yl)phenyl]-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-[4-(3-benzoyloxiran-2-yl)phenyl]acetamide
-
IC50 is 0.00027 mM
N-[4-(benzyloxy)phenyl]-2-hydroxy-2-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]acetamide
-
-
N-[4-(benzyloxy)phenyl]-2-hydroxy-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]propanamide
-
-
N-[4-(benzyloxy)phenyl]-2-oxo-2-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]acetamide
-
-
N-[4-(benzyloxy)phenyl]-2-oxo-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]propanamide
-
-
N-[4-chloro-3-(trifluoromethyl)benzyl]-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
96% inhibition at 200 nM
N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
Ni2+
-
25% inhibition at 1 mM
ninhydrin
-
13% inhibition at 1 mM at pH 7.4
octadecan-9-yl sulfate
-
IC50 is 0.021 mM
okadaic acid
-
12% inhibition at 0.1 mM
p-Hydroxymercuriphenylsulfonate
-
-
phenyl(3-phenyloxiran-2-yl)methanol
-
IC50 is 0.022 mM
phenyl(3-phenyloxiran-2-yl)methanone
-
IC50 is 0.0003 mM
Phenylglyoxal
-
19% inhibition at 1 mM at pH 7.4
phenylthioisocyanate
-
54% inhibition at 1 mM at pH 7.4
Sodium dodecyl sulfate
-
IC50 is above 0.1 mM
sodium dodecyl sulfonate
-
IC50 is 0.05 mM
sodium orthovanadate
-
9% inhibition at 0.1 mM
sorafenib
-
a vascular endothelial growth factor receptor, inhibits sEH, effects in vivo, causes a shift in oxylipid profile and reduces the acute inflammatory response, overview. Reverses lipopolysaccharide-induced hypotension
substituted chalcone oxides
-
-
-
taurocholic acid
-
IC50 is 0.09 mM
taurolithocholic acid 3-sulfate
-
IC50 is above 0.1 mM
tert-butyl 4-[([1-[(2,4-dimethylphenyl)sulfonyl]piperidin-4-yl]carbonyl)amino]piperidine-1-carboxylate
-
-
tetraisopropyl methylenediphosphonate
-
IC50 is above 0.1 mM
trans-4-((4-(3-adamantylureido)-cyclohexyl)oxy)-benzoic acid
-
-
trans-4-(4-(3-adamantan-1-yl-ureido)-cyclohexyloxy)-benzoic acid
-
i.e. t-AUCB
trans-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]-benzoic acid
-
-
trans-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid
-
potent sEH inhibitor
trans-4-[4-(3-adamantan-1-ylureido)cyclohexyloxy]benzoic acid
-
-
[3-(2-naphthyl)oxiran-2-yl](4-nitrophenyl)methanone
-
IC50 is 0.00016 mM
[3-(2-naphthyl)oxiran-2-yl](phenyl)methanol
-
IC50 is 0.00072 mM
[3-(2-naphthyl)oxiran-2-yl](phenyl)methanone
[3-(4-bromophenyl)oxiran-2-yl](phenyl)methanone
-
IC50 is 0.0002 mM
[3-(4-butylphenyl)oxiran-2-yl](phenyl)methanone
-
IC50 is 0.00015 mM
[3-(4-fluorophenyl)oxiran-2-yl](phenyl)methanol
-
IC50 is 0.018 mM
[3-(4-fluorophenyl)oxiran-2-yl](phenyl)methanone
-
IC50 is 0.0003 mM
[3-(4-heptylphenyl)oxiran-2-yl](phenyl)methanone
-
IC50 is 0.00048 mM
[3-(4-isopropylphenyl)oxiran-2-yl](phenyl)methanone
-
IC50 is 0.00048 mM
[3-(4-methoxyphenyl)oxiran-2-yl](phenyl)methanone
-
IC50 is 0.00011 mM
[3-(4-methylphenyl)oxiran-2-yl](phenyl)methanone
-
IC50 is 0.00036 mM
[3-(4-nitrophenyl)oxiran-2-yl](phenyl)methanol
-
IC50 is 0.028 mM
[3-(4-nitrophenyl)oxiran-2-yl](phenyl)methanone
-
IC50 is 0.00063 mM
[3-(4-phenoxycyclohexa-1,5-dien-1-yl)oxiran-2-yl](phenyl)methanone
-
IC50 is 0.00051 mM
[4-(allyloxy)phenyl](3-phenyloxiran-2-yl)methanone
-
IC50 is 0.00014 mM
[4-(bromomethyl)phenyl][3-(2-naphthyl)oxiran-2-yl]methanone
-
IC50 is 0.00016 mM
1-(1-acetypiperidin-4-yl)-3-adamantanylurea
-
1-(1-acetypiperidin-4-yl)-3-adamantanylurea
APAU, a tight binding inhibitor of enzyme sEH
1-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]-3-tricyclo[3.3.1.13,7]dec-1-ylurea
-
1-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]-3-tricyclo[3.3.1.13,7]dec-1-ylurea
-
-
12-(3-adamantan-1-yl-ureido)-dodecanoic acid
-
12-(3-adamantan-1-yl-ureido)-dodecanoic acid
AUDA
12-(3-adamantan-1-yl-ureido)dodecanoic acid
-
12-(3-adamantan-1-yl-ureido)dodecanoic acid
AUDA
12-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]dodecanoic acid
-
12-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]dodecanoic acid
-
-
12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid
AUDA
12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid
i.e. AUDA
5,7-dihydroxy-2-(2-hydroxy-6-methoxyphenyl)-4H-1-benzopyran-4-one
65.12% inhibition
5,7-dihydroxy-2-(2-hydroxy-6-methoxyphenyl)-4H-1-benzopyran-4-one
76.33% inhibition
AUDA
-
AUDA
i.e. 12-(3-adamantan-1-ylureido)dodecanoic acid
N,N'-dicyclohexylurea
-
N,N'-dicyclohexylurea
DCU
N-adamantan-1-yl-N'-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]urea
-
N-adamantan-1-yl-N'-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]urea
AEPU, a tight binding inhibitor of enzyme sEH
N-cyclohexyl-N'-(iodophenyl)urea
-
N-cyclohexyl-N'-(iodophenyl)urea
binding structure at the C-terminus
trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid
-
trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid
i.e. t-AUCB
trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid
-
trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid
t-AUCB
trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid
t-AUCB, a tight binding inhibitor of enzyme sEH
1,3-dicyclohexyl urea
-
-
1,3-dicyclohexyl urea
-
complete inhibition at 0.1 mM
1,3-dicyclohexyl urea
-
0.1 mM, complete inhibition of epoxide hydrolase activity, no inhibition of phosphatase activity
1-cyclohexyl-3-dodecyl urea
-
-
1-cyclohexyl-3-dodecyl urea
-
complete inhibition at 0.1 mM
1-cyclohexyl-3-dodecyl urea
-
0.1 mM, complete inhibition of epoxide hydrolase activity, no inhibition of phosphatase activity
1-cyclohexyl-3-dodecyl urea
-
i.e. CDU
1-cyclohexyl-3-ethyl urea
-
-
1-cyclohexyl-3-ethyl urea
-
54% inhibition at 0.1 mM
1-cyclohexyl-3-ethyl urea
-
0.1 mM, 54% inhibition of epoxide hydrolase activity, no inhibition of phosphatase activity
1-cyclohexyl-3-hexyl urea
-
-
1-cyclohexyl-3-hexyl urea
-
complete inhibition at 0.1 mM
1-cyclohexyl-3-hexyl urea
-
0.1 mM, complete inhibition of epoxide hydrolase activity, 4% inhibition of phosphatase activity
12-(3-adamantan-1-yl-ureido)-dodecanoic acid
-
-
12-(3-adamantan-1-yl-ureido)-dodecanoic acid
-
i.e. AUDA
12-(3-adamantan-1-yl-ureido)dodecanoic acid
-
-
12-(3-adamantan-1-yl-ureido)dodecanoic acid
-
potent transition state inhibitor of sEH
2-Bromo-4'-nitroacetophenone
-
-
2-Bromo-4'-nitroacetophenone
-
complete inhibition at 1 mM at pH 7.4
4-Phenylchalcone oxide
-
-
4-Phenylchalcone oxide
-
complete inhibition at 0.1 mM, competitive substrate
Ca2+
-
25% inhibition at 1 mM
Ca2+
-
inhibition of Mg2+-dependent acrtivity
Cd2+
-
-
Cd2+
-
complete inhibition at 1 mM
Cd2+
-
inhibition of phosphatase activity and epoxide hydrolase activity
Chalcone oxide
-
0.1 mM, 80% inhibition of epoxide hydrolase activity, no inhibition of phosphatase activity
Chalcone oxide
-
80% inhibition at 0.1 mM, competitive substrate
Co2+
-
30% inhibition at 1 mM
Co2+
-
inhibition of Mg2+-dependent acrtivity
Cu2+
-
-
Cu2+
-
nearly complete inhibition at 1 mM
Cu2+
-
inhibition of phosphatase activity and epoxide hydrolase activity
Cyclohexene oxide
-
-
Cyclohexene oxide
-
weak inhibitor
Fe2+
-
20% inhibition at 1 mM
Fe2+
-
inhibition of Mg2+-dependent acrtivity
Fe3+
-
15% inhibition at 1 mM
Fe3+
-
inhibition of Mg2+-dependent acrtivity
Hg2+
-
-
Hg2+
-
complete inhibition at 1 mM
Hg2+
-
inhibition of phosphatase activity and epoxide hydrolase activity
Mn2+
-
30% inhibition at 1 mM
Mn2+
-
inhibition of Mg2+-dependent acrtivity
N-cycloheptyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
-
N-cycloheptyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
-
90% inhibition at 200 nM
Pb2+
-
20% inhibition at 1 mM
Pb2+
-
inhibition of Mg2+-dependent acrtivity
trichloropropene oxide
-
-
trichloropropene oxide
-
weak inhibitor
Zn2+
-
-
Zn2+
-
complete inhibition at 1 mM
Zn2+
-
inhibition of phosphatase activity and epoxide hydrolase activity
Zn2+
-
noncompetitive, inhibits epoxide hydrolase and phosphatase activities, allosteric mechanism
[3-(2-naphthyl)oxiran-2-yl](phenyl)methanone
-
IC50 is 0.0002 mM
[3-(2-naphthyl)oxiran-2-yl](phenyl)methanone
-
IC50 is 0.00085 mM
additional information
design and synthesis of a series of potent nicotinamide inhibitors of soluble epoxides hydrolase, structure-guided optimization, overview
-
additional information
-
design and synthesis of a series of potent nicotinamide inhibitors of soluble epoxides hydrolase, structure-guided optimization, overview
-
additional information
evaluation of spirocyclic secondary amine-derived trisubstituted ureas as highly potent, bioavailable and selective soluble epoxide hydrolase inhibitors, overview
-
additional information
inhibitor screening and structure-function analysis, overview
-
additional information
Inhibitors of human sEH are effective drug candidates for the treatment of cardiovascular diseases, inhibitor screening with recombinant enzyme, overview
-
additional information
-
Inhibitors of human sEH are effective drug candidates for the treatment of cardiovascular diseases, inhibitor screening with recombinant enzyme, overview
-
additional information
sEH inhibitors are developed to enhance the cardiovascular actions of epoxyeicosatrienoic acids, treatment potentials, cardiovascular therapeutic effects, antihypertensive effects, kidney-protective properties, cardiac-protective properties, and protection against ischaemic stroke and vascular disease of sEH inhibitors, overview
-
additional information
synthesis and structure-based optimization of arylamides sEH inhibitors based on the solid-state costructure of N-(3,3-diphenyl-propyl)-nicotinamide, overview. Assessment of inhibitor stability in liver microsomes, overview
-
additional information
-
synthesis and structure-based optimization of arylamides sEH inhibitors based on the solid-state costructure of N-(3,3-diphenyl-propyl)-nicotinamide, overview. Assessment of inhibitor stability in liver microsomes, overview
-
additional information
design and synthesis of three substituted cyclopropyl urea derivatives as strong sEH inhibitors using X-ray co-crystal structure of sEH catalytic domain and 3-[4-[(1-[[(1S,2R)-2-phenylcyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid, overview. cis-Configuration together with a phenyl group result in increased human and rat sEH inhibitory activity with minimal species difference
-
additional information
-
design and synthesis of three substituted cyclopropyl urea derivatives as strong sEH inhibitors using X-ray co-crystal structure of sEH catalytic domain and 3-[4-[(1-[[(1S,2R)-2-phenylcyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid, overview. cis-Configuration together with a phenyl group result in increased human and rat sEH inhibitory activity with minimal species difference
-
additional information
identification of N-ethylmethylamine as a scaffold for inhibitors of soluble epoxide hydrolase by crystallographic fragment screening, overview. N-Ethylmethylamine is identified as a promising scaffold that forms hydrogen bonds with the catalytic residues of sEH, Asp335, Tyr383, and Tyr466. Compounds containing this scaffold are selected from a chemical library and evaluated for inhibitory potency. Enzyme-inhibitor interaction analysis
-
additional information
in vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors, identification of ligands structures by mass spectrometry and NMR spectroscopy, overview
-
additional information
-
in vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors, identification of ligands structures by mass spectrometry and NMR spectroscopy, overview
-
additional information
inhibitory potency and metabolic stability of adamantyl ureas and diureas bearing substituents in bridgehead positions of adamantane and/or spacers between urea groups and adamantane group. Comparison of the effects of the inhibitors on human, rat, and murine enzymes, overview
-
additional information
-
inhibitory potency and metabolic stability of adamantyl ureas and diureas bearing substituents in bridgehead positions of adamantane and/or spacers between urea groups and adamantane group. Comparison of the effects of the inhibitors on human, rat, and murine enzymes, overview
-
additional information
interaction of the enzyme with anthocyanin derivatives, molecular docking study, molecular dynamics study, overview. The molecular docking study shows a small pocket next to the active site, which is thought to be a common allosteric site, which probably is the binding site of noncompetitive and mixed inhibitors. Moreover, the anthocyanin core is located at the hydrophobic position of the inner allosteric site. The sugar moiety interacts with amino acid residues on the outside of the allosteric site. In particular, the hydroxyl group in the sugar of the compounds is bonded with the nitrogen of Trp525. The amino acid residue may play a key role in forming hydrogen bonds with the anthocyanin glycoside. Additionally, the molecular dynamics study confirms that anthocyanin 4 can form hydrogen bonds with this residue for 10 ns
-
additional information
N-benzylbenzamides are a merged scaffold for orally available dual soluble epoxide hydrolase/peroxisome proliferator-activated receptor gamma modulators, synthesis and inhibitory potencies, overview. Design of dual-target ligands that target soluble epoxide hydrolase (sEH) and the peroxisome proliferator-activated receptor type gamma (PPARgamma). Simultaneous modulation of sEH and PPARgamma can improve diabetic conditions and hypertension at once
-
additional information
-
N-benzylbenzamides are a merged scaffold for orally available dual soluble epoxide hydrolase/peroxisome proliferator-activated receptor gamma modulators, synthesis and inhibitory potencies, overview. Design of dual-target ligands that target soluble epoxide hydrolase (sEH) and the peroxisome proliferator-activated receptor type gamma (PPARgamma). Simultaneous modulation of sEH and PPARgamma can improve diabetic conditions and hypertension at once
-
additional information
phytochemical constituents from Scutellaria baicalensis in soluble epoxide hydrolase inhibition: kinetics and interaction mechanism merged with simulations, overview. Extracts of Scutellaria baicalensis are separated, resulting in the isolation of thirty compounds, including six lignins, sixteen flavones, and five amides. Their structures are determined on the basis of 1H and 13C NMR and MS spectra. Molecular docking studies and inhibition mechanisms of (2E,4E)-5-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)penta-2,4-dienamide, (2E)-5-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)pent-2-enamide, and (2E,6E)-7-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)hepta-2,6-dienamide against sEH
-
additional information
structural analysis of enzyme-inhibitor interactions, molecular interaction calculations, active site binding analysis, molecular docking, overview
-
additional information
synthesis and properties of 1-(R-adamant-1-yl)-3-(1-propionylpiperidin-4-yl)ureas and 4-({4-[3-(R-adamant-1-yl)ureido]cyclohexyl}oxy)benzoic acids, efficient target-oriented human soluble epoxide hydrolase inhibitors, overview. Determination of solubilities in water, lipophilicity coefficients, and melting points
-
additional information
synthesis and properties of symmetrical N,N-bis(R-adamantan-1-yl)ureas as target-oriented soluble epoxide hydrolase (sEH) inhibitors, structure is confirmed by 1H NMR and mass spectra and elemental analyses
-
additional information
synthesis of series of targetx02oriented competitive inhibitors of human soluble epoxide hydrolase. Molecular modeling reveals that the high inhibitory activity of this series of compounds is achieved by a unique mode of the binding to the active site of the enzyme, molecular docking study
-
additional information
-
IC50 values with different substrates and structure-activity relationships of enzyme inhibitors, development of an in vitro inhibition assay using fluorogenic substrates
-
additional information
-
inhibition mechanism of sulfates, sulfonates, and phosphonates
-
additional information
-
irreversible inhibition mechanism of chalcone oxide derivatives, quantitative structure-activity relationship, QSAR, overview
-
additional information
-
metal chelators like 1,10-phenanthroline, 1,7-phenanthroline, EDTA, EGTA, and dipicolinic acid preserve enzyme activity in presence of metal ions
-
additional information
-
most enzyme inhibitors do not influence the enzyme's phosphatase activity
-
additional information
-
N-acetyl imidazole, N-bromosuccimide, cyclohexandione, acetaldehyde/borohydride and benzaldehyde/borohydride are poor inhibitors, no inhibition by PMSF and diisopropyl fluorophosphate, no inhibition by amino-, guanido-, or activated serine-selective reagents
-
additional information
-
poor or no inhibition by tartaric acid, sodium fluoride, and sodium molybdate
-
additional information
-
QSAR and classification in a seven-discriptor model of enzyme inhibition by 348 urea-like compounds, IC50 ranging from 60 nM to 0.5 mM, overview
-
additional information
-
the herb extract prepared from Sophora flavescens root afford the strongest inhibition of sEH with an IC50 of 0.00207 mg/ml, this is followed by other three extracts derived from the rhizome of Glycyrrhiza uralensis (IC50 0.0071 mg/ml), the root of Bupleurum chinense (IC50 0.00956 mg/ml), and the whole weed of Swertia pseudochinensis (IC50 0.01131 mg/ml)
-
additional information
-
no inhibition by sunitinib, another vascular endothelial growth factor receptor. The classical sEH inhibitors do not cause growth inhibition and apoptosis and do not synergize with sorafenib
-
additional information
-
sEH inhibition has antihypertensive and antiinflammatory actions, presumably due to the increased bioavailability of endogenous EETs and other epoxylipids, and several potent sEH inhibitors are developed and tested in animal models of cardiovascular disease including hypertension, cardiac hypertrophy, and ischemia/reperfusion injury
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acute Coronary Syndrome
Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome.
Acute Coronary Syndrome
Effects of soluble epoxide hydrolase inhibitor on the expression of fatty acid synthase in peripheral blood mononuclear cell in patients with acute coronary syndrome.
Acute Coronary Syndrome
[Effects of soluble epoxide hydrolase inhibitors on the expression of fatty acid synthase in peripheral blood mononuclear cell of patients and inflammatory response with acute coronary syndrome].
Acute Kidney Injury
Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery.
Acute Kidney Injury
Change in soluble epoxide hydrolase (sEH) during cisplatin-induced acute renal failure in mice.
Acute Kidney Injury
Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury.
Acute Lung Injury
Deletion of soluble epoxide hydrolase attenuates mice Hyperoxic acute lung injury.
Acute Lung Injury
Effect of Soluble Epoxide Hydrolase in Hyperoxic Acute Lung Injury in Mice.
Acute Lung Injury
Effects of a Soluble Epoxide Hydrolase Inhibitor on Lipopolysaccharide-Induced Acute Lung Injury in Mice.
Acute Lung Injury
Epoxyeicosatrienoic acids inhibit the activation of NLRP3 inflammasome in murine macrophages.
Acute Lung Injury
Soluble Epoxide Hydrolase Inhibitor Attenuates Lipopolysaccharide-Induced Acute Lung Injury and Improves Survival in Mice.
Adenocarcinoma
Xenobiotic metabolising enzyme expression in colonic neoplasia.
Adenoma
Epoxide hydrolase polymorphisms, cigarette smoking and risk of colorectal adenoma in the Nurses' Health Study and the Health Professionals Follow-up Study.
Adenoma
Levels of cytochrome P-450, steroidogenesis and microsomal and cytosolic epoxide hydrolases in normal human adrenal tissue and corresponding tumors.
Adenoma
Xenobiotic metabolising enzyme expression in colonic neoplasia.
Albuminuria
Association of rs11780592 Polymorphism in the Human Soluble Epoxide Hydrolase Gene (EPHX2) with Oxidized LDL and Mortality in Patients with Diabetic Chronic Kidney Disease.
Albuminuria
Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease.
Alveolar Bone Loss
Soluble epoxide hydrolase pharmacological inhibition decreases alveolar bone loss by modulating host inflammatory response, RANK-related signaling, ER stress and apoptosis.
Alzheimer Disease
14,15-epoxyeicosatrienoic acid alleviates pathology in a mouse model of Alzheimer's disease.
Alzheimer Disease
An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease.
Alzheimer Disease
Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer's disease.
Alzheimer Disease
Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer's disease.
Alzheimer Disease
PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP.
Alzheimer Disease
Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease.
Anemia, Aplastic
Glutathione S transferase theta 1 gene (GSTT1) null genotype is associated with an increased risk for acquired aplastic anemia in children.
Aneurysm
Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins.
Aortic Aneurysm, Abdominal
Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia.
arachidonate 12-lipoxygenase deficiency
Inhibition of 12/15-Lipoxygenase Reduces Renal Inflammation and Injury in Streptozotocin-Induced Diabetic Mice.
Arrhythmias, Cardiac
Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease.
Arthralgia
Targeting Soluble Epoxide Hydrolase and Cyclooxygenases Enhance Joint Pain Control, Stimulate Collagen Synthesis, and Protect Chondrocytes From Cytokine-Induced Apoptosis.
Arthritis
Peripheral soluble epoxide hydrolase inhibition reduces hypernociception and inflammation in albumin-induced arthritis in temporomandibular joint of rats.
Arthritis
Soluble epoxide hydrolase inhibitor, TPPU, increases regulatory T cells pathway in an arthritis model.
Asthma
Elevated faecal 12,13-diHOME concentration in neonates at high risk for asthma is produced by gut bacteria and impedes immune tolerance.
Asthma
Inhibition of soluble epoxide hydrolase attenuates airway remodeling in a chronic asthma model.
Asthma
Interactions between polycyclic aromatic hydrocarbons and epoxide hydrolase 1 play roles in asthma.
Asthma
Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma.
Atherosclerosis
A potent soluble epoxide hydrolase inhibitor, t-AUCB, modulates cholesterol balance and oxidized low density lipoprotein metabolism in adipocytes in vitro.
Atherosclerosis
Association of rs11780592 Polymorphism in the Human Soluble Epoxide Hydrolase Gene (EPHX2) with Oxidized LDL and Mortality in Patients with Diabetic Chronic Kidney Disease.
Atherosclerosis
Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.
Atherosclerosis
Discovery of novel drug candidates for inhibition of soluble epoxide hydrolase of arachidonic acid cascade pathway implicated in atherosclerosis.
Atherosclerosis
Effects of soluble epoxide hydrolase inhibitor on the expression of fatty acid synthase in peripheral blood mononuclear cell in patients with acute coronary syndrome.
Atherosclerosis
Endothelial Nox4 dysfunction aggravates atherosclerosis by inducing endoplasmic reticulum stress and soluble epoxide hydrolase.
Atherosclerosis
Endothelial Nox4-based NADPH oxidase regulates atherosclerosis via soluble epoxide hydrolase.
Atherosclerosis
Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study.
Atherosclerosis
Inhibition of soluble epoxide hydrolase alleviated atherosclerosis by reducing monocyte infiltration in Ldlr(-/-) mice.
Atherosclerosis
Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia.
Atherosclerosis
Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis.
Atherosclerosis
Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins.
Atherosclerosis
Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking.
Atherosclerosis
Soluble epoxide hydrolase in atherosclerosis.
Atherosclerosis
Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model.
Atherosclerosis
Soluble epoxide hydrolase is involved in the development of atherosclerosis and arterial neointima formation by regulating smooth muscle cell migration.
Atherosclerosis
The phosphatase activity of soluble epoxide hydrolase regulates ATP-binding cassette transporter-A1-dependent cholesterol efflux.
Atherosclerosis
The soluble epoxide hydrolase determines cholesterol homeostasis by regulating AMPK and SREBP activity.
Atherosclerosis
The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke.
Atrial Fibrillation
Molecular Mechanisms and New Treatment Paradigm for Atrial Fibrillation.
Atrial Fibrillation
Variations in the human soluble epoxide hydrolase gene and recurrence of atrial fibrillation after catheter ablation.
Bone Resorption
Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption.
Brain Edema
Soluble Epoxide Hydrolase in Hydrocephalus, Cerebral Edema, and Vascular Inflammation After Subarachnoid Hemorrhage.
Brain Injuries
Genetic deletion or pharmacological inhibition of soluble epoxide hydrolase reduces brain damage and attenuates neuroinflammation after intracerebral hemorrhage.
Brain Injuries
Missense Genetic Polymorphisms of Microsomal (EPHX1) and Soluble Epoxide Hydrolase (EPHX2) and Their Relation to the Risk of Large Artery Atherosclerotic Ischemic Stroke in a Turkish Population.
Brain Injuries
Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury.
Brain Injuries
Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy.
Brain Injuries
Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.
Brain Injuries
Soluble epoxide hydrolase modulates immune responses in activated astrocytes involving regulation of STAT3 activity.
Brain Injuries, Traumatic
Altered behavioral phenotypes in soluble epoxide hydrolase knockout mice: Effects of traumatic brain injury.
Brain Injuries, Traumatic
Deletion or inhibition of soluble epoxide hydrolase protects against brain damage and reduces microglia-mediated neuroinflammation in traumatic brain injury.
Brain Ischemia
Role of soluble epoxide hydrolase in the sex-specific vascular response to cerebral ischemia.
Brain Ischemia
Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.
Brain Ischemia
Soluble epoxide hydrolase gene deletion improves blood flow and reduces infarct size after cerebral ischemia in reproductively senescent female mice.
Brain Ischemia
Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia.
Brain Ischemia
Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia.
Brain Ischemia
Soluble epoxide hydrolase inhibition provides multi-target therapeutic effects in rats after spinal cord injury.
Brain Ischemia
Soluble epoxide hydrolase inhibitor enhances synaptic neurotransmission and plasticity in mouse prefrontal cortex.
Brain Ischemia
Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia.
Brain Ischemia
Soluble Epoxide Inhibition Is Protective Against Cerebral Ischemia via Vascular and Neural Protection.
Breast Neoplasms
Breast cancer: role of polymorphisms in biotransformation enzymes.
Breast Neoplasms
Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer.
Breast Neoplasms
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Breast Neoplasms
Peroxisome proliferator-activated receptor ? (PPAR?)-cytochrome P450 epoxygenases-soluble epoxide hydrolase axis in ER?+?PR?+?HER2- breast cancer.
Breast Neoplasms
The Consequences of Soluble Epoxide Hydrolase Deletion on Tumorigenesis and Metastasis in a Mouse Model of Breast Cancer.
Breast Neoplasms
Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study.
Carcinogenesis
Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy.
Carcinogenesis
Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-Kras(G12D) -LSL-Trp53(R172H) -Pdx1-Cre mice.
Carcinogenesis
Average-12.9 chromosome imbalances coupling with 15 differential expression genes possibly involved in the carcinogenesis, progression and metastasis of supraglottic laryngeal squamous cell cancer.
Carcinogenesis
Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens.
Carcinogenesis
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.
Carcinogenesis
Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis.
Carcinogenesis
Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis.
Carcinogenesis
Immunohistochemical study of epoxide hydrolase during experimental liver carcinogenesis.
Carcinogenesis
Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG12D/Pdx-1-Cre Mice.
Carcinogenesis
Modulation of carcinogen metabolizing enzymes by chromanone A; a new chromone derivative from algicolous marine fungus Penicillium sp.
Carcinogenesis
Proinflammatory enzyme soluble epoxide hydrolase bridges obesity to colonic inflammation and potential carcinogenesis.
Carcinogenesis
Quercetin sensitizes glioblastoma to t-AUCB by dual inhibition of Hsp27 and COX-2 in vitro and in vivo.
Carcinogenesis
Regulation of microsomal, xenobiotic epoxide hydrolase messenger RNA in persistent hepatocyte nodules and hepatomas induced by chemical carcinogens.
Carcinogenesis
Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice.
Carcinogenesis
The Consequences of Soluble Epoxide Hydrolase Deletion on Tumorigenesis and Metastasis in a Mouse Model of Breast Cancer.
Carcinoma
A long-wavelength, fluorogenic probe for epoxide hydrolase: 7-(2-(oxiran-2-yl)ethoxy) resorufin.
Carcinoma
Altered patterns of cutaneous xenobiotic metabolism in UVB-induced squamous cell carcinoma in SKH-1 hairless mice.
Carcinoma
Cytochrome P450 expression in oesophageal cancer.
Carcinoma
Epoxide hydrolase Tyr113His polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma in population of North China.
Carcinoma
Identification of EPHX2 and RMI2 as two novel key genes in cervical squamous cell carcinoma by an integrated bioinformatic analysis.
Carcinoma
Immunohistochemical assessment of human microsomal epoxide hydrolase in primary and secondary liver neoplasm: a quantitative approach.
Carcinoma
Inhibition of mutant Kras(G12D)-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Carcinoma
Inhibition of Pancreatic Carcinoma Growth Through Enhancing ?-3 Epoxy Polyunsaturated Fatty Acid Profile by Inhibition of Soluble Epoxide Hydrolase.
Carcinoma
Levels of cytochrome P-450, steroidogenesis and microsomal and cytosolic epoxide hydrolases in normal human adrenal tissue and corresponding tumors.
Carcinoma
Monooxygenase, epoxide hydrolase, and glutathione-S-transferase activities in human lung. Variation between groups of bronchogenic carcinoma and non-cancer patients and interindividual differences.
Carcinoma
SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan.
Carcinoma, Bronchogenic
Monooxygenase, epoxide hydrolase, and glutathione-S-transferase activities in human lung. Variation between groups of bronchogenic carcinoma and non-cancer patients and interindividual differences.
Carcinoma, Hepatocellular
Acquired risk factors and susceptibility to environmental toxicants.
Carcinoma, Hepatocellular
Detection of epoxide hydrolase in rat hepatoma cell lines and primary rat liver cells by immunoblotting.
Carcinoma, Hepatocellular
Diethylstilbestrol potentiates and testosterone antagonizes the action of 3-methylcholanthrene on benzo(a)pyrene metabolism in Hep G2 cells.
Carcinoma, Hepatocellular
Effects of various enzyme inducers on monooxygenase, glutathione S-transferase and epoxide hydrolase activities in cultured hepatoma cells.
Carcinoma, Hepatocellular
Epoxide hydrolase: a marker for experimental hepatocarcinogenesis.
Carcinoma, Hepatocellular
Evaluation of a human hepatoma cell line as a target cell in genetic toxicology.
Carcinoma, Hepatocellular
Expression of arylhydrocarbon hydroxylase, epoxide hydrolases, glutathione S-transferase and UDP-glucuronosyltransferases in H5-6 hepatoma cells.
Carcinoma, Hepatocellular
Expression of microsomal and cytosolic epoxide hydrolases in cultured rat hepatocytes and hepatoma cell lines.
Carcinoma, Hepatocellular
Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Immunohistochemical assessment of human microsomal epoxide hydrolase in primary and secondary liver neoplasm: a quantitative approach.
Carcinoma, Hepatocellular
Induction of epoxide hydrolase in cultured rat hepatocytes and hepatoma cell lines.
Carcinoma, Hepatocellular
LINC00205 modulates the expression of EPHX1 through the inhibition of miR-184 in hepatocellular carcinoma as a ceRNA.
Carcinoma, Hepatocellular
Quantiation of epoxide hydrolase released from hyperplastic nodule and hepatoma microsomes.
Carcinoma, Hepatocellular
Regulation of microsomal, xenobiotic epoxide hydrolase messenger RNA in persistent hepatocyte nodules and hepatomas induced by chemical carcinogens.
Carcinoma, Hepatocellular
Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression.
Carcinoma, Hepatocellular
Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury.
Carcinoma, Hepatocellular
Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase.
Carcinoma, Hepatocellular
Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1.
Carcinoma, Hepatocellular
The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma.
Carcinoma, Hepatocellular
The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol.
Carcinoma, Hepatocellular
[Study on epoxide hydrolase in rat hyperplastic nodule and hepatoma during chemical hepatocarcinogenesis induced by 2-acetylaminofluorene (author's transl)]
Carcinoma, Squamous Cell
Altered patterns of cutaneous xenobiotic metabolism in UVB-induced squamous cell carcinoma in SKH-1 hairless mice.
Carcinoma, Squamous Cell
Identification of EPHX2 and RMI2 as two novel key genes in cervical squamous cell carcinoma by an integrated bioinformatic analysis.
Carcinoma, Transitional Cell
SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan.
Cardio-Renal Syndrome
Soluble Epoxide Hydrolase Inhibition Prevents Experimental Type 4 Cardiorenal Syndrome.
Cardiomegaly
3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats.
Cardiomegaly
Activation of Peroxisome Proliferator-Activated Receptor ? Downregulates Soluble Epoxide Hydrolase in Cardiomyocytes.
Cardiomegaly
Buthionine sulfoximine, an inhibitor of glutathione biosynthesis, induces expression of soluble epoxide hydrolase and markers of cellular hypertrophy in a rat cardiomyoblast cell line: Roles of the NF-?B and MAPK signaling pathways.
Cardiomegaly
Cytochrome P450 epoxygenase metabolite, 14,15-EET, protects against isoproterenol-induced cellular hypertrophy in H9c2 rat cell line.
Cardiomegaly
Deletion of Soluble Epoxide Hydrolase Attenuates Cardiac Hypertrophy via Down-Regulation of Cardiac Fibroblasts-Derived Fibroblast Growth Factor-2.
Cardiomegaly
In vitro inhibitory effects of ethanol extract of Danshen (Salvia miltiorrhiza) and its components on the catalytic activity of soluble epoxide hydrolase.
Cardiomegaly
Inhibition of Soluble Epoxide Hydrolase Confers Cardioprotection and Prevents Cardiac Cytochrome P450 Induction by Benzo(a)pyrene.
Cardiomegaly
Linking an insect enzyme to hypertension: angiotensin II-epoxide hydrolase interactions.
Cardiomegaly
Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis.
Cardiomegaly
Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors.
Cardiomegaly
Soluble epoxide hydrolase inhibitor, TUPS, attenuates isoproterenol/angiotensin II-induced cardiac hypertrophy through mammalian target of rapamycin-mediated autophagy inhibition.
Cardiomegaly
Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy.
Cardiomegaly
Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy.
Cardiomegaly
The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophy.
Cardiomegaly
Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis.
Cardiomyopathies
Soluble epoxide hydrolase and ischemic cardiomyopathy.
Cardiomyopathies
Soluble epoxide hydrolase deficiency attenuates lipotoxic cardiomyopathy via upregulation of AMPK-mTORC mediated autophagy.
Cardiomyopathy, Dilated
Buthionine sulfoximine, an inhibitor of glutathione biosynthesis, induces expression of soluble epoxide hydrolase and markers of cellular hypertrophy in a rat cardiomyoblast cell line: Roles of the NF-?B and MAPK signaling pathways.
Cardiotoxicity
Chronic Doxorubicin Cardiotoxicity Modulates Cardiac Cytochrome P450-Mediated Arachidonic Acid Metabolism in Rats.
Cardiotoxicity
Deficiency of Soluble Epoxide Hydrolase Protects Cardiac Function Impaired by LPS-Induced Acute Inflammation.
Cardiotoxicity
The Role of Soluble Epoxide Hydrolase Enzyme on Daunorubicin-Mediated Cardiotoxicity.
Cardiovascular Diseases
15-deoxy-?12,14-Prostaglandin J2 inhibits human soluble epoxide hydrolase by a dual orthosteric and allosteric mechanism.
Cardiovascular Diseases
A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases.
Cardiovascular Diseases
Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat.
Cardiovascular Diseases
Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease.
Cardiovascular Diseases
Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome.
Cardiovascular Diseases
Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients.
Cardiovascular Diseases
Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced diabetes.
Cardiovascular Diseases
Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases.
Cardiovascular Diseases
Design and synthesis of dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors.
Cardiovascular Diseases
Design, Synthesis and Biological Activity of 4,6-disubstituted Pyridin-2(1H)-ones as Novel Inhibitors of Soluble Epoxide Hydrolase.
Cardiovascular Diseases
Discovery of soluble epoxide hydrolase inhibitors through DNA-encoded library technology (ELT).
Cardiovascular Diseases
Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study.
Cardiovascular Diseases
Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans.
Cardiovascular Diseases
Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease.
Cardiovascular Diseases
In vitro and in silico investigation of anthocyanin derivatives as soluble epoxide hydrolase inhibitors.
Cardiovascular Diseases
In Vitro and In Silico Studies of Soluble Epoxide Hydrolase Inhibitors from the Roots of Lycopus lucidus.
Cardiovascular Diseases
In vitro inhibitory effects of ethanol extract of Danshen (Salvia miltiorrhiza) and its components on the catalytic activity of soluble epoxide hydrolase.
Cardiovascular Diseases
Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis.
Cardiovascular Diseases
No impact of soluble epoxide hydrolase rs4149243, rs2234914 and rs751142 genetic variants on the development of type II diabetes and its hypertensive complication among Jordanian patients.
Cardiovascular Diseases
Novel Role of Soluble Epoxide Hydrolase in Regulating Cholesterol in Mammalian Cells.
Cardiovascular Diseases
Peroxisomal translocation of soluble epoxide hydrolase protects against ischemic stroke injury.
Cardiovascular Diseases
Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury.
Cardiovascular Diseases
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.
Cardiovascular Diseases
Soluble epoxide hydrolase inhibition modulates vascular remodeling.
Cardiovascular Diseases
Soluble Epoxide Hydrolase Inhibitors and Cardiovascular Diseases.
Cardiovascular Diseases
Soluble Epoxide Hydrolase Inhibitory Activity of Selaginellin Derivatives from Selaginella tamariscina.
Cardiovascular Diseases
Soluble epoxide hydrolase: a new target for cardioprotection.
Cardiovascular Diseases
Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.
Cardiovascular Diseases
The Anti-inflammatory Effect of Soluble Epoxide Hydrolase Inhibitor and 14, 15-EET in Kawasaki Disease Through PPAR?/STAT1 Signaling Pathway.
Cardiovascular Diseases
The left ventricle proteome differentiates middle-aged and old left ventricles in mice.
Cardiovascular Diseases
The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease.
Cardiovascular Diseases
The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension.
Cardiovascular Diseases
[Cardiovascular consequences of chronic kidney disease, impact of modulation of epoxyeicosatrienoic acids].
Carotid Artery Diseases
Association of rs11780592 Polymorphism in the Human Soluble Epoxide Hydrolase Gene (EPHX2) with Oxidized LDL and Mortality in Patients with Diabetic Chronic Kidney Disease.
Carotid Stenosis
Soluble epoxide hydrolase inhibition alleviated cognitive impairments via NRG1/ErbB4 signaling after chronic cerebral hypoperfusion induced by bilateral carotid artery stenosis in mice.
Cerebral Hemorrhage
Genetic deletion or pharmacological inhibition of soluble epoxide hydrolase reduces brain damage and attenuates neuroinflammation after intracerebral hemorrhage.
Cerebral Infarction
An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats.
Chorioamnionitis
Increased Soluble Epoxide Hydrolase in Human Gestational Tissues from Pregnancies Complicated by Acute Chorioamnionitis.
Chorioamnionitis
The anti-inflammatory role of placental Hofbauer cells is altered in patients with chorioamnionitis: Are CYP2C8 and soluble epoxide hydrolase involved in immunomodulation?
Colitis
Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis.
Colitis
Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice.
Colitis, Ulcerative
Increased epoxyeicosatrienoic acids may be part of a protective mechanism in human ulcerative colitis, with increased CYP2J2 and reduced soluble epoxide hydrolase expression.
Colonic Neoplasms
Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems.
Colonic Neoplasms
Microsomal epoxide hydrolase gene polymorphism and susceptibility to colon cancer.
Colonic Neoplasms
Synthesis, docking, cytotoxicity, and LTA4H inhibitory activity of new gingerol derivatives as potential colorectal cancer therapy.
Colorectal Neoplasms
Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population.
Colorectal Neoplasms
Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study.
Colorectal Neoplasms
Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer.
Coronary Artery Disease
Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease.
Coronary Artery Disease
Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking.
Coronary Disease
Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study.
Coronary Disease
Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes.
Coronary Disease
Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention.
Coronary Disease
[Effect of soluble epoxide hydrolase inhibitor on the function of endothelial progenitor cells in patients with coronary heart disease.]
Crohn Disease
Genetic polymorphisms in biotransformation enzymes in Crohn's disease: association with microsomal epoxide hydrolase.
Cystic Fibrosis
Active-Site Flexibility and Substrate Specificity in a Bacterial Virulence Factor: Crystallographic Snapshots of an Epoxide Hydrolase.
Cystic Fibrosis
Crystal structure of the cystic fibrosis transmembrane conductance regulator inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factor.
Cystic Fibrosis
Epoxide-Mediated CifR Repression of cif Gene Expression Utilizes Two Binding Sites in Pseudomonas aeruginosa.
Cystic Fibrosis
Pseudomonas aeruginosa Cif Defines a Distinct Class of ?/? Epoxide Hydrolases Utilizing a His/Tyr Ring-Opening Pair.
Cystic Fibrosis
Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediators.
Cysts
Inhibition of catalase and epoxide hydrolase by the renal cystogen 2-amino-4,5-diphenylthiazole and its metabolites.
Dehydration
Characterization of an Arabidopsis cDNA for a soluble epoxide hydrolase gene that is inducible by auxin and water stress.
Dementia
Antibody Protection against Long-Term Memory Loss Induced by Monomeric C-Reactive Protein in a Mouse Model of Dementia.
Diabetes Mellitus
Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.
Diabetes Mellitus
Mapping the genetic basis of diabetes mellitus in the Australian Burmese cat (Felis catus).
Diabetes Mellitus
Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus.
Diabetes Mellitus
Soluble Epoxide Hydrolase Blockade after Stroke Onset Protects Normal but Not Diabetic Mice.
Diabetes Mellitus
The Human Genetic Variants CYP2J2 rs2280275 and EPHX2 rs751141 and Risk of Diabetic Nephropathy in Egyptian Type 2 Diabetic Patients.
Diabetes Mellitus, Type 1
Epoxyeicosatrienoic acids and glucose homeostasis in mice and men.
Diabetes Mellitus, Type 1
Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus.
Diabetes Mellitus, Type 2
Altered bioavailability of epoxyeicosatrienoic acids is associated with conduit artery endothelial dysfunction in type 2 diabetic patients.
Diabetes Mellitus, Type 2
Association of EPHX2 R287Q Polymorphism with Diabetic Nephropathy in Chinese Type 2 Diabetic Patients.
Diabetes Mellitus, Type 2
Epoxyeicosatrienoic acids and glucose homeostasis in mice and men.
Diabetes Mellitus, Type 2
Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single- and Multiple-Dose Studies in Healthy Human Subjects.
Diabetes Mellitus, Type 2
Serum soluble epoxide hydrolase related oxylipins and major depression in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Soluble Epoxide Hydrolase Blockade after Stroke Onset Protects Normal but Not Diabetic Mice.
Diabetes Mellitus, Type 2
Soluble epoxide hydrolase inhibitor protects against blood-brain barrier dysfunction in a mouse model of type 2 diabetes via the AMPK/HO-1 pathway.
Diabetes Mellitus, Type 2
The Human Genetic Variants CYP2J2 rs2280275 and EPHX2 rs751141 and Risk of Diabetic Nephropathy in Egyptian Type 2 Diabetic Patients.
Diabetic Cardiomyopathies
Proteomic analysis of hearts from akita mice suggests that increases in soluble epoxide hydrolase and antioxidative programming are key changes in early stages of diabetic cardiomyopathy.
Diabetic Cardiomyopathies
Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy.
Diabetic Nephropathies
Association of EPHX2 R287Q Polymorphism with Diabetic Nephropathy in Chinese Type 2 Diabetic Patients.
Diabetic Nephropathies
Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.
Diabetic Nephropathies
Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice.
Diabetic Nephropathies
Inhibition of soluble epoxide hydrolase attenuates renal tubular mitochondrial dysfunction and ER stress by restoring autophagic flux in diabetic nephropathy.
Diabetic Nephropathies
Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats.
Diabetic Nephropathies
The Human Genetic Variants CYP2J2 rs2280275 and EPHX2 rs751141 and Risk of Diabetic Nephropathy in Egyptian Type 2 Diabetic Patients.
Diabetic Neuropathies
Simultaneous Target-Mediated Drug Disposition Model for Two Small-Molecule Compounds Competing for Their Pharmacological Target: Soluble Epoxide Hydrolase.
Diabetic Neuropathies
Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.
Diabetic Retinopathy
Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy.
Dyslipidemias
A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases.
Dyslipidemias
Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia.
Encephalomyelitis
A Soluble Epoxide Hydrolase Inhibitor, 1-TrifluoromethoxyPhenyl-3-(1-Propionylpiperidin-4-yl) Urea, Ameliorates Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis
Pharmacological inhibition of soluble epoxide hydrolase attenuates chronic experimental autoimmune encephalomyelitis by modulating inflammatory and anti-inflammatory pathways in an inflammasome-dependent and -independent manner.
Encephalomyelitis, Autoimmune, Experimental
A Soluble Epoxide Hydrolase Inhibitor, 1-TrifluoromethoxyPhenyl-3-(1-Propionylpiperidin-4-yl) Urea, Ameliorates Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Pharmacological inhibition of soluble epoxide hydrolase attenuates chronic experimental autoimmune encephalomyelitis by modulating inflammatory and anti-inflammatory pathways in an inflammasome-dependent and -independent manner.
Epilepsy
Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy.
Epilepsy, Temporal Lobe
Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy.
Erectile Dysfunction
Erectogenic and Aphrodisiac Property of Moringa oleifera: Involvement of Soluble Epoxide Hydrolase Enzyme.
Esophageal Neoplasms
Role of epoxide hydrolase 1 gene polymorphisms in esophageal cancer in a high-risk area in India.
Esophageal Squamous Cell Carcinoma
Epoxide hydrolase Tyr113His polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma in population of North China.
Essential Hypertension
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease.
Essential Hypertension
Relationship between EPHX2 gene polymorphisms and essential hypertension in Uygur, Kazakh, and Han.
Essential Hypertension
[Relationship between EPHX2 gene polymorphism and essential hypertension in Kazaks and Hans in Xinjiang].
Eye Diseases
Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future.
Fatty Liver
A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.
Fatty Liver
Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast.
Fetal Diseases
Phenytoin embryopathy: effect of epoxide hydrolase inhibitor on phenytoin exposure in utero in C57BL/6J mice.
Glioblastoma
?-secretase inhibitor DAPT sensitizes t-AUCB-induced apoptosis of human glioblastoma cells in vitro via blocking the p38 MAPK/MAPKAPK2/Hsp27 pathway.
Glomerulonephritis
In-vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathy.
Glomerulonephritis, IGA
Expression of soluble epoxide hydrolase in renal tubular epithelial cells regulates macrophage infiltration and polarization in IgA nephropathy.
Glomerulonephritis, IGA
In-vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathy.
Glucose Intolerance
6D.05: ENDOTHELIAL DYSFUNCTION IN ANIMAL MODELS OF GLUCOSE INTOLERANCE AND DIABETES IS ACCOMPANIED BY DIFFERENT EXPRESSION OF KEY ENZYMES OF EPOXYEICOSATRIENOIC ACIDS PATHWAY.
Glucose Intolerance
Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis.
Hearing Loss
[Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients from Yakutia].
Heart Arrest
Neurologic effects of short-term treatment with a soluble epoxide hydrolase inhibitor after cardiac arrest in pediatric swine.
Heart Arrest
Single administration of soluble epoxide hydrolase inhibitor suppresses neuroinflammation and improves neuronal damage after cardiac arrest in mice.
Heart Arrest
Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation.
Heart Failure
A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases.
Heart Failure
A novel dual PPAR-? agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes.
Heart Failure
Buthionine sulfoximine, an inhibitor of glutathione biosynthesis, induces expression of soluble epoxide hydrolase and markers of cellular hypertrophy in a rat cardiomyoblast cell line: Roles of the NF-?B and MAPK signaling pathways.
Heart Failure
Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
Heart Failure
Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats.
Heart Failure
Evaluation of the Effects of Urotensin II and Soluble Epoxide Hydrolase Inhibitor on Skin Microvessel Tone in Healthy Controls and Heart Failure Patients.
Heart Failure
Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
Heart Failure
Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula.
Heart Failure
NADPH Oxidase 4 Regulates Inflammation in Ischemic Heart Failure: Role of Soluble Epoxide Hydrolase.
Heart Failure
Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats.
Heart Failure
Sex-linked differences in the mortality in Ren-2 transgenic hypertensive rats with aorto-caval fistula: effects of treatment with angiotensin converting enzyme alone and combined with inhibitor of soluble epoxide hydrolase.
Heart Failure
Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure.
Heart Failure
Soluble Epoxide Hydrolase Inhibitors and Heart Failure.
Heart Failure
Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease.
HELLP Syndrome
A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia.
Hepatitis B
Acquired risk factors and susceptibility to environmental toxicants.
Hydrocephalus
Soluble Epoxide Hydrolase in Hydrocephalus, Cerebral Edema, and Vascular Inflammation After Subarachnoid Hemorrhage.
Hyperalgesia
Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain.
Hyperalgesia
Soluble epoxide hydrolase inhibitor trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea prevents hyperalgesia through regulating NLRC4 inflammasome-related pro-inflammatory and anti-inflammatory signaling pathways in the lipopolysaccharide-induced pain mouse model.
Hyperalgesia
Soluble epoxide hydrolase limits mechanical hyperalgesia during inflammation.
Hyperalgesia
The oxidized linoleic acid metabolite 12,13-DiHOME mediates thermal hyperalgesia during inflammatory pain.
Hypercholesterolemia
Evidence for the role of EPHX2 gene variants in anorexia nervosa.
Hyperemia
Deletion of Soluble Epoxide Hydrolase Enhances Coronary Reactive Hyperemia in Isolated Mouse Heart: Role of Oxylipins and PPAR?.
Hyperemia
Effect of Soluble Epoxide Hydrolase on the Modulation of Coronary Reactive Hyperemia: Role of Oxylipins and PPAR?.
Hyperemia
Reduced coronary reactive hyperemia in mice was reversed by the soluble epoxide hydrolase inhibitor (t-AUCB): Role of adenosine A2A receptor and plasma oxylipins.
Hyperemia
Vascular Endothelial Over-Expression of Human Soluble Epoxide Hydrolase (Tie2-sEH Tr) Attenuates Coronary Reactive Hyperemia in Mice: Role of Oxylipins and ?-Hydroxylases.
Hyperglycemia
Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis.
Hyperglycemia
Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia.
Hyperlipoproteinemia Type II
Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred.
Hypersensitivity
Anticonvulsant hypersensitivity syndrome with an epoxide hydrolase defect.
Hypersensitivity
Carbamazepine hypersensitivity syndrome triggered by a human herpes virus reactivation in a genetically predisposed patient.
Hypertension
1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.
Hypertension
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
Hypertension
1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), a soluble epoxide hydrolase inhibitor, lowers L-NAME-induced hypertension through suppression of angiotensin-converting enzyme in rats.
Hypertension
15-deoxy-?12,14-Prostaglandin J2 inhibits human soluble epoxide hydrolase by a dual orthosteric and allosteric mechanism.
Hypertension
A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases.
Hypertension
An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.
Hypertension
Anti-inflammatory Effects of ?-3 Polyunsaturated Fatty Acids and Soluble Epoxide Hydrolase Inhibitors in Angiotensin-II-Dependent Hypertension.
Hypertension
Application of Silver Nanoparticles in the Multicomponent Reaction Domain: A Combined Catalytic Reduction Methodology to Efficiently Access Potential Hypertension or Inflammation Inhibitors.
Hypertension
Association of Epoxide Hydrolase 2 Gene Arg287Gln with the Risk for Primary Hypertension in Chinese.
Hypertension
Association of rs11780592 Polymorphism in the Human Soluble Epoxide Hydrolase Gene (EPHX2) with Oxidized LDL and Mortality in Patients with Diabetic Chronic Kidney Disease.
Hypertension
Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.
Hypertension
Design, Synthesis and Biological Activity of 4,6-disubstituted Pyridin-2(1H)-ones as Novel Inhibitors of Soluble Epoxide Hydrolase.
Hypertension
Design, synthesis and biological evaluation of 4-benzamidobenzoic Acid hydrazide derivatives as novel soluble epoxide hydrolase inhibitors.
Hypertension
Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase.
Hypertension
Development of an online SPE-LC-MS-based assay using endogenous substrate for investigation of soluble epoxide hydrolase (sEH) inhibitors.
Hypertension
Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats.
Hypertension
Discovery of 2,8-diazaspiro[4.5]decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension.
Hypertension
Discovery of enantioselectivity of urea inhibitors of soluble epoxide hydrolase.
Hypertension
Discovery of potent non-urea inhibitors of soluble epoxide hydrolase.
Hypertension
Early postnatal treatment with soluble epoxide hydrolase inhibitor or 15-deoxy-?(12,14)-prostagandin J2 prevents prenatal dexamethasone and postnatal high saturated fat diet induced programmed hypertension in adult rat offspring.
Hypertension
Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats.
Hypertension
Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function.
Hypertension
Expression of the human soluble epoxide hydrolase in Escherichia coli by auto-induction for the study of high-throughput inhibition assays.
Hypertension
Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an ?-linolenic acid-induced inhibition of soluble epoxide hydrolase.
Hypertension
Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies.
Hypertension
Gene expression in the adrenal glands of three spontaneously hypertensive rat substrains.
Hypertension
Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical.
Hypertension
Heavy chain single-domain antibodies to detect native human soluble epoxide hydrolase.
Hypertension
Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes.
Hypertension
Identification of N-ethylmethylamine as a novel scaffold for inhibitors of soluble epoxide hydrolase by crystallographic fragment screening.
Hypertension
In vitro and in vivo Metabolism of a Potent Inhibitor of Soluble Epoxide Hydrolase, 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea.
Hypertension
In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors.
Hypertension
In vitro inhibitory effects of ethanol extract of Danshen (Salvia miltiorrhiza) and its components on the catalytic activity of soluble epoxide hydrolase.
Hypertension
Incorporation of Piperazino Functionality into 1,3-Disubstituted Urea as the Tertiary Pharmacophore Affording Potent Inhibitors of Soluble Epoxide Hydrolase with Improved Pharmacokinetic Properties.
Hypertension
Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney.
Hypertension
Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension.
Hypertension
Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension.
Hypertension
Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats.
Hypertension
Inhibition of soluble epoxide hydrolase offers protection against fructose-induced diabetes and related metabolic complications in rats.
Hypertension
Inhibition of the soluble epoxide hydrolase by tyrosine nitration.
Hypertension
Insight into the binding modes and inhibition mechanisms of adamantyl-based 1,3-disubstituted urea inhibitors in the active site of the human soluble epoxide hydrolase.
Hypertension
Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins.
Hypertension
Isothermal Titration Calorimetry Enables Rapid Characterization of Enzyme Kinetics and Inhibition for the Human Soluble Epoxide Hydrolase.
Hypertension
Linking an insect enzyme to hypertension: angiotensin II-epoxide hydrolase interactions.
Hypertension
Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?
Hypertension
Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology.
Hypertension
Nanobody Based Immunoassay for Human Soluble Epoxide Hydrolase Detection Using Polymeric Horseradish Peroxidase (PolyHRP) for Signal Enhancement: The Rediscovery of PolyHRP?
Hypertension
No impact of soluble epoxide hydrolase rs4149243, rs2234914 and rs751142 genetic variants on the development of type II diabetes and its hypertensive complication among Jordanian patients.
Hypertension
Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors.
Hypertension
Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat.
Hypertension
Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition.
Hypertension
Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single- and Multiple-Dose Studies in Healthy Human Subjects.
Hypertension
Prevention of Hypertension in DOCA-Salt Rats by an Inhibitor of Soluble Epoxide Hydrolase.
Hypertension
Protection from hypertension in mice by the Mediterranean diet is mediated by nitro fatty acid inhibition of soluble epoxide hydrolase.
Hypertension
Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension.
Hypertension
Reprogramming: A Preventive Strategy in Hypertension Focusing on the Kidney.
Hypertension
Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.
Hypertension
Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension.
Hypertension
Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats.
Hypertension
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension.
Hypertension
Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension.
Hypertension
Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
Hypertension
Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension.
Hypertension
Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.
Hypertension
Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery.
Hypertension
Soluble epoxide hydrolase: a novel target for the treatment of hypertension.
Hypertension
Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography.
Hypertension
Structure-based optimization of the piperazino-containing 1,3-disubstituted ureas affording sub-nanomolar inhibitors of soluble epoxide hydrolase.
Hypertension
Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation.
Hypertension
Tetramethylpyrazine suppresses angiotensin II-induced soluble epoxide hydrolase expression in coronary endothelium via anti-ER stress mechanism.
Hypertension
The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension.
Hypertension
The soluble epoxide hydrolase as a pharmaceutical target for hypertension.
Hypertension
The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension.
Hypertension
Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension.
Hypertension
Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention.
Hypertension
Whole rat DNA array survey for candidate genes related to hypertension in kidneys from three spontaneously hypertensive rat substrains at two stages of age and with hypotensive induction caused by hydralazine hydrochloride.
Hypertension
[Expression and role of soluble epoxide hydrolase in renal tissue of two kidneys one clip hypertension rats model].
Hypertension
[Renal over expression of soluble epoxide hydrolase in rat with hypertension induced by high-salt.]
Hypertension, Malignant
Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME.
Hypertension, Portal
Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis.
Hypertension, Pulmonary
EET-dependent potentiation of pulmonary arterial pressure: sex-different regulation of soluble epoxide hydrolase.
Hypertension, Pulmonary
Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition.
Hypertension, Pulmonary
Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.
Hypertension, Pulmonary
Sexually Dimorphic Regulation of EET Synthesis and Metabolism: Roles of Estrogen.
Hypertension, Renovascular
Soluble Epoxide Hydrolase Inhibition Exhibits Antihypertensive Actions Independently of Nitric Oxide in Mice with Renovascular Hypertension.
Hypertension, Renovascular
Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension.
Hypotension
5,14-HEDGE, a 20-HETE mimetic, reverses hypotension and improves survival in a rodent model of septic shock: Contribution of soluble epoxide hydrolase, CYP2C23, MEK1/ERK1/2/IKK?/I?B-?/NF-?B pathway, and proinflammatory cytokine formation.
Hypotension
Inhibition of soluble epoxide hydrolase as a novel approach to high dose diazepam induced hypotension.
Hypotension
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.
Infarction, Middle Cerebral Artery
1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea Exerts Neuro-Protective Effects Against Ischemic Injury via Suppressing JNK/p38 MAPK-Mediated Mitochondrial Apoptosis Pathway.
Infarction, Middle Cerebral Artery
Hyperbaric oxygenation and 20-HETE inhibition reduce stroke volume in female diabetic Sprague-Dawley rats.
Infarction, Middle Cerebral Artery
Protective Effects of the Soluble Epoxide Hydrolase Inhibitor 1-Trifluoromethoxyphenyl-3-(1-Propionylpiperidin-4-yl) Urea in a Rat Model of Permanent Middle Cerebral Artery Occlusion.
Infections
Fasciola hepatica: liver microsomal membrane functions in host rat.
Infections
Overexpression of hydroperoxide lyase, peroxygenase and epoxide hydrolase in tobacco for the biotechnological production of flavours and polymer precursors.
Infections
Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediators.
Inflammatory Bowel Diseases
Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.
Inflammatory Bowel Diseases
Soluble Epoxide Hydrolase Gene Deficiency or Inhibition Attenuates Chronic Active Inflammatory Bowel Disease in IL-10(-/-) Mice.
Insulin Resistance
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
Insulin Resistance
15-deoxy-?12,14-Prostaglandin J2 inhibits human soluble epoxide hydrolase by a dual orthosteric and allosteric mechanism.
Insulin Resistance
Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans.
Insulin Resistance
Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients.
Insulin Resistance
Attenuation of inflammation and cellular stress-related pathways maintains insulin sensitivity in obese type I interleukin-1 receptor knockout mice on a high-fat diet.
Insulin Resistance
Discovery of novel heterocyclic amide-based inhibitors: an integrative in-silico approach to targeting soluble epoxide hydrolase.
Insulin Resistance
EET Agonist Rescues the Metabolic Syndrome Phenotype of HO-2 Null Mice.
Insulin Resistance
Epoxyeicosatrienoic acids and glucose homeostasis in mice and men.
Insulin Resistance
Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney.
Insulin Resistance
Isothermal Titration Calorimetry Enables Rapid Characterization of Enzyme Kinetics and Inhibition for the Human Soluble Epoxide Hydrolase.
Insulin Resistance
Quinazoline-4(3H)-one derivatives as novel and potent inhibitors of soluble epoxide hydrolase: Design, synthesis and biological evaluation.
Insulin Resistance
Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance.
Insulin Resistance
Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.
Insulin Resistance
The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.
Ischemic Stroke
Blockade of soluble epoxide hydrolase attenuates post-ischemic neuronal hyperexcitation and confers resilience against stroke with TrkB activation.
Ischemic Stroke
CYP2C8 rs17110453 and EPHX2 rs751141 two-locus interaction increases susceptibility to ischemic stroke.
Ischemic Stroke
Epoxyeicosatrienoic Acids are Mediated by EPHX2 Variants and may be a Predictor of Early Neurological Deterioration in Acute Minor Ischemic Stroke.
Ischemic Stroke
Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population.
Ischemic Stroke
Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans.
Ischemic Stroke
Genetic variation in soluble epoxide hydrolase: association with outcome after aneurysmal subarachnoid hemorrhage.
Ischemic Stroke
Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease.
Ischemic Stroke
Genetics of ischemic stroke.
Ischemic Stroke
Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes.
Ischemic Stroke
Impact of SMTP Targeting Plasminogen and Soluble Epoxide Hydrolase on Thrombolysis, Inflammation, and Ischemic Stroke.
Ischemic Stroke
Inhibition of soluble epoxide hydrolase augments astrocyte release of vascular endothelial growth factor and neuronal recovery after oxygen-glucose deprivation.
Ischemic Stroke
Inhibition of soluble epoxide hydrolase regulates monocyte/macrophage polarization and improves neurological outcome in a rat model of ischemic stroke.
Ischemic Stroke
Interaction among CYP2C8, EPHX2, and CYP4A11 Gene Variants Significantly Increases the Risk for Ischemic Stroke in Chinese Populations.
Ischemic Stroke
Interactions Among CYP2C8, EPHX2, and CYP4A11 Variants and CYP Plasma Metabolite Levels in Ischemic Stroke.
Ischemic Stroke
Ischemic Stroke and Six Genetic Variants in CRP, EPHX2, FGA, and NOTCH3 Genes: A Meta-Analysis.
Ischemic Stroke
Missense Genetic Polymorphisms of Microsomal (EPHX1) and Soluble Epoxide Hydrolase (EPHX2) and Their Relation to the Risk of Large Artery Atherosclerotic Ischemic Stroke in a Turkish Population.
Ischemic Stroke
Peroxisomal translocation of soluble epoxide hydrolase protects against ischemic stroke injury.
Ischemic Stroke
Protection of salvianolic acid A on rat brain from ischemic damage via soluble epoxide hydrolase inhibition.
Ischemic Stroke
Role of endothelial soluble epoxide hydrolase in cerebrovascular function and ischemic injury.
Ischemic Stroke
Soluble epoxide hydrolase inhibition enhances anti-inflammatory and antioxidative processes, modulates microglia polarization, and promotes recovery after ischemic stroke.
Ischemic Stroke
Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.
Ischemic Stroke
Soluble epoxide hydrolase inhibitor enhances synaptic neurotransmission and plasticity in mouse prefrontal cortex.
Ischemic Stroke
Soluble Epoxide Hydrolase Inhibitor trans-4-[4-(3-Adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic Acid (t-AUCB) is Neuroprotective in Rat Model of Ischemic Stroke.
Ischemic Stroke
Structure-activity relationships of the plasminogen modulator SMTP with respect to the inhibition of soluble epoxide hydrolase.
Ischemic Stroke
Synergistic Effect of the MTHFR C677T and EPHX2 G860A Polymorphism on the Increased Risk of Ischemic Stroke in Chinese Type 2 Diabetic Patients.
Ischemic Stroke
The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke.
Kidney Diseases
The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension.
Kidney Failure, Chronic
Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease.
Leishmaniasis
Changes in hepatic xenobiotic-metabolising enzymes in mouse liver following infection with Leishmania donovani.
Leukemia
Automated Extraction of DNA and RNA from a Single Formalin-Fixed Paraffin-Embedded Tissue Section for Analysis of Both Single-Nucleotide Polymorphisms and mRNA Expression.
Leukemia
Leukotriene A4: preparation and enzymatic conversion in a cell-free system to leukotriene B4.
Leukemia
Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo.
Liver Cirrhosis
Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis.
Liver Cirrhosis
Soluble epoxide hydrolase inhibition with t-TUCB alleviates liver fibrosis and portal pressure in carbon tetrachloride-induced cirrhosis in rats.
Liver Cirrhosis, Alcoholic
The effect of alcoholic cirrhosis on the activities of microsomal aldrin epoxidase, 7-ethoxycoumarin O-de-ethylase and epoxide hydrolase, and on the concentrations of reduced glutathione in human liver.
Liver Diseases
Soluble Epoxide Hydrolase Hepatic Deficiency Ameliorates Alcohol-Associated Liver Disease.
Liver Diseases
Soluble Epoxide Hydrolase Inhibition in Liver Diseases: A Review of Current Research and Knowledge Gaps.
Liver Neoplasms
Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer.
Lung Diseases
Deletion of soluble epoxide hydrolase attenuates mice Hyperoxic acute lung injury.
Lung Injury
Alleviation of lung injury by glycyrrhizic acid in benzo(a)pyrene exposed rats: Probable role of soluble epoxide hydrolase and thioredoxin reductase.
Lung Injury
Soluble Epoxide Hydrolase Plays a Vital role In Angiotensin II-Induced Lung Injury in Mice.
Lung Neoplasms
A long-wavelength, fluorogenic probe for epoxide hydrolase: 7-(2-(oxiran-2-yl)ethoxy) resorufin.
Lung Neoplasms
Effect of epoxide hydrolase polymorphisms on chromosome aberrations and risk for lung cancer.
Lung Neoplasms
Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer.
Lung Neoplasms
Genetic Polymorphism of Epoxide Hydrolase and GSTM1 in Lung Cancer Susceptibility of Korean Population.
Lung Neoplasms
Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers.
Lung Neoplasms
Hierarchical modeling identifies novel lung cancer susceptibility variants in inflammation pathways among 10,140 cases and 11,012 controls.
Lung Neoplasms
Impact of epoxide hydrolase 1 polymorphisms on lung cancer susceptibility in asian populations.
Lung Neoplasms
[Role of ancestral genotypes of the genes of xenobiotics biotransformation in susceptibility to lung cancer among Mayak workers].
Lupus Nephritis
Prophylactic inhibition of soluble epoxide hydrolase delays onset of nephritis and ameliorates kidney damage in NZB/W F1 mice.
Lymphatic Metastasis
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Lymphoma
Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas.
Lymphoma
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Lymphoma, B-Cell
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Metabolic Diseases
Diabetic CVD - Soluble Epoxide Hydrolase as A Target.
Metabolic Diseases
Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue.
Metabolic Diseases
Soluble epoxide hydrolase: A potential target for metabolic diseases.
Metabolic Diseases
The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.
Metabolic Syndrome
A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases.
Metabolic Syndrome
Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.
Metabolic Syndrome
Eicosanoids and renal damage in cardiometabolic syndrome.
Metabolic Syndrome
Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats.
Metabolic Syndrome
The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease.
Metabolic Syndrome
Zafirlukast Is a Dual Modulator of Human Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptor ?.
MPTP Poisoning
Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.
Mucocutaneous Lymph Node Syndrome
The Anti-inflammatory Effect of Soluble Epoxide Hydrolase Inhibitor and 14, 15-EET in Kawasaki Disease Through PPAR?/STAT1 Signaling Pathway.
Multiple Myeloma
Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma.
Multiple Sclerosis
Development of Improved Double-Nanobody Sandwich ELISAs for Human Soluble Epoxide Hydrolase Detection in Peripheral Blood Mononuclear Cells of Diabetic Patients and the Prefrontal Cortex of Multiple Sclerosis Patients.
Multiple Sclerosis
Pharmacological inhibition of soluble epoxide hydrolase attenuates chronic experimental autoimmune encephalomyelitis by modulating inflammatory and anti-inflammatory pathways in an inflammasome-dependent and -independent manner.
Myocardial Infarction
A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPAR? to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction.
Myocardial Infarction
A Soluble Epoxide Hydrolase Inhibitor Upregulated KCNJ12 and KCNIP2 by Downregulating MicroRNA-29 in a Mouse Model of Myocardial Infarction.
Myocardial Infarction
Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches.
Myocardial Infarction
Buthionine sulfoximine, an inhibitor of glutathione biosynthesis, induces expression of soluble epoxide hydrolase and markers of cellular hypertrophy in a rat cardiomyoblast cell line: Roles of the NF-?B and MAPK signaling pathways.
Myocardial Infarction
Genetic deletion of soluble epoxide hydrolase provides cardioprotective responses following myocardial infarction in aged mice.
Myocardial Infarction
Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease.
Myocardial Infarction
Soluble epoxide hydrolase inhibitors improve angiogenic function of endothelial progenitor cells via ERK/p38-mediated miR-126 upregulation in myocardial infarction mice after exercise.
Myocardial Infarction
Soluble epoxide hydrolase inhibitors, t-AUCB, downregulated miR-133 in a mouse model of myocardial infarction.
Myocardial Infarction
Soluble epoxide hydrolase inhibitors, t-AUCB, regulated microRNA-1 and its target genes in myocardial infarction mice.
Myocardial Ischemia
Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease.
Myocardial Stunning
Soluble epoxide hydrolase: a new target for cardioprotection.
Neoplasm Metastasis
Aryl Hydrocarbon Receptor-Dependent inductions of omega-3 and omega-6 polyunsaturated fatty acid metabolism act inversely on tumor progression.
Neoplasm Metastasis
COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor.
Neoplasm Metastasis
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.
Neoplasm Metastasis
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis.
Neoplasm Metastasis
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice.
Neoplasm Metastasis
Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis.
Neoplasm Metastasis
Immunohistochemical assessment of human microsomal epoxide hydrolase in primary and secondary liver neoplasm: a quantitative approach.
Neoplasm Metastasis
The Consequences of Soluble Epoxide Hydrolase Deletion on Tumorigenesis and Metastasis in a Mouse Model of Breast Cancer.
Neoplasms
6-Gingerol abates benzo[a]pyrene-induced colonic injury via suppression of oxido-inflammatory stress responses in BALB/c mice.
Neoplasms
Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy.
Neoplasms
Aryl Hydrocarbon Receptor-Dependent inductions of omega-3 and omega-6 polyunsaturated fatty acid metabolism act inversely on tumor progression.
Neoplasms
Bioactive Hydroperoxyl Cembranoids from the Red Sea Soft Coral Sarcophyton glaucum.
Neoplasms
Carcinogenesis: Failure of resolution of inflammation?
Neoplasms
Clinical significance of EPHX2 deregulation in prostate cancer.
Neoplasms
Complex interrelationships between nitro-alkene-dependent inhibition of soluble epoxide hydrolase, inflammation and tumor growth.
Neoplasms
COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor.
Neoplasms
Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids.
Neoplasms
Cytochrome P-450 isozyme pattern is related to individual susceptibility to diethylnitrosamine-induced liver cancer in rats.
Neoplasms
Cytochrome P450 expression in oesophageal cancer.
Neoplasms
Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
Neoplasms
Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms.
Neoplasms
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.
Neoplasms
Effects of chemical inducers on human microsomal epoxide hydrolase in primary hepatocyte cultures.
Neoplasms
Epoxide hydrolase genotype and orolaryngeal cancer risk: interaction with GSTM1 genotype.
Neoplasms
Epoxide hydrolase: a marker for experimental hepatocarcinogenesis.
Neoplasms
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis.
Neoplasms
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice.
Neoplasms
Expression of xenobiotic metabolizing enzymes in breast cancer.
Neoplasms
Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder.
Neoplasms
Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man.
Neoplasms
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.
Neoplasms
Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers.
Neoplasms
Heavy chain single-domain antibodies to detect native human soluble epoxide hydrolase.
Neoplasms
Immunohistochemical assessment of human microsomal epoxide hydrolase in primary and secondary liver neoplasm: a quantitative approach.
Neoplasms
Induction of alkoxyresorufin O-dealkylases, epoxide hydrolase, and liver weight gain: correlation with liver tumor-promoting potential in a series of barbiturates.
Neoplasms
Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG12D/Pdx-1-Cre Mice.
Neoplasms
LINC00205 modulates the expression of EPHX1 through the inhibition of miR-184 in hepatocellular carcinoma as a ceRNA.
Neoplasms
Localization of microsomal epoxide hydrolase in normal and neoplastic human kidney.
Neoplasms
Main drug- and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues.
Neoplasms
Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues.
Neoplasms
Mechanisms of fat-related modulation of N-nitrosodiethylamine-induced tumors in rats: organ distribution, blood lipids, enzymes and pro-oxidant state.
Neoplasms
Metabolism and pharmacokinetics of allitinib in cancer patients: the roles of cytochrome p450s and epoxide hydrolase in its biotransformation.
Neoplasms
Modulation of carcinogen metabolizing enzymes by new fused heterocycles pendant to 5,6,7,8-tetrahydronaphthalene derivatives.
Neoplasms
Nanobody Based Immunoassay for Human Soluble Epoxide Hydrolase Detection Using Polymeric Horseradish Peroxidase (PolyHRP) for Signal Enhancement: The Rediscovery of PolyHRP?
Neoplasms
Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinoma.
Neoplasms
Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinoma.
Neoplasms
Reduction of inflammatory bowel disease-induced tumor development in IL-10 knockout mice with soluble epoxide hydrolase gene deficiency.
Neoplasms
Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression.
Neoplasms
Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer.
Neoplasms
Species differences in the hydrolysis of 2-cyanoethylene oxide, the epoxide metabolite of acrylonitrile.
Neoplasms
The Consequences of Soluble Epoxide Hydrolase Deletion on Tumorigenesis and Metastasis in a Mouse Model of Breast Cancer.
Neoplasms
The cytochrome P450 pathway in angiogenesis and endothelial cell biology.
Neoplasms
The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma.
Neoplasms
The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer.
Neoplasms
Xenobiotic metabolising enzyme expression in colonic neoplasia.
Neoplasms
Xenobiotic metabolizing enzymes in genetically and chemically initiated mouse liver tumors.
Nephritis
Prophylactic inhibition of soluble epoxide hydrolase delays onset of nephritis and ameliorates kidney damage in NZB/W F1 mice.
Nervous System Diseases
Role of Soluble Epoxide Hydrolase in Metabolism of PUFAs in Psychiatric and Neurological Disorders.
Neural Tube Defects
Pharmacogenetic screening for susceptibility to fetal malformations in women.
Neuralgia
Comparing Gene Expression in the Parabrachial and Amygdala of Diestrus and Proestrus Female Rats after Orofacial Varicella Zoster Injection.
Neuralgia
Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors.
Neuralgia
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
Neuralgia
In vitro and in vivo Metabolism of a Potent Inhibitor of Soluble Epoxide Hydrolase, 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea.
Neuralgia
Lack of rewarding effects of a soluble epoxide hydrolase inhibitor TPPU in mice: Comparison with morphine.
Neuralgia
Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative.
Neuralgia
Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE? induced pain model.
Neuralgia
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
Neuralgia
Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain.
Neuralgia
Probing the orientation of inhibitor and epoxy-eicosatrienoic acid binding in the active site of soluble epoxide hydrolase.
Neuralgia
Soluble epoxide hydrolase activity and pharmacologic inhibition in horses with chronic severe laminitis.
Neuralgia
Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.
Neurodegenerative Diseases
Natural soluble epoxide hydrolase inhibitors from Inula britanica and their potential interactions with soluble epoxide hydrolase: Insight from inhibition kinetics and molecular dynamics.
Neurodegenerative Diseases
Proteomics and bioinformatics analysis of mouse hypothalamic neurogenesis with or without EPHX2 gene deletion.
Neurodegenerative Diseases
Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases.
Neurodegenerative Diseases
Soluble Epoxide Hydrolase Regulation of Lipid Mediators Limits Pain.
Neuroinflammatory Diseases
An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease.
Neuroinflammatory Diseases
Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer's disease.
Neuroinflammatory Diseases
Deletion or inhibition of soluble epoxide hydrolase protects against brain damage and reduces microglia-mediated neuroinflammation in traumatic brain injury.
Neuroinflammatory Diseases
Evaluation of antiparkinson activity of PTUPB by measuring dopamine and its metabolites in Drosophila melanogaster: LC-MS/MS method development.
Neuroinflammatory Diseases
First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET.
Neuroinflammatory Diseases
Genetic deletion or pharmacological inhibition of soluble epoxide hydrolase reduces brain damage and attenuates neuroinflammation after intracerebral hemorrhage.
Neuroinflammatory Diseases
Inhibition of soluble epoxide hydrolase regulates monocyte/macrophage polarization and improves neurological outcome in a rat model of ischemic stroke.
Neuroinflammatory Diseases
Post-exposure administration of diazepam combined with soluble epoxide hydrolase inhibition stops seizures and modulates neuroinflammation in a murine model of acute TETS intoxication.
Neuroinflammatory Diseases
Single administration of soluble epoxide hydrolase inhibitor suppresses neuroinflammation and improves neuronal damage after cardiac arrest in mice.
Neuroinflammatory Diseases
Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson's Disease: A New Therapeutic Strategy.
Neuroinflammatory Diseases
Soluble epoxide hydrolase modulates immune responses in activated astrocytes involving regulation of STAT3 activity.
Neuroinflammatory Diseases
Soluble Epoxide Hydrolase Regulation of Lipid Mediators Limits Pain.
Niemann-Pick Disease, Type C
Inhibition of Soluble Epoxide Hydrolase Ameliorates Phenotype and Cognitive Abilities in a Murine Model of Niemann Pick Type C Disease.
Non-alcoholic Fatty Liver Disease
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
Non-alcoholic Fatty Liver Disease
Regulation of the cytochrome P450 epoxyeicosanoid pathway is associated with distinct histologic features in pediatric non-alcoholic fatty liver disease.
Obesity
1-trifluoromethoxyphenyl-3(1-propionylpiperidin-4-yl) urea (TPPU), a soluble epoxide hydrolase inhibitor attenuates high fat diet-induced cardiovascular and metabolic disorders in rats.
Obesity
A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases.
Obesity
Differential Effects of 17,18-EEQ and 19,20-EDP Combined with Soluble Epoxide Hydrolase Inhibitor t-TUCB on Diet-Induced Obesity in Mice.
Obesity
Epoxyeicosatrienoic acids and glucose homeostasis in mice and men.
Obesity
Expression and Regulation of Soluble Epoxide Hydrolase in Adipose Tissue.
Obesity
High fat diet induced obesity alters ovarian phosphatidylinositol-3 kinase signaling gene expression.
Obesity
Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension.
Obesity
Obesity is positively associated with arachidonic acid-derived 5- and 11-hydroxyeicosatetraenoic acid (HETE).
Obesity
Omega-6 and omega-3 oxylipins are implicated in soybean oil-induced obesity in mice.
Obesity
Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats.
Obesity
Proinflammatory enzyme soluble epoxide hydrolase bridges obesity to colonic inflammation and potential carcinogenesis.
Obesity
Soluble Epoxide Hydrolase 2 Expression Is Elevated in Obese Humans and Decreased by Physical Activity.
Obesity
Soluble Epoxide Hydrolase Inhibition by t-TUCB Promotes Brown Adipogenesis and Reduces Serum Triglycerides in Diet-Induced Obesity.
Obesity
The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.
Obesity, Maternal
Genetic polymorphisms in neuroendocrine disorder-related candidate genes associated with pre-pregnancy obesity in gestational diabetes mellitus patients by using a stratification approach.
Oligospermia
Genetic variants in epoxide hydrolases modify the risk of oligozoospermia and asthenospermia in Han-Chinese population.
Osteoarthritis
Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis.
Osteoarthritis, Knee
Omega-6 oxylipins generated by soluble epoxide hydrolase are associated with knee osteoarthritis.
Ovarian Neoplasms
A long-wavelength, fluorogenic probe for epoxide hydrolase: 7-(2-(oxiran-2-yl)ethoxy) resorufin.
Ovarian Neoplasms
Association between EPHX1 polymorphism rs1051740 and the risk of ovarian cancer: a meta-analysis.
Overweight
Addition of milk fat globule membrane-enriched supplement to a high-fat meal attenuates insulin secretion and induction of soluble epoxide hydrolase gene expression in the postprandial state in overweight and obese subjects.
Overweight
Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice.
Pancreatic Diseases
The role of epoxide hydrolase Y113H gene variant in pancreatic diseases.
Pancreatitis
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis.
Pancreatitis
Effects of soluble epoxide hydrolase deficiency on acute pancreatitis in mice.
Pancreatitis
From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis.
Pancreatitis
Soluble epoxide hydrolase deficiency ameliorates acute pancreatitis in mice.
Pancreatitis
Soluble Epoxide Hydrolase Pharmacological Inhibition Ameliorates Experimental Acute Pancreatitis in Mice.
Pancreatitis, Chronic
Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG12D/Pdx-1-Cre Mice.
Parkinson Disease
Contribution of DHA diols (19,20-DHDP) produced by cytochrome P450s and soluble epoxide hydrolase to the beneficial effects of DHA supplementation in the brains of rotenone-induced rat models of Parkinson's disease.
Parkinson Disease
Genetic polymorphisms of microsomal and soluble epoxide hydrolase and the risk of Parkinson's disease.
Parkinson Disease
PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP.
Parkinson Disease
Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson's Disease: A New Therapeutic Strategy.
Parkinson Disease
Soluble epoxide hydrolase inhibitor, APAU, protects dopaminergic neurons against rotenone induced neurotoxicity: Implications for Parkinson's disease.
Parkinson Disease
Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease.
Peripheral Arterial Disease
Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an ?-linolenic acid-induced inhibition of soluble epoxide hydrolase.
Peroxisomal Disorders
Epoxide hydrolase in human and rat peroxisomes: implication for disorders of peroxisomal biogenesis.
Pneumonia
Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor.
Pneumonia
Soluble Epoxide Hydrolase Inhibitor Attenuates Inflammation and Airway Hyperresponsiveness in Mice.
Polycystic Kidney Diseases
Protective effect of Soluble Epoxide Hydrolase Inhibition in Retinal Vasculopathy associated with Polycystic Kidney Disease.
Polyneuropathies
Polymorphisms of GSTT1, GSTM1, and EPHX genotypes in patients with cryptogenic polyneuropathy: a case-control study.
Pre-Eclampsia
A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia.
Pre-Eclampsia
Association between the soluble epoxide hydrolase gene and preeclampsia.
Pre-Eclampsia
Association of microsomal epoxide hydrolase gene polymorphism and pre-eclampsia in Turkish women.
Pre-Eclampsia
Association of the sEH gene promoter polymorphisms and haplotypes with preeclampsia.
Pre-Eclampsia
Genetic Polymorphism of Microsomal Epoxide Hydrolase Enzyme Gene in Preeclamptic Females.
Pre-Eclampsia
Increased epoxyeicosatrienoic acids and reduced soluble epoxide hydrolase expression in the preeclamptic placenta.
Pre-Eclampsia
Maternal and fetal single nucleotide polymorphisms in the epoxide hydrolase and gluthatione S-transferase P1 genes are not associated with pre-eclampsia in the Coloured population of the Western Cape, South Africa.
Pre-Eclampsia
PP057. ENOSI4 and EPHX1 polymorphisms affect maternal susceptibility topreeclampsia - Analysis of five polymorphisms predisposing tocardiovascular disease in 279 caucasian and 241 african women.
Pre-Eclampsia
Susceptibility to pre-eclampsia is associated with multiple genetic polymorphisms in maternal biotransformation enzymes.
Pre-Eclampsia
The role of soluble epoxide hydrolase in preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children.
Prostatic Neoplasms
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.
Prostatic Neoplasms
Clinical significance of EPHX2 deregulation in prostate cancer.
Protein Deficiency
Effect of a dietary protein deficiency on the development of hepatic drug-metabolizing enzymes in young rats.
Proteinuria
Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat.
Psoriasis
Aryl hydrocarbon hydroxylase, epoxide hydrolase, and benzo[a]-pyrene metabolism in human epidermis: comparative studies in normal subjects and patients with psoriasis.
Pulmonary Disease, Chronic Obstructive
Cigarette Smoke-Induced Pulmonary Inflammation and Autophagy Are Attenuated in Ephx2-Deficient Mice.
Pulmonary Disease, Chronic Obstructive
Exploration of association between EPHX1 and chronic obstructive pulmonary disease on the basis of combined data mining.
Pulmonary Disease, Chronic Obstructive
Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD.
Pulmonary Disease, Chronic Obstructive
Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers.
Pulmonary Disease, Chronic Obstructive
Probing the orientation of inhibitor and epoxy-eicosatrienoic acid binding in the active site of soluble epoxide hydrolase.
Pulmonary Disease, Chronic Obstructive
Use of a Soluble Epoxide Hydrolase Inhibitor in Smoke-Induced Chronic Obstructive Pulmonary Disease.
Pulmonary Fibrosis
Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)?
Pulmonary Fibrosis
Erratum to: Soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice.
Pulmonary Fibrosis
Inula japonica ameliorated bleomycin-induced pulmonary fibrosis via inhibiting soluble epoxide hydrolase.
Pulmonary Fibrosis
Soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3- (1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice.
Renal Insufficiency, Chronic
Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats.
Renal Insufficiency, Chronic
Association of rs11780592 Polymorphism in the Human Soluble Epoxide Hydrolase Gene (EPHX2) with Oxidized LDL and Mortality in Patients with Diabetic Chronic Kidney Disease.
Renal Insufficiency, Chronic
Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.
Renal Insufficiency, Chronic
Discovery of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating of chronic kidney diseases.
Renal Insufficiency, Chronic
Eicosanoids and renal damage in cardiometabolic syndrome.
Renal Insufficiency, Chronic
Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats.
Renal Insufficiency, Chronic
Mechanism of Chronic Kidney Disease Progression and Novel Biomarkers: A Metabolomic Analysis of Experimental Glomerulonephritis.
Renal Insufficiency, Chronic
Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats.
Renal Insufficiency, Chronic
Soluble epoxide hydrolase inhibition ameliorates proteinuria-induced epithelial-mesenchymal transition by regulating the PI3K-Akt-GSK-3? signaling pathway.
Reperfusion Injury
Early antihypertensive treatment and ischemia-induced acute kidney injury.
Reperfusion Injury
In vitro inhibitory effects of ethanol extract of Danshen (Salvia miltiorrhiza) and its components on the catalytic activity of soluble epoxide hydrolase.
Reperfusion Injury
Inhibition of soluble epoxide hydrolase by trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB) is protective against ischemia reperfusion injury.
Reperfusion Injury
Soluble epoxide hydrolase activation by S-nitrosation contributes to cardiac ischemia-reperfusion injury.
Reperfusion Injury
Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney.
Reperfusion Injury
Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
Reperfusion Injury
Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia.
Respiratory Distress Syndrome
Dihydroxyoctadecamonoenoate esters inhibit the neutrophil respiratory burst.
Respiratory Distress Syndrome
Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)?
Retinopathy of Prematurity
Soluble epoxide hydrolase promotes astrocyte survival in retinopathy of prematurity.
Sarcoidosis
Soluble epoxide hydrolase derived lipid mediators are elevated in bronchoalveolar lavage fluid from patients with sarcoidosis: a cross-sectional study.
Scrapie
Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie.
Seizures
Anti-inflammatory treatment with a soluble epoxide hydrolase inhibitor attenuates seizures and epilepsy-associated depression in the LiCl-pilocarpine post-status epilepticus rat model.
Seizures
Epoxy fatty acids and inhibition of the soluble epoxide hydrolase selectively modulate GABA mediated neurotransmission to delay onset of seizures.
Seizures
Post-exposure administration of diazepam combined with soluble epoxide hydrolase inhibition stops seizures and modulates neuroinflammation in a murine model of acute TETS intoxication.
Seizures
Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy.
Sepsis
Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.
Sepsis
Prolonged Soluble Epoxide Hydrolase Reactivity in Brain Endothelial Cells Is Associated with Long Cognitive Deficits in Sepsis.
Shock, Septic
5,14-HEDGE, a 20-HETE mimetic, reverses hypotension and improves survival in a rodent model of septic shock: Contribution of soluble epoxide hydrolase, CYP2C23, MEK1/ERK1/2/IKK?/I?B-?/NF-?B pathway, and proinflammatory cytokine formation.
soluble epoxide hydrolase deficiency
Effects of soluble epoxide hydrolase deficiency on acute pancreatitis in mice.
soluble epoxide hydrolase deficiency
Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury.
soluble epoxide hydrolase deficiency
Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance.
soluble epoxide hydrolase deficiency
Soluble epoxide hydrolase deficiency ameliorates acute pancreatitis in mice.
soluble epoxide hydrolase deficiency
Soluble epoxide hydrolase deficiency attenuates lipotoxic cardiomyopathy via upregulation of AMPK-mTORC mediated autophagy.
soluble epoxide hydrolase deficiency
Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice.
soluble epoxide hydrolase deficiency
Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice.
soluble epoxide hydrolase deficiency
Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue.
soluble epoxide hydrolase deficiency
Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.
soluble epoxide hydrolase deficiency
Soluble epoxide hydrolase deficiency or inhibition enhances murine hypoxic pulmonary vasoconstriction after lipopolysaccharide challenge.
Spinal Cord Injuries
Soluble epoxide hydrolase inhibition provides multi-target therapeutic effects in rats after spinal cord injury.
Squamous Cell Carcinoma of Head and Neck
Analysis of methylation-driven genes for predicting the prognosis of patients with head and neck squamous cell carcinoma.
Starvation
Effect of diabetes and starvation on the activity of rat liver epoxide hydrolases, glutathione S-transferases and peroxisomal beta-oxidation.
Starvation
Preparation and characterization of subcellular fractions from the liver of C57B1/6 mice, with special emphasis on their suitability for use in studies of epoxide hydrolase activities.
Stomach Ulcer
Pharmacological inhibition of soluble epoxide hydrolase or genetic deletion reduces diclofenac-induced gastric ulcers.
Stroke
Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat.
Stroke
Blockade of soluble epoxide hydrolase attenuates post-ischemic neuronal hyperexcitation and confers resilience against stroke with TrkB activation.
Stroke
Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke.
Stroke
Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease.
Stroke
Interaction between ALOX5AP and CYP3A5 gene variants significantly increases the risk for cerebral infarctions in Chinese.
Stroke
Mechanism of protection by soluble epoxide hydrolase inhibition in type 2 diabetic stroke.
Stroke
Mechanism of the sex difference in endothelial dysfunction after stroke.
Stroke
Missense Genetic Polymorphisms of Microsomal (EPHX1) and Soluble Epoxide Hydrolase (EPHX2) and Their Relation to the Risk of Large Artery Atherosclerotic Ischemic Stroke in a Turkish Population.
Stroke
Peroxisomal translocation of soluble epoxide hydrolase protects against ischemic stroke injury.
Stroke
PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP.
Stroke
Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury.
Stroke
Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus.
Stroke
Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7.
Stroke
Soluble Epoxide Hydrolase Blockade after Stroke Onset Protects Normal but Not Diabetic Mice.
Stroke
Soluble epoxide hydrolase: a novel therapeutic target in stroke.
Subarachnoid Hemorrhage
Genetic variation in soluble epoxide hydrolase: association with outcome after aneurysmal subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Soluble Epoxide Hydrolase in Hydrocephalus, Cerebral Edema, and Vascular Inflammation After Subarachnoid Hemorrhage.
Synovitis
Pharmacokinetics and antinociceptive effects of the soluble epoxide hydrolase inhibitor t-TUCB in horses with experimentally induced radiocarpal synovitis.
Tachycardia
5,14-HEDGE, a 20-HETE mimetic, reverses hypotension and improves survival in a rodent model of septic shock: Contribution of soluble epoxide hydrolase, CYP2C23, MEK1/ERK1/2/IKK?/I?B-?/NF-?B pathway, and proinflammatory cytokine formation.
Tachycardia
Genetic variants associated with atrial fibrillationand long-term recurrence after catheter ablation for atrialfibrillation in Turkish patients.
Thrombocytopenia
Thrombocytopenia following administration of phenytoin, dexamethasone and cimetidine: a case report and a potential mechanism.
Thrombosis
Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)?
Triple Negative Breast Neoplasms
Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study.
Tuberculosis
mesT, a unique epoxide hydrolase, is essential for optimal growth of Mycobacterium tuberculosis in the presence of styrene oxide.
Tuberculosis
Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.
Tuberculosis
Structure of an atypical epoxide hydrolase from Mycobacterium tuberculosis gives insights into its function.
Tuberculosis
The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.
Tuberculosis
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
Ureteral Obstruction
Dual soluble epoxide hydrolase inhibitor/PPAR-? agonist attenuates renal fibrosis.
Urinary Bladder Neoplasms
Toxic action/toxicity.
Uveitis
Effect of a Soluble Epoxide Hydrolase Inhibitor, UC1728, on LPS-Induced Uveitis in the Rabbit.
Vaccinia
2,3-epoxy-4-hydroxynonanal, a potential lipid peroxidation product for etheno adduct formation, is not a substrate of human epoxide hydrolase.
Vaccinia
Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase.
Vaccinia
The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol.
Vascular Calcification
The Metabolism of Epoxyeicosatrienoic Acids by Soluble Epoxide Hydrolase Is Protective against the Development of Vascular Calcification.
Vascular Diseases
Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat.
Vascular Diseases
Cytochrome P450 eicosanoids and cerebral vascular function.
Vascular Diseases
Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future.
Vascular Diseases
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.
Vascular System Injuries
Soluble epoxide hydrolase inhibition modulates vascular remodeling.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.1
(1R,2R,4R,5S,6R,7S)-4-[(benzyloxy)methyl]-3,8-dioxatricyclo[5.1.0.02,4]octane-5,6-diyl diacetate
Homo sapiens
above, pH not specified in the publication, 37°C
0.03764
(1S,6S,9R)-1-(4-hydroxy-3-methoxyphenyl)-6-methoxy-9-methyl-4-(prop-2-en-1-yl)-7-oxabicyclo[4.2.1]non-4-ene-3,8-dione
Homo sapiens
pH not specified in the publication, 37°C
0.1
(2E)-4-[(2-methylpropyl)amino]-4-oxobut-2-enoic acid
Homo sapiens
pH not specified in the publication, 37°C
0.00783
(2E)-5-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)pent-2-enamide
Homo sapiens
pH not specified in the publication, 37°C
0.00606
(2E,4E)-5-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)penta-2,4-dienamide
Homo sapiens
pH not specified in the publication, 37°C
0.09368
(2E,4E)-N-(2-methylpropyl)deca-2,4-dienamide
Homo sapiens
pH not specified in the publication, 37°C
0.00632
(2E,6E)-7-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)hepta-2,6-dienamide
Homo sapiens
pH not specified in the publication, 37°C
0.1
(2R,3R)-2-(2,6-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydro-4H-1-benzopyran-4-one
Homo sapiens
above, pH not specified in the publication, 37°C
0.02616
(2R,3R,3aS)-2-(4-hydroperoxy-3-methoxyphenyl)-3a-methoxy-3-methyl-5-(prop-2-en-1-yl)-3,3a-dihydro-1-benzofuran-6(2H)-one
Homo sapiens
pH not specified in the publication, 37°C
0.1
(2R,3R,4S,5S)-2,5-bis(3,4-dimethoxyphenyl)-3,4-dimethyloxolane
Homo sapiens
above, pH not specified in the publication, 37°C
0.1
(2R,3S,4S,5S)-2,5-bis(3,4-dimethoxyphenyl)-3,4-dimethyloxolane
Homo sapiens
above, pH not specified in the publication, 37°C
0.07619
(2S)-5,7-dihydroxy-6-methoxy-2-phenyl-2,3-dihydro-4H-1-benzopyran-4-one
Homo sapiens
pH not specified in the publication, 37°C
0.05661
(2S,3R,3aR)-2-(4-hydroperoxy-3-methoxyphenyl)-3a-methoxy-3-methyl-5-(prop-2-en-1-yl)-3,3a-dihydro-1-benzofuran-6(2H)-one
Homo sapiens
pH not specified in the publication, 37°C
0.0000007
(3R)-N-[(1s,2R,3S)-2,3-diphenylcyclopropyl]-3-[(4-fluorobenzene-1-sulfonyl)amino]piperidine-1-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000014
(3R)-N-[(1s,2R,3S)-2,3-diphenylcyclopropyl]-3-[(methanesulfonyl)amino]piperidine-1-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.091
(4-bromo-3-cyclopropyl-1H-pyrazol-1-yl)acetic acid
Homo sapiens
37°C, pH 7.0
0.00012
(E)-4-[N-((2-trifluoromethyl)benzyl)benzamide]-alpha-ethylcinnamic acid
Homo sapiens
pH 7.0, 22°C
0.00007
(E)-N-methoxy-N-methyl 3-[4-(N-((2-trifluoromethyl)benzyl)-benzamide)]but-2-enamide
Homo sapiens
pH 7.0, 22°C
0.000014
(R)-4-cyano-N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-benzamide
Homo sapiens
-
0.000023
(R)-N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-6-hydroxy-nicotinamide
Homo sapiens
-
0.000008
(S)-4-cyano-N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-benzamide
Homo sapiens
-
0.000006
(S)-N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-6-hydroxy-nicotinamide
Homo sapiens
-
0.0000026
1,1'-(butane-1,4-diyl)bis(3-[1-(adamantan-1-yl) butane-2-yl]urea)
Homo sapiens
pH and temperature not specified in the publication
0.0000012
1,1'-(butane-1,4-diyl)bis(3-[1-(adamantan-1-yl)ethyl]urea)
Homo sapiens
pH and temperature not specified in the publication
0.0000028
1,1'-(hexane-1,6-diyl)bis(3-[1-(adamantan-1-yl) butane 2 yl]urea)
Homo sapiens
pH and temperature not specified in the publication
0.0000005
1,1'-(hexane-1,6-diyl)bis(3-[1-(adamantan-1-yl)ethyl]urea)
Homo sapiens
pH and temperature not specified in the publication
0.001442
1,1'-(octane-1,8-diyl)bis(3-[1-(adamantan-1-yl)butan 2 yl]urea)
Homo sapiens
pH and temperature not specified in the publication
0.0000005
1,1'-(octane-1,8-diyl)bis(3-[1-(adamantan-1-yl)ethyl]urea)
Homo sapiens
pH and temperature not specified in the publication
0.002475
1,1'-(phenylene 1,4)bis(3-[3,5-dimethyl(adamantan-1-yl)]urea)
Homo sapiens
pH and temperature not specified in the publication
0.01
1,1'-(phenylene-1,4)bis(3-[1-(adamantan-1-yl)butan-2-yl]urea)
Homo sapiens
pH and temperature not specified in the publication
0.000162
1,1'-(phenylene-1,4)bis(3-[1-(adamantan-1-yl)ethyl]urea)
Homo sapiens
pH and temperature not specified in the publication
0.00002
1,1'-(phenylene-1,4)bis[3-([adamantan-1-yl)urea]
Homo sapiens
pH and temperature not specified in the publication
0.000028
1-(1-acetylpiperidin-4-yl)-3-cycloheptylurea
Homo sapiens
-
0.000015
1-(1-acetylpiperidin-4-yl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
Homo sapiens
-
0.000012
1-(1-acetylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea
Homo sapiens
-
0.0074
1-(1-cyclopropylethyl)-3-phenylurea
Homo sapiens
in 25 mM Bis-Tris HCl, pH 7.0, and 0.02% (v/v) Triton X-100, at 22°C
0.0000029
1-(1-methanesulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxy-phenyl)-urea
Homo sapiens
-
0.0000016
1-(1-nicotinoylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)-urea
Homo sapiens
-
0.000206 - 0.000258
1-(2-hydroxyphenyl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
0.000007
1-(3,4-dihydro-1'H-spiro[chromene-2,4'-piperidin]-1'-yl)-3-phenylpropan-1-one
Homo sapiens
-
0.000029
1-(3-(5-(hydroxyureido)methyl-2-methoxyphenoxy)propyl)-3-[4-(trifluoromethoxy)phenyl]urea
Homo sapiens
recombinant enzyme, pH 7.0, 22°C
0.000613 - 0.000813
1-(3-hydroxypropyl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
0.0000012
1-(4-(N1-methyl-N2-methyl-N2-(methyloxy)oxalamido)-benzyl)-3-adamantylurea
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.000019
1-(4-(N2-(tetrahydro-2H-pyran-2-yloxy)oxalamido)benzyl)-3-adamantylurea
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.000005
1-(4-(N2-methyl-N2-(methyloxy)oxalamido)benzyl)-3-adamantylurea
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.0000066
1-(4-(N2-methyloxyoxalamido)benzyl)-3-adamantylurea
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.000019
1-(4-(N2-tert-butyloxyoxalamido)benzyl)-3-adamantylurea
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.0000036
1-(4-acetylphenyl)-N-(5-chloro-1,3-benzoxazol-2-yl)piperidine-4-carboxamide
Homo sapiens
pH 7.4, 22°C
0.0000036
1-(4-acetylphenyl)-N-(5-methyl-1,3-benzoxazol-2-yl)piperidine-4-carboxamide
Homo sapiens
pH 7.4, 22°C
0.000013
1-(4-chlorophenyl)-3-(3,4-dichlorophenyl)urea
Homo sapiens
-
0.00012 - 0.000128
1-(5-hydroxypentyl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
0.0000032
1-(adamantan-1-yl)-3-(1-propionylpiperidin-4-yl)urea
Homo sapiens
pH 7.4, 37°C
0.000014
1-adamantan-1-yl-3-(5-[2-(2-ethoxyethoxy)ethoxy]pentyl)urea
Homo sapiens
pH 7.4, 30°C
0.0000147
1-adamantanyl-3-(5-(2-(2-ethoxyethoxy)ethoxy)pentyl)urea
Homo sapiens
-
0.000016
1-benzyl-3-tricyclo[3.3.1.13,7]dec-1-ylurea
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.0000852
1-cyclohexyl-3-dodecyl urea
Homo sapiens
-
0.0000037
1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea
Homo sapiens
pH 7.4, 37°C
0.000003
1-[1-(methylsulfonyl)piperidin-4-yl]-3-[4-(trifluoromethoxy)phenyl]urea
Homo sapiens
-
1.2
1-[3-(trifluoromethyl)pyridin-2-yl]piperazine
Homo sapiens
37°C, pH 7.0
0.052
1-[4-(trifluoromethyl)pyridin-2-yl]-1H-pyrazol-4-ol
Homo sapiens
37°C, pH 7.0
0.000008 - 0.000014
1-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]-3-tricyclo[3.3.1.13,7]dec-1-ylurea
0.0000032
12-(3-adamantan-1-yl-ureido)-dodecanoic acid
Homo sapiens
-
0.0000008
12-(3-adamantan-1-yl-ureido)-dodecanoic acid butylester
Homo sapiens
-
0.0000032
12-(3-adamantan-1-yl-ureido)dodecanoic acid
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.0000022 - 0.000003
12-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]dodecanoic acid
0.000002
12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid
Homo sapiens
pH 7.0, 37°C
0.127
2-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazole
Homo sapiens
in 25 mM Bis-Tris HCl, pH 7.0, and 0.02% (v/v) Triton X-100, at 22°C
0.000001
2-(2,4-dichlorophenyl)-1-[6-(methylsulfonyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidin]-1'-yl]ethanone
Homo sapiens
-
0.1
2-(2,6-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one
Homo sapiens
above, pH not specified in the publication, 37°C
0.009
2-(2-fluorophenyl)-N-[(5-methylthiophen-2-yl)methyl]ethan-1-amine
Homo sapiens
37°C, pH 7.0
0.0043
2-(3,4-dihydroxy-5-methoxyphenyl)-5,7-dihydroxy-1-benzopyran-1-ium-3-yl beta-D-glucopyranoside
Homo sapiens
pH 7.0, 37°C
0.0102
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-1-benzopyran-1-ium
Homo sapiens
pH 7.0, 37°C
0.0146
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-1-benzopyran-1-ium-3-yl beta-D-glucopyranoside
Homo sapiens
pH 7.0, 37°C
0.0000283
2-(tricyclo[3.3.1.13,7]dec-1-yl)-N-[1-(trifluoroacetyl)piperidin-4-yl]acetamide
Homo sapiens
-
0.00051
2-([[2-(adamantan-1-yl)ethyl]amino]methyl)phenol
Homo sapiens
37°C, pH 7.0
0.015
2-cyclopentyl-N-(1,3-thiazol-2-yl)acetamide
Homo sapiens
in 25 mM Bis-Tris HCl, pH 7.0, and 0.02% (v/v) Triton X-100, at 22°C
0.0012
2-ethyl 3-[4-(N-(4-fluoro(2-trifluoromethyl)benzyl)-benzamide)]propionic acid
Homo sapiens
pH 7.0, 22°C
0.0009
2-ethyl-3-[3-(N-((2-trifluoromethyl)benzyl)benzamide)]-propionic acid
Homo sapiens
pH 7.0, 22°C
0.0016
2-ethyl-3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propionic acid
Homo sapiens
pH 7.0, 22°C
0.0015
2-ethyl-3-[4-(N-((4-chloro)benzyl)benzamide)]propionic acid
Homo sapiens
pH 7.0, 22°C
0.012
2-ethyl-3-[4-(N-((4-phenoxy)benzyl)benzamide)]propionic acid
Homo sapiens
pH 7.0, 22°C
0.014
2-ethyl-3-[4-(N-((4-trifluoromethoxy)benzyl)benzamide)]-propionic acid
Homo sapiens
pH 7.0, 22°C
0.0072
2-ethyl-3-[4-(N-((4-trifluoromethyl)benzyl)benzamide)]-propionic acid
Homo sapiens
pH 7.0, 22°C
0.00033
2-ethyl-3-[4-(N-(4-methoxy(2-trifluoromethyl)benzyl)-benzamide)]propionic acid
Homo sapiens
pH 7.0, 22°C
0.02082
2-methoxy-4-[7-methoxy-3-methyl-5-[(1E)-prop-1-en-1-yl]-1-benzofuran-2-yl]phenol
Homo sapiens
pH not specified in the publication, 37°C
0.008
2-methyl 3-[4-(N-((2-Trifluoromethyl)benzyl)benzamide)]-propionic acid
Homo sapiens
pH 7.0, 22°C
0.0025
2-phenyl-3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propionic acid
Homo sapiens
pH 7.0, 22°C
0.005
2-propyl-3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propionic acid
Homo sapiens
pH 7.0, 22°C
0.0001199
2-[2-(adamantan-1-yl)ethyl]-N-(3,5-dimethyladamantan-1-yl)hydrazine-1-carboxamide
Homo sapiens
pH 7.4, 37°C
0.0000285
2-[2-(adamantan-1-yl)ethyl]-N-[(adamantan-1-yl)methyl]hydrazine-1-carboxamide
Homo sapiens
pH 7.4, 37°C
0.0000796
2-[3-(adamantan-1-yl)propyl]-N-(3,5-dimethyladamantan-1-yl)hydrazine-1-carboxamide
Homo sapiens
pH 7.4, 37°C
0.0055
2-[4-(N-((2-trifluoromethyl)benzyl )benzamide)]-cyclopropanecarboxylic acid
Homo sapiens
pH 7.0, 22°C
0.000004
3,4-dihydro-1'H-spiro[chromene-2,4'-piperidin]-1'-yl[4-(trifluoromethyl)phenyl]methanone
Homo sapiens
-
0.195
3-(2-amino-1,3-thiazol-4-yl)-5-methyl-1-(tetrahydrofuran-2-ylmethyl)-1H-pyrrol-2-ol
Homo sapiens
in 25 mM Bis-Tris HCl, pH 7.0, and 0.02% (v/v) Triton X-100, at 22°C
0.000005
3-(3-amino-3-oxopropyl)-N-(4-chlorophenyl)-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.000001
3-([cis-4-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]cyclohexyl]oxy)benzoic acid
Homo sapiens
-
0.0000004
3-([[(adamantan-1-yl)methyl]carbamoyl]amino)adamantan-1-yl trifluoroacetate
Homo sapiens
pH 7.4, 37°C
0.000001
3-methyl-3-phenyl-N-(4-(pyridin-3-yl)benzyl)piperidine-1-carboxamide
Homo sapiens
-
0.00055
3-methyl-3-phenyl-N-(pyridin-4-yl)piperidine-1-carboxamide
Homo sapiens
-
0.000007
3-methyl-3-phenyl-N-[3-(pyridin-3-yl)propyl]piperidine-1-carboxamide
Homo sapiens
-
0.000001
3-methyl-3-phenyl-N-[3-[(1S,2S)-2-phenylcyclopropyl]benzyl]piperidine-1-carboxamide
Homo sapiens
-
0.000005
3-methyl-3-phenyl-N-[3-[2-(quinoxalin-6-yl)ethyl]benzyl]piperidine-1-carboxamide
Homo sapiens
-
0.000008
3-methyl-3-phenyl-N-[[2'-(trifluoromethyl)biphenyl-4-yl]methyl]piperidine-1-carboxamide
Homo sapiens
-
0.000019
3-[1-[(4-chlorophenyl)carbamoyl]-3-(pyridin-2-yl)piperidin-3-yl]propanoic acid
Homo sapiens
-
0.000028
3-[1-[(4-chlorophenyl)carbamoyl]-3-(pyridin-3-yl)piperidin-3-yl]propanoic acid
Homo sapiens
-
0.00003
3-[1-[(4-chlorophenyl)carbamoyl]-3-(pyridin-4-yl)piperidin-3-yl]propanoic acid
Homo sapiens
-
0.000005 - 0.000016
3-[1-[(4-chlorophenyl)carbamoyl]-3-phenylpiperidin-3-yl]propanoic acid
0.000012
3-[1-[(4-chlorophenyl)carbamoyl]-3-[3-(trifluoromethyl)phenyl]piperidin-3-yl]propanoic acid
Homo sapiens
-
0.000005
3-[1-[(4-chlorophenyl)carbamoyl]-3-[4-(trifluoromethyl)phenyl]piperidin-3-yl]propanoic acid
Homo sapiens
-
0.000008
3-[3-(biphenyl-4-yl)-1-[(4-chlorophenyl)carbamoyl]piperidin-3-yl]propanoic acid
Homo sapiens
-
0.15
3-[4-(benzyloxy)phenyl]propan-1-ol
Homo sapiens
37°C, pH 7.0
0.009
3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]propionic acid
Homo sapiens
pH 7.0, 22°C
0.0001
3-[4-[(1-[[(1R,3S)-2,2-dimethyl-3-phenylcyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.0000191
3-[4-[(1-[[(1S,2R)-2-phenylcyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.000012
3-[4-[(1-[[(1S,2R,3R)-2-methyl-3-phenylcyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.0000021
3-[4-[(1-[[(1s,2R,3S)-2,3-bis(4-fluorophenyl)cyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.0000023
3-[4-[(1-[[(1s,2R,3S)-2,3-diphenylcyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.0000757
3-[4-[(1-[[(1S,2S,3R)-2-methyl-3-phenylcyclopropyl]carbamoyl]piperidin-4-yl)oxy]phenyl]propanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.000008
4'-hydroxy-N-(2-phenylcyclopropyl)-3',4'-dihydro-1H-spiro[piperidine-4,2'-pyrano[3,2-b]pyridine]-1-carboxamide
Homo sapiens
-
0.001
4'-[([2-(trifluoromethyl)phenyl]methyl)carbamoyl][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH 7.0, 22°C
0.00017
4'-[([2-(trifluoromethyl)phenyl]methyl)carbamoyl][1,1'-biphenyl]-4-carboxylic acid
Homo sapiens
pH 7.0, 22°C
0.000045
4,4-diphenyl-N-(pyridin-3-yl)-butyramide
Homo sapiens
-
0.000002
4-((4-(3-(adamantan-1-yl)ureido)trans-cyclohexyl)oxy)benzoic acid
Homo sapiens
pH 7.4, 37°C
0.000054
4-(1,2,4-oxadiazol-3-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
Homo sapiens
-
0.000235
4-(1,3,4-oxadiazol-2-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
Homo sapiens
-
0.0000075
4-(1,3-benzoxazol-2-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
Homo sapiens
-
0.00012
4-(1-methyl-1H-1,2,3-triazol-4-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
Homo sapiens
-
0.00043
4-(2,3-dihydro-1H-1,2,3-triazol-1-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
Homo sapiens
-
0.0011
4-(3-hydroxy-4-methyl-1,2-oxazol-5-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
Homo sapiens
-
0.000028
4-(3-methyl-1,2,4-oxadiazol-5-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
Homo sapiens
-
0.0084
4-(4-methyl-4H-1,2,4-triazol-3-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
Homo sapiens
-
0.0000041
4-(5-phenyl-3-[3-[3-(3-trifluoromethyl-phenyl)-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonamide
Homo sapiens
pH 7.0, 30°C
0.0000005
4-(5-phenyl-3-[3-[3-(4-trifluoromethoxy-phenyl)-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonamide
Homo sapiens
pH 7.0, 30°C
0.0000009
4-(5-phenyl-3-[3-[3-(4-trifluoromethyl-phenyl)-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonamide
Homo sapiens
pH 7.0, 30°C
0.000005
4-(5-[1-[(2-phenylcyclopropyl)carbamoyl]piperidin-4-yl]-1,2,4-oxadiazol-3-yl)benzoic acid
Homo sapiens
-
0.000008
4-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.000002
4-([trans-4-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]cyclohexyl]oxy)benzoic acid
Homo sapiens
-
0.061
4-benzyl-3,4-dihydroquinoxalin-2(1H)-one
Homo sapiens
in 25 mM Bis-Tris HCl, pH 7.0, and 0.02% (v/v) Triton X-100, at 22°C
0.000005
4-cyano-N-[3,3-bis-(4-fluorophenyl)-propyl]-benzamide
Homo sapiens
-
0.1
4-hydroxy-3,5-dimethoxybenzaldehyde
Homo sapiens
above, pH not specified in the publication, 37°C
0.1
4-hydroxy-3-methoxybenzaldehyde
Homo sapiens
above, pH not specified in the publication, 37°C
0.000003
4-oxo-N-(1,2,3,4-tetrahydronaphthalen-2-yl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
Homo sapiens
-
0.000001
4-oxo-N-(2-phenylcyclopropyl)-6-(pyridin-4-yl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
Homo sapiens
-
0.000008
4-oxo-N-(3-phenylcyclopentyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
Homo sapiens
-
0.00002
4-oxo-N-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-yl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
Homo sapiens
-
0.000003
4-oxo-N-[(1S,2R)-2-phenylcyclopropyl]-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
Homo sapiens
-
0.0000005
4-[(4-[[(3-methyladamantan-1-yl)carbamoyl]amino]cyclohexyl)oxy]benzoic acid
Homo sapiens
pH 7.4, 37°C
0.000012
4-[1-[(4-chlorophenyl)carbamoyl]-3-phenylpiperidin-3-yl]butanoic acid
Homo sapiens
-
0.00001
4-[3-(isoquinolin-1-yl)-1,2,4-oxadiazol-5-yl]-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
Homo sapiens
-
0.000008
4-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]-N-(1,2,3,4-tetrahydronaphthalen-2-yl)piperidine-1-carboxamide
Homo sapiens
-
0.000036
4-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]-N-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-yl)piperidine-1-carboxamide
Homo sapiens
-
0.000007
4-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]-N-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide
Homo sapiens
-
0.000004
4-[3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl]-N-(2-phenylcyclopropyl)piperidine-1-carboxamide
Homo sapiens
-
0.0000016
4-[[(1r,4r)-4-([[(adamantan-1-yl)methyl]carbamoyl]amino)cyclohexyl]oxy]benzoic acid
Homo sapiens
pH 7.4, 37°C
0.0000017
4-[[(1r,4r)-4-[[(3,5,7-trimethyladamantan-1-yl)carbamoyl]amino]cyclohexyl]oxy]benzoic acid
Homo sapiens
pH 7.4, 37°C
0.0000008
4-[[(1r,4r)-4-[[(3,5-dimethyladamantan-1-yl)carbamoyl]amino]cyclohexyl]oxy]benzoic acid
Homo sapiens
pH 7.4, 37°C
0.0000014
4-[[(1r,4r)-4-[[(3-chloroadamantan-1-yl)carbamoyl]amino]cyclohexyl]oxy]benzoic acid
Homo sapiens
pH 7.4, 37°C
0.0000018
4-[[(1r,4r)-4-[[(3-ethyladamantan-1-yl)carbamoyl]amino]cyclohexyl]oxy]benzoic acid
Homo sapiens
pH 7.4, 37°C
0.0000005
4-[[(1r,4r)-4-[[(3-methyladamantan-1-yl)carbamoyl]amino]cyclohexyl]oxy]benzoic acid
Homo sapiens
pH 7.4, 37°C
0.0000045
4-[[(2R,5R)-5-[[(2-oxoadamantan-1-yl)carbamoyl]amino]piperidin-2-yl]oxy]benzoic acid
Homo sapiens
pH 7.4, 37°C
0.000001
4-[[cis-4-([[4-(trifluoromethoxy)phenyl]carbamoyl]amino)cyclohexyl]oxy]benzoic acid
Homo sapiens
-
0.1
5,6,7-trihydroxy-2-phenyl-4H-1-benzopyran-4-one
Homo sapiens
above, pH not specified in the publication, 37°C
0.1
5,6,7-trihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one
Homo sapiens
above, pH not specified in the publication, 37°C
0.03389
5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl D-threo-hexopyranosiduronic acid
Homo sapiens
pH not specified in the publication, 37°C
0.1
5,7,8-trihydroxy-2-phenyl-4H-1-benzopyran-4-one
Homo sapiens
above, pH not specified in the publication, 37°C
0.03391 - 0.08008
5,7-dihydroxy-2-(2-hydroxy-6-methoxyphenyl)-4H-1-benzopyran-4-one
0.1
5,7-dihydroxy-2-(2-hydroxyphenyl)-4H-1-benzopyran-4-one
Homo sapiens
above, pH not specified in the publication, 37°C
0.1
5,7-dihydroxy-2-(2-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-one
Homo sapiens
above, pH not specified in the publication, 37°C
0.0112
5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyran-1-ium-3-yl beta-D-galactopyranoside
Homo sapiens
pH 7.0, 37°C
0.0253
5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyran-1-ium-3-yl beta-D-glucopyranoside
Homo sapiens
pH 7.0, 37°C
0.1
5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one
Homo sapiens
above, pH not specified in the publication, 37°C
0.04482
5,7-dihydroxy-6-methoxy-2-phenyl-4H-1-benzopyran-4-one
Homo sapiens
pH not specified in the publication, 37°C
0.1
5,7-dihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one
Homo sapiens
above, pH not specified in the publication, 37°C
0.07
5-(4-bromobenzyl)-1,3-thiazol-2-amine
Homo sapiens
in 25 mM Bis-Tris HCl, pH 7.0, and 0.02% (v/v) Triton X-100, at 22°C
0.00004
5-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.01
5-benzyl-N-phenyl-1,3,4-oxadiazol-2-amine
Homo sapiens
above
0.1
5-hydroxy-2-(2-hydroxy-6-methoxyphenyl)-6,7,8-trimethoxy-4H-1-benzopyran-4-one
Homo sapiens
above, pH not specified in the publication, 37°C
0.1
5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-methoxy-4H-1-benzopyran-4-one
Homo sapiens
pH not specified in the publication, 37°C
0.0063
5-methyl-N-(2-phenylethyl)-4,5-dihydro-1,3-thiazol-2-amine
Homo sapiens
in 25 mM Bis-Tris HCl, pH 7.0, and 0.02% (v/v) Triton X-100, at 22°C
0.0047
5-phenyl-N-[4-(trifluoromethyl)benzyl]-1,2-oxazol-3-amine
Homo sapiens
-
0.01
5-phenyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazol-3-amine
Homo sapiens
above
0.000005
5-[1-[(4-chlorophenyl)carbamoyl]-3-phenylpiperidin-3-yl]pentanoic acid
Homo sapiens
-
0.000008 - 0.000011
6'-(methylsulfonyl)-N-(2-phenylcyclopropyl)-1H,4'H-spiro[azepane-4,3'-chromene]-1-carboxamide
0.000004
6-(1-methyl-1H-pyrazol-5-yl)-4-oxo-N-(2-phenylcyclopropyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
Homo sapiens
-
0.00007
6-(1H-indol-5-yl)-N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.000091
6-(2-fluorophenyl)-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.00007
6-(3-methylpyridin-2-yl)-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.000019
6-(isoquinolin-5-yl)-N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.000003 - 0.000011
6-(methylsulfonyl)-4-oxo-N-(2-phenylcyclopropyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
0.000023
6-(pyridin-3-yl)-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.000058
6-(pyridin-4-yl)-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.049
6-(trifluoromethyl)-1,3-benzothiazol-2-amine
Homo sapiens
in 25 mM Bis-Tris HCl, pH 7.0, and 0.02% (v/v) Triton X-100, at 22°C
0.000018
6-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.029
6-amino-1-methyl-5-(piperidin-1-yl)pyrimidine-2,4(1H,3H)-dione
Homo sapiens
in 25 mM Bis-Tris HCl, pH 7.0, and 0.02% (v/v) Triton X-100, at 22°C
0.00052
6-amino-N-(2,4-dichlorobenzyl)pyridine-3-carboxamide
Homo sapiens
-
0.0000091
6-amino-N-(3,3-diphenylpropyl)pyridine-3-carboxamide
Homo sapiens
-
0.000003
6-fluoro-N-(2-phenylcyclopropyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
Homo sapiens
-
0.01
6-phenyl-N-[3-(trifluoromethyl)benzyl]pyrimidin-4-amine
Homo sapiens
above
0.000003
6-[(1-methyl-1H-pyrazol-5-yl)amino]-4-oxo-N-(2-phenylcyclopropyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
Homo sapiens
-
0.00047
6-[3-(trifluoromethyl)phenyl]-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.000008
7-(1H-indol-5-yl)-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.000004
7-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.01
7-(trifluoromethyl)-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
Homo sapiens
above
0.000019
7-(trifluoromethyl)-N-[5-(trifluoromethyl)pyridin-2-yl][1,2]oxazolo[5,4-c]pyridin-3-amine
Homo sapiens
-
0.000074
7-(trifluoromethyl)-N-[6-(trifluoromethyl)pyridin-3-yl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.000004
7-[2-(trifluoromethyl)phenyl]-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.00001
7-[3-(trifluoromethyl)phenyl]-N-[5-(trifluoromethyl)pyridin-2-yl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.000015
APAU
Homo sapiens
pH 7.4, 30°C
0.000003
AUDA
Homo sapiens
pH 7.4, 30°C
0.000001
butyl 12-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]dodecanoate
Homo sapiens
recombinant enzyme expressed in Escherichia coli or Sf9 cells
0.0000009
cis-1-adamantan-1-yl-3-(4-benzyloxycyclohexyl)urea
Homo sapiens
pH 7.4, 30°C
0.0000015
cis-1-adamantan-1-yl-3-[4-(2,6-dichlorobenzyloxy)cyclohexyl]-urea
Homo sapiens
pH 7.4, 30°C
0.0000011
cis-1-adamantan-1-yl-3-[4-(2,6-difluorobenzyloxy)cyclohexyl]-urea
Homo sapiens
pH 7.4, 30°C
0.0000013
cis-1-adamantan-1-yl-3-[4-(4-bromophenoxy)cyclohexyl]urea
Homo sapiens
pH 7.4, 30°C
0.000001
cis-1-adamantan-1-yl-3-[4-(4-fluorophenoxy)cyclohexyl]-urea
Homo sapiens
pH 7.4, 30°C
0.00000055
cis-1-adamantan-1-yl-3-[4-(4-methoxyphenoxy)cyclohexyl]-urea
Homo sapiens
pH 7.4, 30°C
0.00000072
cis-1-adamantan-1-yl-3-[4-(4-nitrophenoxy)cyclohexyl]urea
Homo sapiens
pH 7.4, 30°C
0.0000019
cis-3-[4-(3-adamantan-1-ylureido)cyclohexyloxy]benzoic acid
Homo sapiens
pH 7.4, 30°C
0.0000006
cis-4-(4-[3-(4-trifluoromethoxyphenyl)ureido]cyclohexyloxy)-benzoic acid
Homo sapiens
pH 7.4, 30°C
0.00004
ethyl (E)-3-[N-((2-trifluoromethyl)benzyl)benzamide]-alpha-ethylcinnamate
Homo sapiens
pH 7.0, 22°C
0.0004
ethyl (E)-3-[N-((2-trifluoromethyl)benzyl)benzamide]-alpha-ethylcinnamic acid
Homo sapiens
pH 7.0, 22°C
0.000063
ethyl (E)-4-[N-((2-(trifluoromethyl)-benzyl)benzamide]-alpha-ethylcinnamate
Homo sapiens
pH 7.0, 22°C
0.000027
ethyl 2-ethyl 3-[3-(N-((2-trifluoromethyl)benzyl)benzamide)]-propanoate
Homo sapiens
pH 7.0, 22°C
0.000044
ethyl 2-ethyl 3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]propanoate
Homo sapiens
pH 7.0, 22°C
0.0017
ethyl 2-ethyl 3-[4-(N-((4-chloro)benzyl)benzamide)]-propanoate
Homo sapiens
pH 7.0, 22°C
0.0022
ethyl 2-ethyl 3-[4-(N-((4-fluoro)benzyl)benzamide)]-propanoate
Homo sapiens
pH 7.0, 22°C
0.00062
ethyl 2-ethyl 3-[4-(N-((4-methoxy)benzyl)benzamide)]-propanoate
Homo sapiens
pH 7.0, 22°C
0.0009
ethyl 2-ethyl 3-[4-(N-((4-trifluoromethoxy)benzyl)-benzamide)]propanoate
Homo sapiens
pH 7.0, 22°C
0.00057
ethyl 2-ethyl 3-[4-(N-((4-trifluoromethyl)benzyl)benzamide)]-propanoate
Homo sapiens
pH 7.0, 22°C
0.00012
ethyl 2-ethyl 3-[4-(N-(4-fluoro(2-trifluoromethyl)benzyl)-benzamide)]propanoate
Homo sapiens
pH 7.0, 22°C
0.00003
ethyl 2-ethyl 3-[4-(N-(4-methoxy(2-trifluoromethyl)benzyl)-benzamide)]propanoate
Homo sapiens
pH 7.0, 22°C
0.004
ethyl 2-ethyl-3-[4-(N-((2-bromo)benzyl)benzamide)]-propanoate
Homo sapiens
pH 7.0, 22°C
0.0038
ethyl 2-ethyl-3-[4-(N-((2-chloro)benzyl)benzamide)]-propanoate
Homo sapiens
pH 7.0, 22°C
0.0009
ethyl 2-ethyl-3-[4-(N-((2-methyl)benzyl)benzamide)]-propanoate
Homo sapiens
pH 7.0, 22°C
0.00003
ethyl 2-ethyl-3-[4-(N-((2-trifluoromethoxy)benzyl)-benzamide)]prop
Homo sapiens
pH 7.0, 22°C
0.0085
ethyl 2-ethyl-3-[4-(N-benzylbenzamide)]propanoate
Homo sapiens
pH 7.0, 22°C
0.00025
ethyl 2-methyl 3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propanoate
Homo sapiens
pH 7.0, 22°C
0.00012
ethyl 2-phenyl 3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propanoate
Homo sapiens
pH 7.0, 22°C
0.00017
ethyl 2-propyl 3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propanoate
Homo sapiens
pH 7.0, 22°C
0.00011
ethyl 3-[4-(N-((2-trifluoromethyl)benzyl)benzamide)]-propanoate
Homo sapiens
pH 7.0, 22°C
0.000014
IK950
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.0000017
methyl 2-([4-[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]piperidin-1-yl]carbonyl)benzoate
Homo sapiens
-
0.000003
methyl 2-hydroxy-4-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]benzoate
Homo sapiens
-
0.0000018
methyl 2-[(4-[[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]methyl]piperidin-1-yl)carbonyl]benzoate
Homo sapiens
-
0.0000011
methyl 3-([4-[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]piperidin-1-yl]carbonyl)benzoate
Homo sapiens
-
0.0000041
methyl 3-[(4-[[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]methyl]piperidin-1-yl)carbonyl]benzoate
Homo sapiens
-
0.000001
methyl 3-[1-[(4-chlorophenyl)carbamoyl]-3-phenylpiperidin-3-yl]propanoate
Homo sapiens
below
0.0000011
methyl 4-([4-[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]piperidin-1-yl]carbonyl)benzoate
Homo sapiens
-
0.0000015
methyl 4-[(4-[[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]methyl]piperidin-1-yl)carbonyl]benzoate
Homo sapiens
-
0.0000091
methyl 4-[[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]methyl]benzoate
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.0000034
methyl 5-oxo-5-(4-[[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]methyl]piperidin-1-yl)pentanoate
Homo sapiens
-
0.0000027
methyl 5-oxo-5-[4-[(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)amino]piperidin-1-yl]pentanoate
Homo sapiens
-
0.01
N,5-dibenzyl-1,3,4-oxadiazol-2-amine
Homo sapiens
above
0.0168
N,N'-(butane-1,4-diyl)bis[4-(adamantan-2-yl)piperazine-1-carboxamide]
Homo sapiens
pH 7.4, 37°C
0.0004086
N,N'-1,2-phenylenebis[N'-(3-chloroadamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.001364
N,N'-1,2-phenylenebis[N'-[(adamantan-1-yl)methyl]urea]
Homo sapiens
pH 7.4, 37°C
0.000779
N,N'-1,4-phenylenebis[N'-[(adamantan-1-yl)methyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000016
N,N'-bis(3,5,7-trimethyladamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.0000011
N,N'-bis(3,5-dimethyladamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.0000006
N,N'-bis(3-chloroadamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.000004
N,N'-bis(3-ethyladamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.0000054
N,N'-bis[(adamantan-1-yl)methyl]urea
Homo sapiens
pH 7.4, 37°C
0.0000234
N,N'-butane-1,4-diylbis[N'-(3,5-dimethyladamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.0000013
N,N'-butane-1,4-diylbis[N'-(3-chloroadamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.0000011
N,N'-butane-1,4-diylbis[N'-(3-ethyladamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.0000007
N,N'-butane-1,4-diylbis[N'-[(3,5-dimethyladamantan-1-yl)methyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000009
N,N'-butane-1,4-diylbis[N'-[(adamantan-1-yl)methyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000019
N,N'-butane-1,4-diylbis[N'-[1-(adamantan-1-yl)-2-methylpropan-2-yl]urea]
Homo sapiens
pH 7.4, 37°C
0.000605
N,N'-butane-1,4-diylbis[N'-[2-(adamantan-1-yl)-2-phenylethyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000034
N,N'-butane-1,4-diylbis[N'-[2-(adamantan-1-yl)ethyl]urea]
Homo sapiens
pH 7.4, 37°C
0.003299
N,N'-butane-1,4-diylbis[N'-[2-(adamantan-1-yl)pentyl]urea]
Homo sapiens
pH 7.4, 37°C
0.001792
N,N'-butane-1,4-diylbis[N'-[4-(adamantan-1-yl)phenyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000009
N,N'-decane-1,10-diylbis[N'-(3-chloroadamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.0001445
N,N'-ethane-1,2-diylbis[N'-(3-chloroadamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.0001792
N,N'-ethane-1,2-diylbis[N'-[(adamantan-1-yl)methyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000014
N,N'-heptane-1,7-diylbis[N'-(3-chloroadamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.0000004
N,N'-heptane-1,7-diylbis[N'-[(adamantan-1-yl)methyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000094
N,N'-hexane-1,6-diylbis(N'-[3-[(adamantan-1-yl)oxy]propyl]urea)
Homo sapiens
pH 7.4, 37°C
0.0000016
N,N'-hexane-1,6-diylbis[N'-(3-chloroadamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.0000085
N,N'-hexane-1,6-diylbis[N'-(3-ethyladamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.000001
N,N'-hexane-1,6-diylbis[N'-[(3,5-dimethyladamantan-1-yl)methyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000005
N,N'-hexane-1,6-diylbis[N'-[1-(adamantan-1-yl)ethyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000043
N,N'-hexane-1,6-diylbis[N'-[2-(adamantan-1-yl)-2-methylpropyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000915
N,N'-hexane-1,6-diylbis[N'-[2-(adamantan-1-yl)-2-phenylethyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000028
N,N'-hexane-1,6-diylbis[N'-[2-(adamantan-1-yl)butyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000008
N,N'-hexane-1,6-diylbis[N'-[2-(adamantan-1-yl)ethyl]urea]
Homo sapiens
pH 7.4, 37°C
0.035
N,N'-hexane-1,6-diylbis[N'-[2-(adamantan-1-yl)pentyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0005293
N,N'-hexane-1,6-diylbis[N'-[4-(adamantan-1-yl)phenyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000027
N,N'-octane-1,8-diylbis(N'-[3-[(adamantan-1-yl)oxy]propyl]urea)
Homo sapiens
pH 7.4, 37°C
0.0000037
N,N'-octane-1,8-diylbis[N'-(3,5-dimethyladamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.0000012
N,N'-octane-1,8-diylbis[N'-(3-chloroadamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.0000025
N,N'-octane-1,8-diylbis[N'-[(3,5-dimethyladamantan-1-yl)methyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000006 - 0.0000007
N,N'-octane-1,8-diylbis[N'-[(adamantan-1-yl)methyl]urea]
0.0000067
N,N'-octane-1,8-diylbis[N'-[2-(adamantan-1-yl)-2-methylpropyl]urea]
Homo sapiens
pH 7.4, 37°C
0.000205
N,N'-octane-1,8-diylbis[N'-[2-(adamantan-1-yl)-2-phenylethyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000015
N,N'-octane-1,8-diylbis[N'-[2-(adamantan-1-yl)ethyl]urea]
Homo sapiens
pH 7.4, 37°C
0.1
N,N'-octane-1,8-diylbis[N'-[2-(adamantan-1-yl)pentyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0002591
N,N'-octane-1,8-diylbis[N'-[4-(adamantan-1-yl)phenyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000018
N,N'-pentane-1,5-diylbis[N'-(3-chloroadamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.0000012
N,N'-pentane-1,5-diylbis[N'-(3-ethyladamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.0000009
N,N'-pentane-1,5-diylbis[N'-[(adamantan-1-yl)methyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000017
N,N'-propane-1,3-diylbis[N'-(3-chloroadamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.0000017
N,N'-propane-1,3-diylbis[N'-(3-ethyladamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.0000009
N,N'-propane-1,3-diylbis[N'-[(adamantan-1-yl)methyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000012
N,N'-undecane-1,11-diylbis[N'-[(adamantan-1-yl)methyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000019
N,N'-[1,4-phenylenebis(methylene)]bis[N'-(3,5-dimethyladamantan-1-yl)urea]
Homo sapiens
pH 7.4, 37°C
0.000059
N-(1,2-benzoxazol-3-yl)-3-methyl-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.000274
N-(1-acetylpiperidin-4-yl)-2-(tricyclo[3.3.1.13,7]dec-1-yl)acetamide
Homo sapiens
-
0.000007
N-(1-acetylpiperidin-4-yl)-N'-(adamant-1-yl) urea
Homo sapiens
-
0.58
N-(1-tert-butoxyethenyl)-1,2,3,4-tetrahydroquinolin-3-amine
Homo sapiens
37°C, pH 7.0
0.0000011
N-(1-trifluoroacetylpiperidin-4-yl)-N'-(adamant-1-yl) urea
Homo sapiens
-
0.003
N-(2,2-diphenyl-ethyl)-nicotinamide
Homo sapiens
-
0.000005
N-(2,3-dihydro-1H-inden-1-yl)-4-oxo-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
Homo sapiens
-
0.00013
N-(2,3-dihydro-1H-inden-1-yl)-4-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
Homo sapiens
-
0.000016
N-(2,4-dichlorobenzyl)-1-(2-ethoxyethyl)-6-oxo-1,6-dihydropyridine-3-carboxamide
Homo sapiens
-
0.000001
N-(2,4-dichlorobenzyl)-3-methyl-3-phenylpiperidine-1-carboxamide
Homo sapiens
below
0.0000066
N-(2,4-dichlorobenzyl)-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide
Homo sapiens
-
0.0004
N-(2,4-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxamide
Homo sapiens
-
0.0015
N-(2,4-dichlorobenzyl)-6-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-carboxamide
Homo sapiens
-
0.000014
N-(2-chloro-4-cyanobenzyl)-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
Homo sapiens
-
0.000021
N-(2-chlorobenzyl)-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
Homo sapiens
-
0.0000004
N-(2-oxoadamantan-1-yl)-N'-1,3,5-triazatricyclo[3.3.1.13,7]decan-7-ylurea
Homo sapiens
pH 7.4, 37°C
0.000005
N-(2-phenylcyclopropyl)-3',4'-dihydro-1H-spiro[piperidine-4,2'-pyrano[3,2-b]pyridine]-1-carboxamide
Homo sapiens
-
0.000004
N-(2-phenylcyclopropyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
Homo sapiens
-
0.0011
N-(2-phenylcyclopropyl)-4-(1H-1,2,4-triazol-1-yl)piperidine-1-carboxamide
Homo sapiens
-
0.00048
N-(2-phenylcyclopropyl)-4-(1H-pyrazol-1-yl)piperidine-1-carboxamide
Homo sapiens
-
0.000013
N-(2-phenylcyclopropyl)-4-[3-(pyrazin-2-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
Homo sapiens
-
0.000009
N-(2-phenylcyclopropyl)-4-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
Homo sapiens
-
0.000007
N-(2-phenylcyclopropyl)-4-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
Homo sapiens
-
0.000014
N-(2-phenylcyclopropyl)-4-[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
Homo sapiens
-
0.000033
N-(2-phenylcyclopropyl)-4-[3-(pyrimidin-2-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
Homo sapiens
-
0.000007
N-(2-phenylcyclopropyl)-4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
Homo sapiens
-
0.000009
N-(2-phenylcyclopropyl)-4-[3-[2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]piperidine-1-carboxamide
Homo sapiens
-
0.000031
N-(3,3-diphenyl-propyl)-2-pyridine-3-ylacetamide
Homo sapiens
-
0.0000079
N-(3,3-diphenyl-propyl)-isonicotinamide
Homo sapiens
-
0.000007
N-(3,3-diphenyl-propyl)-nicotinamide
Homo sapiens
-
0.0000026
N-(3,3-diphenylpropyl)-1-(2-ethoxyethyl)-6-oxo-1,6-dihydropyridine-3-carboxamide
Homo sapiens
-
0.0000054
N-(3,3-diphenylpropyl)-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide
Homo sapiens
-
0.0000081
N-(3,3-diphenylpropyl)-6-oxo-1,6-dihydropyridine-3-carboxamide
Homo sapiens
-
0.000018
N-(3,3-diphenylpropyl)-6-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-carboxamide
Homo sapiens
-
0.0000065
N-(3,5,7-trimethyladamantan-1-yl)-4-([[(3,5,7-trimethyladamantan-1-yl)carbamoyl]amino]methyl)piperidine-1-carboxamide
Homo sapiens
pH 7.4, 37°C
0.0000033
N-(3,5-dimethyladamantan-1-yl)-N'-(1-propanoylpiperidin-4-yl)urea
Homo sapiens
pH 7.4, 37°C
0.00016
N-(3,5-dimethyladamantan-1-yl)-N'-(3,5,7-trimethyladamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.002894
N-(3,5-dimethyladamantan-1-yl)-N'-1,3,5-triazatricyclo[3.3.1.13,7]decan-7-ylurea
Homo sapiens
pH 7.4, 37°C
0.0000015
N-(3,5-dimethyladamantan-1-yl)-N'-[(3-ethyladamantan-1-yl)methyl]urea
Homo sapiens
pH 7.4, 37°C
0.002475
N-(3,5-dimethyladamantan-1-yl)-N'-[4-([[(3,5-dimethyladamantan-1-yl)carbamoyl]amino]methyl)phenyl]urea
Homo sapiens
pH 7.4, 37°C
0.0000038 - 0.0002686
N-(3-ethyladamantan-1-yl)-N'-(1-propanoylpiperidin-4-yl)urea
0.0000399
N-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-2-(tricyclo[3.3.1.13,7]dec-1-yl)acetamide
Homo sapiens
-
0.0007
N-(3-phenyl-propyl)-nicotinamide
Homo sapiens
-
0.00012
N-(4,4-diphenyl-butyl)-nicotinamide
Homo sapiens
-
0.000204
N-(4-(N1-methyl-N2-methyl-N2-(methyloxy)oxalamido)-benzyl)adamantanecarboxamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.001
N-(4-(N2-(tetrahydro-2H-pyran-2-yloxy)oxalamido)benzyl)adamantanecarboxamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.00019
N-(4-(N2-methyl-N2-(methyloxy)oxalamido)benzyl)adamantanecarboxamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.00018
N-(4-(N2-methyloxyoxalamido)benzyl)adamantanecarboxamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.000408
N-(4-(N2-tert-butyloxyoxalamido)benzyl)adamantanecarboxamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.000012
N-(4-bromo-2-cyanobenzyl)-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
Homo sapiens
-
0.000077
N-(4-chlorobenzyl)-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
Homo sapiens
-
0.000003
N-(4-chlorophenyl)-3-(2-cyanoethyl)-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.000001
N-(4-chlorophenyl)-3-(2-hydroxyethyl)-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.0000013
N-(4-chlorophenyl)-3-(3-hydroxypropyl)-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.000001
N-(4-chlorophenyl)-3-methyl-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.000005
N-(4-chlorophenyl)-3-phenyl-3-[2-(1H-tetrazol-5-yl)ethyl]piperidine-1-carboxamide
Homo sapiens
-
0.000012
N-(4-chlorophenyl)-3-[2-(dimethylamino)ethyl]-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.0000014
N-(4-chlorophenyl)-3-[2-oxo-2-(1H-tetrazol-5-ylamino)ethyl]-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.000003
N-(4-chlorophenyl)-3-[3-(diethylamino)-3-oxopropyl]-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.000005
N-(4-chlorophenyl)-3-[3-(methylamino)-3-oxopropyl]-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.000008
N-(4-chlorophenyl)-3-[3-(morpholin-4-yl)-3-oxopropyl]-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.000029
N-(4-chlorophenyl)-3-[3-oxo-3-(1H-tetrazol-5-ylamino)propyl]-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.0000072
N-(4-[[(adamantan-1-yl)carbamoyl]amino]butyl)-N'-(3,5-dimethyladamantan-1-yl)urea
Homo sapiens
pH and temperature not specified in the publication
0.000032
N-(5-chloro-1,3-benzoxazol-2-yl)-2-cyclopentylacetamide
Homo sapiens
pH 7.4, 22°C
0.0000003
N-(6-[[(adamantan-1-yl)carbamoyl]amino]hexyl)-N'-(3,5-dimethyladamantan-1-yl)urea
Homo sapiens
pH and temperature not specified in the publication
0.000997
N-(8-[[(adamantan-1-yl)carbamoyl]amino]octyl)-N'-(3,5-dimethyladamantan-1-yl)urea
Homo sapiens
pH and temperature not specified in the publication
0.01
N-(benzyloxy)-2-(adamant-2-ylamino)acetamide
Homo sapiens
IC50 above 0.01 mM, in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.00096
N-(biphenyl-3-yl)-1,2-benzoxazol-3-amine
Homo sapiens
-
0.000007
N-(biphenyl-3-yl)-3-methyl-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.00017
N-(biphenyl-4-yl)-1,2-benzoxazol-3-amine
Homo sapiens
-
0.00084
N-(naphthalen-1-yl)-1,2-benzoxazol-3-amine
Homo sapiens
-
0.0012
N-(naphthalen-2-yl)-1,2-benzoxazol-3-amine
Homo sapiens
-
0.0000012
N-([1-(phenylcarbonyl)piperidin-4-yl]methyl)-N'-(adamant-1-yl) urea
Homo sapiens
-
0.0000032
N-([1-(trifluoroacetyl)piperidin-4-yl]methyl)-N'-(adamant-1-yl) urea
Homo sapiens
-
0.0000061
N-adamantan-1-yl-N'-(3,5,7-trimethyladamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.0000096
N-adamantan-1-yl-N'-(3,5-dimethyladamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.000084
N-adamantan-1-yl-N'-(5-hydroxypentyl)urea
Homo sapiens
pH 7.4, 37°C
0.0000024 - 0.0000027
N-adamantan-1-yl-N'-[(3-ethyladamantan-1-yl)methyl]urea
0.000014
N-adamantan-1-yl-N'-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]urea
Homo sapiens
pH 7.4, 37°C
0.000015
N-adamantan-1-yl-N'-[5-[2-(2-hydroxyethoxy)ethoxy]pentyl]urea
Homo sapiens
pH 7.4, 37°C
0.01
N-benzyl-1,3-benzothiazol-2-amine
Homo sapiens
above
0.01
N-benzyl-1,3-benzoxazol-2-amine
Homo sapiens
above
0.01
N-benzyl-4-phenylpyridin-2-amine
Homo sapiens
above
0.01
N-benzyl-5-phenyl-1,3,4-oxadiazol-2-amine
Homo sapiens
above
0.01
N-benzyl-5-phenylpyrazin-2-amine
Homo sapiens
above
0.01
N-benzyl-5-phenylpyridin-2-amine
Homo sapiens
above
0.0012
N-benzyl-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
Homo sapiens
-
0.01
N-benzylquinoxalin-2-amine
Homo sapiens
above
0.001
N-benzyltricyclo[3.3.1.13,7]decane-1-carboxamide
Homo sapiens
IC50 above 0.001 mM, in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.00014
N-cyclohexyl-N'-(4-iodophenyl)urea
Homo sapiens
recombinant enzyme, pH 7.0, 22°C
0.00008
N-methoxy-N-methyl 3-[4-(N-((2-trifluoromethyl)benzyl)-benzamide)]cyclopropanecarboxamide
Homo sapiens
pH 7.0, 22°C
2.2
N-methyl-1-[3-(pyridin-3-yl)phenyl]methanamine
Homo sapiens
37°C, pH 7.0
0.002
N-phenyl-5-(trifluoromethyl)-1,3,4-oxadiazol-2-amine
Homo sapiens
-
0.8
N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-phenylethan-1-amine
Homo sapiens
37°C, pH 7.0
0.0000144
N-[(1s,2R,3S)-2,3-diphenylcyclopropyl]-4-methylpiperazine-1-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000018
N-[(1s,2R,3S)-2,3-diphenylcyclopropyl]piperidine-1-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000014
N-[(3'-chlorobiphenyl-4-yl)methyl]-3-methyl-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.0000028
N-[(3,5-dimethyladamantan-1-yl)methyl]-N'-(3,5,7-trimethyladamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.0000018
N-[(3-ethyladamantan-1-yl)methyl]-N'-(1-propanoylpiperidin-4-yl)urea
Homo sapiens
pH 7.4, 37°C
0.0000606
N-[(3-ethyladamantan-1-yl)methyl]-N'-1,3,5-triazatricyclo[3.3.1.13,7]decan-7-ylurea
Homo sapiens
pH 7.4, 37°C
0.0000172
N-[(adamantan-1-yl)methyl]-2-[3-(adamantan-1-yl)propyl]hydrazine-1-carboxamide
Homo sapiens
pH 7.4, 37°C
0.0000397
N-[(adamantan-1-yl)methyl]-4-[([[(adamantan-1-yl)methyl]carbamoyl]amino)methyl]piperidine-1-carboxamide
Homo sapiens
pH 7.4, 37°C
0.0000008
N-[(adamantan-1-yl)methyl]-N'-(1-propanoylpiperidin-4-yl)urea
Homo sapiens
pH 7.4, 37°C
0.001992
N-[(adamantan-1-yl)methyl]-N'-[2-(adamantan-1-yl)pentyl]urea
Homo sapiens
pH 7.4, 37°C
0.0000122
N-[(adamantan-1-yl)methyl]-N'-[4-(adamantan-1-yl)phenyl]urea
Homo sapiens
pH 7.4, 37°C
0.0000254
N-[1-(adamantan-1-yl)ethyl]-N'-(3,5,7-trimethyladamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.0000128
N-[1-(adamantan-1-yl)ethyl]-N'-[(3-ethyladamantan-1-yl)methyl]urea
Homo sapiens
pH 7.4, 37°C
0.0000013
N-[1-(phenylcarbonyl)piperidin-4-yl]-N'-(adamant-1-yl) urea
Homo sapiens
-
0.0000018
N-[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]-N'-(adamant-1-yl) urea
Homo sapiens
-
0.0000229
N-[2-(adamantan-1-yl)butyl]-N'-(3,5,7-trimethyladamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.0000138
N-[2-(adamantan-1-yl)butyl]-N'-(3,5-dimethyladamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.0000044
N-[2-(adamantan-1-yl)ethyl]-N'-[(adamantan-1-yl)methyl]urea
Homo sapiens
pH 7.4, 37°C
0.0000031
N-[2-(adamantan-1-yl)pentyl]-N'-(3-chloroadamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.00027
N-[2-(methylsulfonyl)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
Homo sapiens
-
0.171
N-[2-(morpholin-4-yl)phenyl]thiophene-3-carboxamide
Homo sapiens
in 25 mM Bis-Tris HCl, pH 7.0, and 0.02% (v/v) Triton X-100, at 22°C
0.0000046
N-[2-(trifluoromethoxy)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
Homo sapiens
-
0.0052
N-[2-(trifluoromethoxy)phenyl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.000096
N-[2-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.000021
N-[2-chloro-4-(1H-tetrazol-5-yl)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
Homo sapiens
-
0.000014
N-[2-chloro-4-(methylsulfamoyl)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
Homo sapiens
-
0.000015
N-[2-chloro-4-(methylsulfonyl)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
Homo sapiens
-
0.000005
N-[3,3-bis-(4-fluorophenyl)-propyl]-2-(2,2,2-trifluoro-ethoxy)-isonicotinamide
Homo sapiens
-
0.000005
N-[3,3-bis-(4-fluorophenyl)-propyl]-4-methanesulfonyl-benzamide
Homo sapiens
-
0.000005
N-[3,3-bis-(4-fluorophenyl)-propyl]-6-(2,2,2-trifluoro-ethoxy)-nicotinamide
Homo sapiens
-
0.000005
N-[3,3-bis-(4-fluorophenyl)-propyl]-6-hydroxy-nicotinamide
Homo sapiens
-
0.0000051
N-[3,3-bis-(4-fluorophenyl)-propyl]-benzamide
Homo sapiens
-
0.000008
N-[3,3-bis-(4-fluorophenyl)-propyl]-nicotinamide
Homo sapiens
-
0.000007
N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-4-methanesulfonyl-benzamide
Homo sapiens
-
0.000004
N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-6-(2,2,2-trifluoro-ethoxy)-nicotinamide
Homo sapiens
-
0.000008
N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-nicotinamide
Homo sapiens
-
0.00016
N-[3-(trifluoromethoxy)phenyl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.00034
N-[3-[(2',4'-difluorobiphenyl-4-yl)methoxy]phenyl]piperidine-4-carboxamide
Homo sapiens
-
0.000001
N-[3-[2-(4-chlorophenyl)ethyl]benzyl]-3-methyl-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.000007
N-[4-(1H-indol-5-yl)benzyl]-3-methyl-3-phenylpiperidine-1-carboxamide
Homo sapiens
-
0.00011
N-[4-(methylsulfonyl)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
Homo sapiens
-
0.00006
N-[4-(trifluoromethoxy)phenyl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.0012
N-[4-(trifluoromethyl)benzyl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.0025
N-[4-(trifluoromethyl)phenyl]-1,2-benzothiazol-3-amine
Homo sapiens
-
0.000025
N-[4-(trifluoromethyl)phenyl]-1,2-benzoxazol-3-amine
Homo sapiens
-
0.01
N-[4-(trifluoromethyl)phenyl]-1H-indazol-3-amine
Homo sapiens
above
0.0011
N-[4-(trifluoromethyl)phenyl][1,2]oxazolo[4,5-b]pyridin-3-amine
Homo sapiens
-
0.000027
N-[4-(trifluoromethyl)phenyl][1,2]oxazolo[5,4-b]pyridin-3-amine
Homo sapiens
-
0.000031
N-[4-(trifluoromethyl)phenyl][1,2]oxazolo[5,4-c]pyridin-3-amine
Homo sapiens
-
0.0000263
N-[4-([[(adamantan-1-yl)methyl]carbamoyl]amino)butyl]-N'-[(3,5-dimethyladamantan-1-yl)methyl]urea
Homo sapiens
pH and temperature not specified in the publication
0.00078
N-[4-([[(adamantan-1-yl)methyl]carbamoyl]amino)phenyl]-N'-[(3,5-dimethyladamantan-1-yl)methyl]urea
Homo sapiens
pH and temperature not specified in the publication
0.000066
N-[4-chloro-2-(methylsulfonyl)benzyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
Homo sapiens
-
0.00048 - 0.00087
N-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]-N'-(4-hydroxyadamantan-1-yl)urea
0.0000004
N-[6-([[(adamantan-1-yl)methyl]carbamoyl]amino)hexyl]-N'-[(3,5-dimethyladamantan-1-yl)methyl]urea
Homo sapiens
pH and temperature not specified in the publication
0.0000073
N-[8-([[(adamantan-1-yl)methyl]carbamoyl]amino)octyl]-N'-[(3,5-dimethyladamantan-1-yl)methyl]urea
Homo sapiens
pH and temperature not specified in the publication
0.000012
N-[[4'-(methylsulfonyl)biphenyl-4-yl]methyl]-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
Homo sapiens
-
0.002006
N1,N4-bis[(adamantan-1-yl)methyl]piperazine-1,4-dicarboxamide
Homo sapiens
pH 7.4, 37°C
0.0000079
N1-(4-((2-adamantylacetamido)methyl)phenyl)-N1-methyl-N2-methyl-N2-methyloxyoxalamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.000069
N1-(4-((2-adamantylacetamido)methyl)phenyl)-N2-methyl-N2-methyloxyoxalamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.0000044
N1-(4-(2-adamantylacetamido)phenyl)-N1-methyl-N2-methyl-N2-(methyloxy)oxalamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.000035
N1-(4-(2-adamantylacetamido)phenyl)-N2-methyl-N2-(methyloxy)oxalamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.01
N1-(adamant-1-yl)-N2-(benzyloxy)oxalamide
Homo sapiens
IC50 above 0.01 mM, in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.000838
N1-(adamant-1-ylmethyl)-N2-(benzyloxy)oxalamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.0044
N1-(adamant-2-yl)-N2-(2-phenylethyloxy)oxalamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.00055
N1-(adamant-2-yl)-N2-(3-phenylpropyloxy)oxalamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.0023
N1-(adamant-2-yl)-N2-(4-chlorobenzyloxy)oxalamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.0015
N1-(adamant-2-yl)-N2-(4-methoxycarbonylbenzyloxy)oxalamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.01
N1-(adamant-2-yl)-N2-(4-nitrobenzyloxy)oxalamide
Homo sapiens
IC50 above 0.01 mM, in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.0032
N1-(adamant-2-yl)-N2-(benzyloxy)-N2-methyloxalamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.00005
N1-(adamant-2-yl)-N2-(benzyloxy)oxalamide
Homo sapiens
in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.01
N1-(adamant-2-yl)-N2-(phenyloxy)oxalamide
Homo sapiens
IC50 above 0.01 mM, in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.01
N1-(adamant-2-yl)-N2-(tetrahydro-2H-pyran-2-yloxy)oxalamide
Homo sapiens
IC50 above 0.01 mM, in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.01
N1-(adamant-2-yl)-N2-methyl-N2-(methyloxy)oxalamide
Homo sapiens
IC50 above 0.01 mM, in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.01
N1-(benzyloxy)-N2-(3-phenylpropyl)oxalamide
Homo sapiens
IC50 above 0.01 mM, in 25 mM Bis-Tris/HCl, pH 7.0, at 30°C
0.0001
pyridine-2-carboxylic acid (3,3-diphenyl-propyl)-amide
Homo sapiens
-
0.003
pyridine-3-sulfonic acid 3,3-(diphenylpropyl)-amide
Homo sapiens
-
0.0000069
t-butyl 4-[2-[(5-chloro-1,3-benzoxazol-2-yl)amino]-2-oxoethyl]piperidine-1-carboxylate
Homo sapiens
pH 7.4, 22°C
0.0000017
trans-1-adamantan-1-yl-3-(4-benzyloxycyclohexyl)urea
Homo sapiens
pH 7.4, 30°C
0.0000017
trans-1-adamantan-1-yl-3-[4-(2,6-dichlorobenzyloxy)cyclohexyl]-urea
Homo sapiens
pH 7.4, 30°C
0.0000017
trans-1-adamantan-1-yl-3-[4-(2,6-difluorobenzyloxy)cyclohexyl]-urea
Homo sapiens
pH 7.4, 30°C
0.0000016
trans-1-adamantan-1-yl-3-[4-(2-methylbenzyloxy)cyclohexyl]-urea
Homo sapiens
pH 7.4, 30°C
0.000001
trans-1-adamantan-1-yl-3-[4-(3,5-difluorophenoxy)cyclohexyl]-urea
Homo sapiens
pH 7.4, 30°C
0.0000017
trans-1-adamantan-1-yl-3-[4-(4-bromobenzyloxy)cyclohexyl]-urea
Homo sapiens
pH 7.4, 30°C
0.0000013
trans-4-(4-(3-adamantan-1-yl-ureido)-cyclohexyloxy)-benzoic acid
Homo sapiens
-
0.0000009
trans-4-(4-[3-(4-trifluoromethoxyphenyl)ureido]cyclohexyloxy)benzoic acid
Homo sapiens
pH 7.4, 30°C
0.0000013
trans-4-[4-(3-adamantan-1-ylureido)cyclohexyloxy]benzoic acid
Homo sapiens
pH 7.4, 30°C
0.000052
[1-[(4-chlorophenyl)carbamoyl]-3-phenylpiperidin-3-yl]acetic acid
Homo sapiens
-
0.000002
[6-(methylsulfonyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidin]-1'-yl][4-(trifluoromethyl)phenyl]methanone
Homo sapiens
-
0.005
[N-(2-(trifluoromethyl)benzyl)benzamide]-4-(1H-tetrazole)
Homo sapiens
pH 7.0, 22°C
0.00029
(3-[4-(allyloxy)phenyl]oxiran-2-yl)(phenyl)methanone
Homo sapiens
-
IC50 is 0.00029 mM
0.00023
(3-[4-(benzyloxy)phenyl]oxiran-2-yl)(phenyl)methanone
Homo sapiens
-
IC50 is 0.00023 mM
0.00022
(4-bromophenyl)(3-phenyloxiran-2-yl)methanone
Homo sapiens
-
IC50 is 0.00022 mM
0.00018
(4-bromophenyl)[3-(2-naphthyl)oxiran-2-yl]methanone
Homo sapiens
-
IC50 is 0.00018 mM
0.00039
(4-fluorophenyl)(3-phenyloxiran-2-yl)methanone
Homo sapiens
-
IC50 is 0.00039 mM
0.00042
(4-iodophenyl)(3-phenyloxiran-2-yl)methanone
Homo sapiens
-
IC50 is 0.00042 mM
0.0002
(4-methoxyphenyl)(3-phenyloxiran-2-yl)methanone
Homo sapiens
-
IC50 is 0.00020 mM
0.00023
(4-methylphenyl)(3-phenyloxiran-2-yl)methanone
Homo sapiens
-
IC50 is 0.00023 mM
0.00015
(4-methylphenyl)[3-(2-naphthyl)oxiran-2-yl]methanol
Homo sapiens
-
IC50 is 0.00015 mM
0.00019
(4-methylphenyl)[3-(2-naphthyl)oxiran-2-yl]methanone
Homo sapiens
-
IC50 is 0.00019 mM
0.00025
(4-nitrophenyl)(3-phenyloxiran-2-yl)methanone
Homo sapiens
-
IC50 is 0.00025 mM
0.00029
(E)-phenyl(3-phenyloxiran-2-yl)methanone oxime
Homo sapiens
-
IC50 is 0.00029 mM
0.035
(E)-[3-(2-naphthyl)oxiran-2-yl](phenyl)methanone oxime
Homo sapiens
-
IC50 is 0.035 mM
0.000005
(R)-N-(2-(diphenylamino)ethyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide
Homo sapiens
-
pH 7, 37°C
-
0.0000012
(R)-N-(3,3-bis(4-fluorophenyl)propyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide
Homo sapiens
-
pH 7, 37°C
-
0.0002
1,1'-(benzene-1,3-diyldicarbonyl)bis[N-(2,4-dichlorobenzyl)piperidine-4-carboxamide]
Homo sapiens
-
-
0.0001792
1,2-(ethylene)bis[[(adamant-1-yl)methyl]urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.000033
1,3-dicyclohexyl urea
Homo sapiens
-
pH 7.0, 23°C
0.0000195
1,4-(phenylene)bis[(adamant-2-yl)urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.000161
1,4-(phenylene)bis[[(adamant-1-yl)ethyl-1]urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.0007796
1,4-(phenylene)bis[[(adamant-1-yl)methyl]urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.0000263
1,4-(tetramethylene)bis[(adamant-1-yl)methyl]urea
Homo sapiens
-
pH and temperature not specified in the publication
0.0000072
1,4-(tetramethylene)bis[(adamant-1-yl)urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.0000012
1,4-(tetramethylene)bis[[(adamant-1-yl)ethyl-1]urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.0000023
1,4-(tetramethylene)bis[[(adamant-1-yl)sec-butyl-1]urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.0000104
1,4-(tetramthylene)bis[(adamant-2-yl)urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.0000004
1,6-(hexamethylene)bis[[(adamant-1-yl)methyl]urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.000997
1,8-(octamethylene)bis[(adamant-1-yl)urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.0000005
1,8-(octamethylene)bis[(adamant-1-ylethyl)urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.0000026
1,8-(octamethylene)bis[(adamant-2-yl)urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.0000005
1,8-(octamethylene)bis[[(adamant-1-yl)ethyl-1]urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.0000073
1,8-(octamethylene)bis[[(adamant-1-yl)methyl]urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.00144
1,8-(octamethylene)bis[[(adamant-1-yl)sec-butyl-1]urea]
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
1-(1-methylsulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxy-phenyl)-urea
Homo sapiens
-
-
0.000178
1-(2-((3-((3s,5s,7s)-adamantan-1-yl)ureido)methyl)benzyl)-1H-pyrrole-2-carboxylic acid
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.000304
1-(3-((3-((3s,5s,7s)-adamantan-1-yl)ureido)methyl)benzyl)-1H-pyrrole-2-carboxylic acid
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.000073
1-(4-((3-((3s,5s,7s)-adamantan-1-yl)ureido)methyl)benzyl)-1H-pyrrole-2-carboxylic acid
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.0000014
1-adamantan-1-yl-3-(5-(2-[2-(2,2,2-trifluoroethoxy)ethoxy]-ethoxy)pentyl)urea
Homo sapiens
-
30°C, pH 7.0
0.0000017
1-adamantan-1-yl-3-(5-(2-[2-(4-ethylphenoxy)ethoxy]-ethoxy)pentyl)urea
Homo sapiens
-
30°C, pH 7.0
0.0000041
1-adamantan-1-yl-3-(5-butoxypentyl)urea
Homo sapiens
-
30°C, pH 7.0
0.0000056
1-adamantan-1-yl-3-(5-hexoxypropyl)urea
Homo sapiens
-
30°C, pH 7.0
0.0000044
1-adamantan-1-yl-3-(5-pentoxybutyl)urea
Homo sapiens
-
30°C, pH 7.0
0.0000037
1-adamantan-1-yl-3-(5-propyloxyhexyl)urea
Homo sapiens
-
30°C, pH 7.0
0.0000023
1-adamantan-1-yl-3-(5-[4-propyloxy]butyl)-urea
Homo sapiens
-
30°C, pH 7.0
0.0000025
1-adamantan-1-yl-3-(5-[4-propyloxy]propyl)-urea
Homo sapiens
-
30°C, pH 7.0
0.000014
1-adamantan-3-(5-(2-(2-ethylethoxy)ethoxy)pentyl)urea
Homo sapiens
-
purified recombinant enzyme
0.000019
1-cyclohexyl-3-dodecyl urea
Homo sapiens
-
pH 7.0, 23°C
0.0098
1-cyclohexyl-3-ethyl urea
Homo sapiens
-
pH 7.0, 23°C
0.000029
1-cyclohexyl-3-hexyl urea
Homo sapiens
-
pH 7.0, 23°C
0.0000039
1-cyclohexyl-3-[3-(3-morpholin-4-ylpropoxy)phenyl]urea
Homo sapiens
-
-
0.000012
1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl)urea
Homo sapiens
-
in bis-Tris/HCl buffer, pH 7.0, at 25°C
0.000041
1-[(2,4-dimethylphenyl)sulfonyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000011
1-[(2,4-dimethylphenyl)sulfonyl]-N-(2-fluorophenyl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000012
1-[(2,4-dimethylphenyl)sulfonyl]-N-(2-hydroxyphenyl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00002
1-[(2,4-dimethylphenyl)sulfonyl]-N-(2-methylphenyl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000018
1-[(2,4-dimethylphenyl)sulfonyl]-N-(2-methylpropyl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00029
1-[(2,4-dimethylphenyl)sulfonyl]-N-(4-fluorophenyl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000004
1-[(2,4-dimethylphenyl)sulfonyl]-N-(4-hydroxyphenyl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
1-[(2,4-dimethylphenyl)sulfonyl]-N-(4-methoxyphenyl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000012
1-[(2,4-dimethylphenyl)sulfonyl]-N-(4-nitrophenyl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00002
1-[(2,4-dimethylphenyl)sulfonyl]-N-(4-phenoxyphenyl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.03
1-[(2,4-dimethylphenyl)sulfonyl]-N-(6-methoxy-1,3-benzodioxol-5-yl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000023
1-[(2,4-dimethylphenyl)sulfonyl]-N-(isoquinolin-5-yl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000083
1-[(2,4-dimethylphenyl)sulfonyl]-N-(naphthalen-2-yl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000023
1-[(2,4-dimethylphenyl)sulfonyl]-N-(quinolin-3-yl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000013
1-[(2,4-dimethylphenyl)sulfonyl]-N-(quinolin-6-yl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000006
1-[(2,4-dimethylphenyl)sulfonyl]-N-(quinolin-8-yl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000017
1-[(2,4-dimethylphenyl)sulfonyl]-N-(tricyclo[3.3.1.13,7]dec-1-yl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000069
1-[(2,4-dimethylphenyl)sulfonyl]-N-phenylpiperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0069
1-[(2,4-dimethylphenyl)sulfonyl]-N-[(1R,2S)-2-phenylcyclopropyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00064
1-[(2,4-dimethylphenyl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00025
1-[(2,4-dimethylphenyl)sulfonyl]-N-[4-(morpholin-4-yl)phenyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00002
1-[(2,4-dimethylphenyl)sulfonyl]-N-[4-(piperidin-1-yl)phenyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000067
1-[(2,4-dimethylphenyl)sulfonyl]-N-[4-(propan-2-yl)phenyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000023
1-[(2,4-dimethylphenyl)sulfonyl]-N-[4-(trifluoromethoxy)phenyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00003
1-[(2,4-dimethylphenyl)sulfonyl]-N-[4-(trifluoromethyl)phenyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000016
1-[(2,4-dimethylphenyl)sulfonyl]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000911
1-[(2-bromophenyl)sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
Homo sapiens
-
-
0.0000521
1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
Homo sapiens
-
-
0.000164
1-[(4-tert-butylphenyl)sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
Homo sapiens
-
-
0.0002
1-[(5-chlorothiophen-2-yl)sulfonyl]-N-(2,4-dichlorobenzyl)piperidine-4-carboxamide
Homo sapiens
-
-
0.000747
1-[2-[(cyclohexylcarbamoyl)amino]benzyl]-1H-pyrrole-2-carboxylic acid
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.000022
1-[3-(3-morpholin-4-ylpropoxy)phenyl]-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]thiourea
Homo sapiens
-
-
0.0000008
1-[3-(3-morpholin-4-ylpropoxy)phenyl]-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]urea
Homo sapiens
-
-
0.0000082
1-[3-(3-morpholin-4-ylpropoxy)phenyl]-3-[4-(trifluoromethoxy)phenyl]urea
Homo sapiens
-
-
0.0000012
1-[3-(3-morpholin-4-ylpropoxy)phenyl]-3-[4-(trifluoromethyl)phenyl]urea
Homo sapiens
-
-
0.0187
1-[3-(4-nitrophenyl)oxiran-2-yl]ethanol
Homo sapiens
-
IC50 is 0.0187 mM
0.269
1-[3-(4-nitrophenyl)oxiran-2-yl]ethanone
Homo sapiens
-
IC50 is 0.269 mM
0.000943
1-[3-([[4-(trifluoromethoxy)phenyl]carbamoyl]amino)benzyl]-1H-pyrrole-2-carboxylic acid
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.001923
1-[3-[(cyclohexylcarbamoyl)amino]benzyl]-1H-pyrrole-2-carboxylic acid
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.000258
1-[4-([[4-(trifluoromethoxy)phenyl]carbamoyl]amino)benzyl]-1H-pyrrole-2-carboxylic acid
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.000252
1-[4-[(cyclohexylcarbamoyl)amino]benzyl]-1H-pyrrole-2-carboxylic acid
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.0000397
1-[[1-((adamant-1-yl)methylcarbamoyl)piperidin-4-yl]methyl]-3-[(adamant-1-yl)methyl]urea
Homo sapiens
-
pH and temperature not specified in the publication
0.028
10-(sulfooxy)octadecanoic acid
Homo sapiens
-
IC50 is 0.028 mM
0.0000017
12-(3-adamantan-1-yl-ureido) 2-chlorobenzyl dodecanoate
Homo sapiens
-
-
0.0000012
12-(3-adamantan-1-yl-ureido) 2-methylpropyl dodecanoate
Homo sapiens
-
-
0.0000007
12-(3-adamantan-1-yl-ureido) butan-2-yl dodecanoate
Homo sapiens
-
-
0.0000008
12-(3-adamantan-1-yl-ureido) butyl dodecanoate
Homo sapiens
-
-
0.0000016
12-(3-adamantan-1-yl-ureido) ethyl dodecanoate
Homo sapiens
-
-
0.0000021
12-(3-adamantan-1-yl-ureido) N-(methylsulfonyl)dodecanylamide
Homo sapiens
-
-
0.0000019
12-(3-adamantan-1-yl-ureido) N-(phenylsulfonyl)dodecanylamide
Homo sapiens
-
-
0.000001
12-(3-adamantan-1-yl-ureido) prop-2-en-1-yl dodecanoate
Homo sapiens
-
-
0.0000018
12-(3-adamantan-1-yl-ureido) prop-2-yn-1-yl dodecanoate
Homo sapiens
-
-
0.0000011
12-(3-adamantan-1-yl-ureido) propan-2-yl dodecanoate
Homo sapiens
-
-
0.000001
12-(3-adamantan-1-yl-ureido) propyl dodecanoate
Homo sapiens
-
-
0.0000013
12-(3-adamantan-1-yl-ureido) tert-butyl dodecanoate
Homo sapiens
-
-
0.000003 - 0.000107
12-(3-adamantan-1-yl-ureido)dodecanoic acid
0.000003
12-(3-adamantan-1-ylureido)dodecanoic acid
Homo sapiens
-
in bis-Tris/HCl buffer, pH 7.0, at 25°C
0.0000008
12-(3-adamantan-1-ylureido)dodecanoic acid butyl ester
Homo sapiens
-
in bis-Tris/HCl buffer, pH 7.0, at 25°C
0.0000046
12-(3-adamantane-1-yl-ureido)-dodecanoic acid
Homo sapiens
-
pH 7.0, 23°C
0.1
12-sulfonoxy-cis-9-octadecenoic acid
Homo sapiens
-
IC50 is above 0.1 mM
0.016
12-sulfonoxy-trans-9-octadecenoic acid
Homo sapiens
-
IC50 is 0.016 mM
0.07
2-(2-naphthyl)-3-(phenylsulfinyl)oxirane
Homo sapiens
-
IC50 is 0.070 mM
0.00031
2-cyclohexa-1,5-dien-1-yl-3-(phenylsulfinyl)oxirane
Homo sapiens
-
IC50 is 0.00031 mM
0.034
2-cyclohexa-1,5-dien-1-yl-3-[methoxy(phenyl)methyl]oxirane
Homo sapiens
-
IC50 is 0.034 mM
0.000028
2-cyclohexyl-N-[3-(3-morpholin-4-ylpropoxy)phenyl]acetamide
Homo sapiens
-
-
0.002
2-hydroxy-N-[3-(3-morpholin-4-ylpropoxy)phenyl]-2-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]acetamide
Homo sapiens
-
IC50 above 0.02 mM
0.000023
2-hydroxy-N-[3-(3-morpholin-4-ylpropoxy)phenyl]-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]propanamide
Homo sapiens
-
-
0.00053
2-hydroxy-N-[3-(3-morpholin-4-ylpropoxy)phenyl]-4-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]butanamide
Homo sapiens
-
-
0.00028
2-naphthyl(3-phenyloxiran-2-yl)methanone
Homo sapiens
-
IC50 is 0.00028 mM
0.00134
2-[methoxy(phenyl)methyl]-3-(2-naphthyl)oxirane
Homo sapiens
-
IC50 is 0.00134 mM
0.00009
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
Homo sapiens
-
pH 7, 37°C
-
0.00007
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(3-phenyl-3-(4-(trifluoromethoxy)phenyl)propyl)benzamide
Homo sapiens
-
pH 7, 37°C
-
0.000004
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(4-methoxy-2-(trifluoromethyl)benzyl)-benzamide
Homo sapiens
-
pH 7, 37°C
-
0.0003
3-(3-(1-hydroxyureido)hex-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
Homo sapiens
-
pH 7, 37°C
-
0.0000753
4,5-dimethoxy-2-nitrophenyl 4-[(2,4-dichlorobenzyl)carbamoyl]piperidine-1-carboxylate
Homo sapiens
-
-
0.0026
4-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
Homo sapiens
-
pH 7, 37°C
-
0.5
4-(3-benzoyloxiran-2-yl)benzoic acid
Homo sapiens
-
IC50 is above 0.5 mM
0.00016
4-([3-(2-naphthyl)oxiran-2-yl]carbonyl)benzoic acid
Homo sapiens
-
IC50 is 0.00016 mM
0.113
4-([3-(4-fluorophenyl)oxiran-2-yl]carbonyl)benzoic acid
Homo sapiens
-
IC50 is 0.113 mM
0.1
4-nitrophenyl sulfate
Homo sapiens
-
IC50 is above 0.1 mM
0.144
4-[(3-phenyloxiran-2-yl)carbonyl]benzoic acid
Homo sapiens
-
IC50 is 0.144 mM
0.000017
4-[([1-[(2,4-dimethylphenyl)sulfonyl]piperidin-4-yl]carbonyl)amino]benzoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.5
4-[3-(4-fluorobenzoyl)oxiran-2-yl]benzoic acid
Homo sapiens
-
IC50 is above 0.5 mM
0.0000006
6-[([1-[(2,4-dimethylphenyl)sulfonyl]piperidin-4-yl]carbonyl)amino]naphthalene-2-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.09
9-hydroxy-10-(sulfooxy)octadecanoic acid
Homo sapiens
-
IC50 is 0.09 mM
0.073
alpha-hydroxyfarnesyl phosphonic acid
Homo sapiens
-
IC50 is 0.073 mM
0.1
alpha-sulfostearic acid
Homo sapiens
-
IC50 is above 0.1 mM
0.0000009
cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid
Homo sapiens
-
in bis-Tris/HCl buffer, pH 7.0, at 25°C
0.1
D-galactose 6-sulfate
Homo sapiens
-
IC50 is above 0.1 mM
0.1
dibenzyl phosphonate
Homo sapiens
-
IC50 is above 0.1 mM
0.1
diethyl 2,2,2-trifluoro-1-hydroxyethyl phosphonate
Homo sapiens
-
IC50 is above 0.1 mM
0.1
diethyl 4-methylbenzyl phosphonate
Homo sapiens
-
IC50 is above 0.1 mM
0.1
diethyl allyl phosphonate
Homo sapiens
-
IC50 is above 0.1 mM
0.1
diethyl benzoylphosphonate
Homo sapiens
-
IC50 is above 0.1 mM
0.1
diethyl cyclopropyl methylphosphonate
Homo sapiens
-
IC50 is above 0.1 mM
0.1
diethyl ethylthiomethyl phosphonate
Homo sapiens
-
IC50 is above 0.1 mM
0.1
diethyl trans-cinnamyl phosphonate
Homo sapiens
-
IC50 is above 0.1 mM
0.1
diethyl vinylphosphonate
Homo sapiens
-
IC50 is above 0.1 mM
0.1
dimethyl 2-oxoheptyl phosphonate
Homo sapiens
-
IC50 is above 0.1 mM
0.092
dioctyl phenyl phosphonate
Homo sapiens
-
IC50 is 0.092 mM
0.04
dodecyl phosphonic acid
Homo sapiens
-
IC50 is 0.040 mM
0.1
Estrone 3-sulfate
Homo sapiens
-
IC50 is above 0.1 mM
0.000043
ethyl 1-(2-((3-((3s,5s,7s)-adamantan-1-yl)ureido)methyl)benzyl)-1H-pyrrole-2-carboxylate
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.000046
ethyl 1-(3-((3-((3s,5s,7s)-adamantan-1-yl)ureido)methyl)benzyl)-1H-pyrrole-2-carboxylate
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.000087
ethyl 1-(4-((3-((3s,5s,7s)-adamantan-1-yl)ureido)methyl)benzyl)-1H-pyrrole-2-carboxylate
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.002009
ethyl 1-[2-([[4-(trifluoromethoxy)phenyl]carbamoyl]amino)benzyl]-1H-pyrrole-2-carboxylate
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.000039
ethyl 1-[2-[(cyclohexylcarbamoyl)amino]benzyl]-1H-pyrrole-2-carboxylate
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.000027
ethyl 1-[3-[(cyclohexylcarbamoyl)amino]benzyl]-1H-pyrrole-2-carboxylate
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.000611
ethyl 1-[4-([[4-(trifluoromethoxy)phenyl]carbamoyl]amino)benzyl]-1H-pyrrole-2-carboxylate
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.000023
ethyl 1-[4-[(cyclohexylcarbamoyl)amino]benzyl]-1H-pyrrole-2-carboxylate
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.1
L-ascorbic acid 2-sulfate
Homo sapiens
-
IC50 is above 0.1 mM
0.0000021
methyl 4-((1,2,3,4-tetrahydronaphthalene-2-carboxamido)methyl)benzoic acid
Homo sapiens
-
pH 7.0, 30°C
0.0000018
methyl 4-([[(6-hydroxynaphthalen-2-yl)carbonyl]amino]methyl)benzoate
Homo sapiens
-
pH 7.0, 30°C
0.0000024
methyl 4-([[(6-methoxynaphthalen-2-yl)carbonyl]amino]methyl)benzoate
Homo sapiens
-
pH 7.0, 30°C
0.0000085
methyl 4-[([1-[(2,4-dimethylphenyl)sulfonyl]piperidin-4-yl]carbonyl)amino]benzoate
Homo sapiens
-
pH and temperature not specified in the publication
0.00011
methyl 6-[([1-[(2,4-dimethylphenyl)sulfonyl]piperidin-4-yl]carbonyl)amino]naphthalene-2-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.0000336
N'-(2-chlorophenyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carbohydrazide
Homo sapiens
-
-
0.000064
N'-[2-(3-chlorophenyl)ethyl]-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carbohydrazide
Homo sapiens
-
-
0.0000201
N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000052
N-(1,3-benzodioxol-5-yl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000007
N-(1-acetylpiperidin-4-yl)-N'-(adamant-1-yl)urea
Homo sapiens
-
in bis-Tris/HCl buffer, pH 7.0, at 25°C
0.000011
N-(1-tert-butoxypiperidin-4-yl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000491
N-(2,3-dihydro-1H-inden-2-yl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.000128
N-(2,4-dichloro-6-methylbenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000445
N-(2,4-dichlorobenzyl)-1-[(2,4,6-tri-tert-butylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.00002
N-(2,4-dichlorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000469
N-(2,4-dichlorobenzyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000876
N-(2,4-dichlorobenzyl)-1-[(2-fluorophenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.00015
N-(2,4-dichlorobenzyl)-1-[(4-fluoro-2-nitrophenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000239
N-(2,4-dichlorobenzyl)-1-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000322
N-(2,4-difluorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000591
N-(2,5-dichlorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000006
N-(2-bromophenyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000541
N-(2-chloro-4-fluorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000127
N-(2-chloro-6-fluorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000274
N-(2-chlorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000087
N-(2-chlorophenyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000372
N-(2-methylcyclohexyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000433
N-(2-phenylethyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.000035
N-(3,3-diphenylpropyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.000032
N-(3,4-dichlorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.000055
N-(3,4-dichlorophenyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
N-(3,5-dichlorophenyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000002
N-(3-(4-chlorophenyl)-3-phenylpropyl)-3-(3-(1-hydroxyureido)-but-1-yn-1-yl)benzamide
Homo sapiens
-
pH 7, 37°C
-
0.0000251
N-(3-methylbutyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.000045
N-(4-bromophenyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00005
N-(4-chlorobenzyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0022
N-(4-chlorophenyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000396
N-(4-methylcyclohexyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.00014
N-(4-[(3-phenyloxiran-2-yl)carbonyl]phenyl)acetamide
Homo sapiens
-
IC50 is 0.00014 mM
0.0000126
N-(cyclohexylmethyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000058
N-(cyclohexylmethyl)-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000394
N-(naphthalen-1-ylmethyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.1
N-acetyl-D-galactosamine 4-sulfate
Homo sapiens
-
IC50 is above 0.1 mM
0.000042
N-benzyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.000029
N-cyclobutyl-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000079
N-cycloheptyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
0.0000026
N-cycloheptyl-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000164
N-cyclohexyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.000102
N-cyclohexyl-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000028
N-cyclooctyl-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000373
N-cyclopentyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000052
N-cyclopentyl-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000046
N-cyclopropyl-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0002
N-naphthalen-1-yl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0002
N-piperidin-1-yl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000291
N-[1-(4-chlorophenyl)ethyl]-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000287
N-[2-chloro-5-(trifluoromethyl)benzyl]-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.000185
N-[2-[4-(benzyloxy)phenyl]ethyl]-2-hydroxy-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]propanamide
Homo sapiens
-
-
0.000011
N-[2-[4-(benzyloxy)phenyl]ethyl]-2-hydroxy-4-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]butanamide
Homo sapiens
-
-
0.00154
N-[2-[4-(benzyloxy)phenyl]ethyl]-2-oxo-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]propanamide
Homo sapiens
-
-
0.000685
N-[2-[4-(benzyloxy)phenyl]ethyl]-2-oxo-4-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]butanamide
Homo sapiens
-
-
0.002
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-2-oxo-2-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]acetamide
Homo sapiens
-
IC50 above 0.02 mM
0.000049
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-2-oxo-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]propanamide
Homo sapiens
-
-
0.000048
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-2-oxo-4-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]butanamide
Homo sapiens
-
-
0.000055
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-2-[4-(trifluoromethyl)phenyl]acetamide
Homo sapiens
-
-
0.000093
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-4-(trifluoromethyl)benzamide
Homo sapiens
-
-
0.015
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-4-(trifluoromethyl)benzenesulfonamide
Homo sapiens
-
-
0.0036
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-N'-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]sulfamide
Homo sapiens
-
-
0.0000025
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-N-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-ylmethyl]formamide
Homo sapiens
-
-
0.000088
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-N-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]formamide
Homo sapiens
-
-
0.00011
N-[3-(3-morpholin-4-ylpropoxy)phenyl]-N2-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]glycinamide
Homo sapiens
-
-
0.00039
N-[3-(3-morpholin-4-ylpropoxy)phenyl]cyclohexanecarboxamide
Homo sapiens
-
-
0.000043
N-[3-carbamoyl-4-(piperidin-1-yl)phenyl]-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00027
N-[4-(3-benzoyloxiran-2-yl)phenyl]acetamide
Homo sapiens
-
IC50 is 0.00027 mM
0.00031
N-[4-(benzyloxy)phenyl]-2-hydroxy-2-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]acetamide
Homo sapiens
-
-
0.00027
N-[4-(benzyloxy)phenyl]-2-hydroxy-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]propanamide
Homo sapiens
-
-
0.00021
N-[4-(benzyloxy)phenyl]-2-oxo-2-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]acetamide
Homo sapiens
-
-
0.0011
N-[4-(benzyloxy)phenyl]-2-oxo-3-[(3S,5S)-tricyclo[3.3.1.13,7]dec-1-yl]propanamide
Homo sapiens
-
-
0.000173
N-[4-chloro-3-(trifluoromethyl)benzyl]-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.000078
N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(2,4-dimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.021
octadecan-9-yl sulfate
Homo sapiens
-
IC50 is 0.021 mM
0.022
phenyl(3-phenyloxiran-2-yl)methanol
Homo sapiens
-
IC50 is 0.022 mM
0.0003
phenyl(3-phenyloxiran-2-yl)methanone
Homo sapiens
-
IC50 is 0.0003 mM
0.1
Sodium dodecyl sulfate
Homo sapiens
-
IC50 is above 0.1 mM
0.05
sodium dodecyl sulfonate
Homo sapiens
-
IC50 is 0.05 mM
0.09
taurocholic acid
Homo sapiens
-
IC50 is 0.09 mM
0.1
taurolithocholic acid 3-sulfate
Homo sapiens
-
IC50 is above 0.1 mM
0.000263
tert-butyl 4-[([1-[(2,4-dimethylphenyl)sulfonyl]piperidin-4-yl]carbonyl)amino]piperidine-1-carboxylate
Homo sapiens
-
pH and temperature not specified in the publication
0.1
tetraisopropyl methylenediphosphonate
Homo sapiens
-
IC50 is above 0.1 mM
0.0000013
trans-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid
Homo sapiens
-
in bis-Tris/HCl buffer, pH 7.0, at 25°C
0.00016
[3-(2-naphthyl)oxiran-2-yl](4-nitrophenyl)methanone
Homo sapiens
-
IC50 is 0.00016 mM
0.00072
[3-(2-naphthyl)oxiran-2-yl](phenyl)methanol
Homo sapiens
-
IC50 is 0.00072 mM
0.0002 - 0.00085
[3-(2-naphthyl)oxiran-2-yl](phenyl)methanone
0.0002
[3-(4-bromophenyl)oxiran-2-yl](phenyl)methanone
Homo sapiens
-
IC50 is 0.0002 mM
0.00015
[3-(4-butylphenyl)oxiran-2-yl](phenyl)methanone
Homo sapiens
-
IC50 is 0.00015 mM
0.018
[3-(4-fluorophenyl)oxiran-2-yl](phenyl)methanol
Homo sapiens
-
IC50 is 0.018 mM
0.0003
[3-(4-fluorophenyl)oxiran-2-yl](phenyl)methanone
Homo sapiens
-
IC50 is 0.0003 mM
0.00048
[3-(4-heptylphenyl)oxiran-2-yl](phenyl)methanone
Homo sapiens
-
IC50 is 0.00048 mM
0.00048
[3-(4-isopropylphenyl)oxiran-2-yl](phenyl)methanone
Homo sapiens
-
IC50 is 0.00048 mM
0.00011
[3-(4-methoxyphenyl)oxiran-2-yl](phenyl)methanone
Homo sapiens
-
IC50 is 0.00011 mM
0.00036
[3-(4-methylphenyl)oxiran-2-yl](phenyl)methanone
Homo sapiens
-
IC50 is 0.00036 mM
0.028
[3-(4-nitrophenyl)oxiran-2-yl](phenyl)methanol
Homo sapiens
-
IC50 is 0.028 mM
0.00063
[3-(4-nitrophenyl)oxiran-2-yl](phenyl)methanone
Homo sapiens
-
IC50 is 0.00063 mM
0.00051
[3-(4-phenoxycyclohexa-1,5-dien-1-yl)oxiran-2-yl](phenyl)methanone
Homo sapiens
-
IC50 is 0.00051 mM
0.00014
[4-(allyloxy)phenyl](3-phenyloxiran-2-yl)methanone
Homo sapiens
-
IC50 is 0.00014 mM
0.00016
[4-(bromomethyl)phenyl][3-(2-naphthyl)oxiran-2-yl]methanone
Homo sapiens
-
IC50 is 0.00016 mM
0.00006 - 0.5
additional information
Homo sapiens
-
QSAR and classification in a seven-discriptor model of enzyme inhibition by 348 urea-like compounds, IC50 ranging from 60 nM to 0.5 mM, overview
-
0.000206
1-(2-hydroxyphenyl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
Homo sapiens
recombinant enzyme expressed in Escherichia coli
0.000258
1-(2-hydroxyphenyl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
Homo sapiens
recombinant enzyme expressed in Sf9 cells
0.000613
1-(3-hydroxypropyl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
Homo sapiens
recombinant enzyme expressed in Escherichia coli
0.000813
1-(3-hydroxypropyl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
Homo sapiens
recombinant enzyme expressed in Sf9 cells
0.00012
1-(5-hydroxypentyl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
Homo sapiens
recombinant enzyme expressed in Escherichia coli
0.000128
1-(5-hydroxypentyl)-3-tricyclo[3.3.1.13,7]dec-1-ylurea
Homo sapiens
recombinant enzyme expressed in Sf9 cells
0.000008
1-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]-3-tricyclo[3.3.1.13,7]dec-1-ylurea
Homo sapiens
recombinant enzyme expressed in Escherichia coli
0.000009
1-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]-3-tricyclo[3.3.1.13,7]dec-1-ylurea
Homo sapiens
recombinant enzyme expressed in Sf9 cells
0.000014
1-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]-3-tricyclo[3.3.1.13,7]dec-1-ylurea
Homo sapiens
-
0.0000022
12-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]dodecanoic acid
Homo sapiens
recombinant enzyme expressed in Escherichia coli
0.0000023
12-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]dodecanoic acid
Homo sapiens
recombinant enzyme expressed in Sf9 cells
0.000003
12-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamoyl)amino]dodecanoic acid
Homo sapiens
-
0.000005
3-[1-[(4-chlorophenyl)carbamoyl]-3-phenylpiperidin-3-yl]propanoic acid
Homo sapiens
-
0.000016
3-[1-[(4-chlorophenyl)carbamoyl]-3-phenylpiperidin-3-yl]propanoic acid
Homo sapiens
-
0.03391
5,7-dihydroxy-2-(2-hydroxy-6-methoxyphenyl)-4H-1-benzopyran-4-one
Homo sapiens
pH not specified in the publication, 37°C
0.08008
5,7-dihydroxy-2-(2-hydroxy-6-methoxyphenyl)-4H-1-benzopyran-4-one
Homo sapiens
pH not specified in the publication, 37°C
0.000008
6'-(methylsulfonyl)-N-(2-phenylcyclopropyl)-1H,4'H-spiro[azepane-4,3'-chromene]-1-carboxamide
Homo sapiens
-
0.000011
6'-(methylsulfonyl)-N-(2-phenylcyclopropyl)-1H,4'H-spiro[azepane-4,3'-chromene]-1-carboxamide
Homo sapiens
-
0.000003
6-(methylsulfonyl)-4-oxo-N-(2-phenylcyclopropyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
Homo sapiens
-
0.000004
6-(methylsulfonyl)-4-oxo-N-(2-phenylcyclopropyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
Homo sapiens
-
0.000011
6-(methylsulfonyl)-4-oxo-N-(2-phenylcyclopropyl)-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamide
Homo sapiens
-
0.0000006
N,N'-octane-1,8-diylbis[N'-[(adamantan-1-yl)methyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000007
N,N'-octane-1,8-diylbis[N'-[(adamantan-1-yl)methyl]urea]
Homo sapiens
pH 7.4, 37°C
0.0000038
N-(3-ethyladamantan-1-yl)-N'-(1-propanoylpiperidin-4-yl)urea
Homo sapiens
pH 7.4, 37°C
0.0002686
N-(3-ethyladamantan-1-yl)-N'-(1-propanoylpiperidin-4-yl)urea
Homo sapiens
pH 7.4, 37°C
0.0000024
N-adamantan-1-yl-N'-[(3-ethyladamantan-1-yl)methyl]urea
Homo sapiens
pH 7.4, 37°C
0.0000027
N-adamantan-1-yl-N'-[(3-ethyladamantan-1-yl)methyl]urea
Homo sapiens
pH 7.4, 37°C
0.00048
N-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]-N'-(4-hydroxyadamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.00087
N-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]-N'-(4-hydroxyadamantan-1-yl)urea
Homo sapiens
pH 7.4, 37°C
0.000003
12-(3-adamantan-1-yl-ureido)dodecanoic acid
Homo sapiens
-
purified recombinant enzyme
0.000107
12-(3-adamantan-1-yl-ureido)dodecanoic acid
Homo sapiens
-
in 25 mM Bis-Tris-HCl, pH 7.0, at 37°C
0.0000079
N-cycloheptyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000079
N-cycloheptyl-1-[(2,4,6-trimethylphenyl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0002
[3-(2-naphthyl)oxiran-2-yl](phenyl)methanone
Homo sapiens
-
IC50 is 0.0002 mM
0.00085
[3-(2-naphthyl)oxiran-2-yl](phenyl)methanone
Homo sapiens
-
IC50 is 0.00085 mM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Wixtrom, R.N.; Hammock, B.D.
Membrane-bound and soluble-fraction epoxide hydrolases
Biochem. Pharmacol. Toxicol.
1
1-93
1985
Oryctolagus cuniculus, Homo sapiens, Macaca mulatta, Mus musculus, Rattus norvegicus
-
brenda
Wang, P.; Meijer, J.; Guengerich, F.P.
Purification of human liver cytosolic epoxide hydrolase and comparison to the microsomal enzyme
Biochemistry
21
5769-5776
1982
Homo sapiens, Rattus norvegicus
brenda
Meijer, J.; DePierre, J.W.
Cytosolic epoxide hydrolase
Chem. Biol. Interact.
64
207-249
1988
Oryctolagus cuniculus, Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Schladt, L.; Thomas, H.; Hartmann, R.; Oesch, F.
Human liver cytosolic epoxide hydrolases
Eur. J. Biochem.
176
715-723
1988
Homo sapiens
brenda
Dietze, E.C.; Magdalou, J.; Hammock, B.D.
Human and murine cytosolic epoxide hydrolase: Physical and structural properties
Int. J. Biochem.
22
461-470
1990
Homo sapiens, Mus musculus
brenda
Morisseau, C.; Beetham, J.K.; Pinot, F.; Debernard, S.; Newman, J.W.; Hammock, B.D.
Cress and potato soluble epoxide hydrolases: purification, biochemical characterization, and comparison to mammalian enzymes
Arch. Biochem. Biophys.
378
321-332
2000
Arabidopsis thaliana, cress, Homo sapiens, Mus musculus, Rattus norvegicus, Solanum tuberosum
brenda
Thomas, H.; Schladt, L.; Doehmer, J.; Knehr, M.; Oesch, F.
Rat and human liver cytosolic epoxide hydrolases: evidence for multiple forms at the level of protein and mRNA
Environ. Health Perspect.
88
49-55
1990
Homo sapiens, Rattus norvegicus
brenda
Gomez, G.A.; Morisseau, C.; Hammock, B.D.; Christianson, D.W.
Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis
Biochemistry
43
4716-4723
2004
Homo sapiens (P34913), Homo sapiens
brenda
Newman, J.W.; Morisseau, C.; Harris, T.R.; Hammock, B.D.
The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity
Proc. Natl. Acad. Sci. USA
100
1558-1563
2003
Homo sapiens
brenda
Yu, Z.; Davis, B.B.; Morisseau, C.; Hammock, B.D.; Olson, J.L.; Kroetz, D.L.; Weiss, R.H.
Vascular localization of soluble epoxide hydrolase in the human kidney
Am. J. Physiol.
286
F720-726
2004
Homo sapiens
brenda
Jones, P.D.; Wolf, N.M.; Morisseau, C.; Whetstone, P.; Hock, B.; Hammock, B.D.
Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies
Anal. Biochem.
343
66-75
2005
Homo sapiens, Mus musculus
brenda
Morisseau, C.; Hammock, B.D.
Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles
Annu. Rev. Pharmacol. Toxicol.
45
311-333
2005
Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Morisseau, C.; Du, G.; Newman, J.W.; Hammock, B.D.
Mechanism of mammalian soluble epoxide hydrolase inhibition by chalcone oxide derivatives
Arch. Biochem. Biophys.
356
214-228
1998
Homo sapiens, Mus musculus
brenda
Srivastava, P.K.; Sharma, V.K.; Kalonia, D.S.; Grant, D.F.
Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quarternary structure
Arch. Biochem. Biophys.
427
164-169
2004
Homo sapiens
brenda
Enayetallah, A.E.; Grant, D.F.
Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis
Biochem. Biophys. Res. Commun.
341
254-260
2006
Homo sapiens
brenda
Tran, K.L.; Aronov, P.A.; Tanaka, H.; Newman, J.W.; Hammock, B.D.; Morisseau, C.
Lipid sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the mammalian soluble poxide hydrolase
Biochemistry
44
12179-12187
2005
Homo sapiens
brenda
Dietze, E.C.; Stephens, J.; Magdalou, J.; Bender, D.M.; Moyer, M.; Fowler, B.; Hammock, B.D.
Inhibition of human and murine cytosolic epoxide hydrolase by group-selective reagents
Comp. Biochem. Physiol. B
104
299-308
1993
Homo sapiens, Mus musculus
brenda
Enayetallah, A.E.; French, R.A.; Barber, M.; Grant, D.F.
Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues
J. Histochem. Cytochem.
54
329-335
2006
Homo sapiens
brenda
McElroy, N.R.; Jurs, P.C.
QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds
J. Med. Chem.
46
1066-1080
2003
Homo sapiens, Mus musculus
brenda
Cronin, A.; Mowbray, S.; Duerk, H.; Homburg, S.; Fleming, I.; Fisslthaler, B.; Oesch, F.; Arand, M.
The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase
Proc. Natl. Acad. Sci. USA
100
1552-1557
2003
Homo sapiens, Rattus norvegicus, Mus musculus (P34914)
brenda
Newman, J.W.; Morisseau, C.; Hammock, B.D.
Epoxide hydrolases: their roles and interactions with lipid metabolism
Prog. Lipid Res.
44
1-51
2005
Ananas comosus, Apium graveolens, Arabidopsis thaliana, Papio sp., Brassica napus, Ricinus communis, Cavia porcellus, Oryctolagus cuniculus, Equus caballus, Euphorbia lagascae, Glycine max, Homo sapiens, Macaca mulatta, Oryzias latipes, Mesocricetus auratus, Nicotiana tabacum, Oncorhynchus mykiss, Oryza sativa, Rattus norvegicus, Solanum tuberosum, Spinacia oleracea, Sus scrofa, Triticum aestivum, Vicia sativa, Zea mays, Citrus jambhiri, Malus pumila, Pimephales promelas, Stenotomus chrysops, Mus musculus (P34914)
brenda
Gomez, G.A.; Morisseau, C.; Hammock, B.D.; Christianson, D.W.
Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids
Protein Sci.
15
58-64
2006
Homo sapiens (P34913), Homo sapiens
brenda
Draper, A.J.; Hammock, B.D.
Inhibition of soluble and microsomal epoxide hydrolase by zinc and other metals
Toxicol. Sci.
52
26-32
1999
Homo sapiens, Mus musculus, Rattus norvegicus, Solanum tuberosum
brenda
Enayetallah, A.E.; French, R.A.; Grant, D.F.
Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9, and 2J2 in human malignant neoplasms
J. Mol. Histol.
37
133-141
2006
Homo sapiens
brenda
Wolf, N.M.; Morisseau, C.; Jones, P.D.; Hock, B.; Hammock, B.D.
Development of a high-throughput screen for soluble epoxide hydrolase inhibition
Anal. Biochem.
355
71-80
2006
Homo sapiens
brenda
Kim, I.H.; Nishi, K.; Tsai, H.J.; Bradford, T.; Koda, Y.; Watanabe, T.; Morisseau, C.; Blanchfield, J.; Toth, I.; Hammock, B.D.
Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase
Bioorg. Med. Chem.
15
312-323
2007
Homo sapiens
brenda
Jones, P.D.; Tsai, H.J.; Do, Z.N.; Morisseau, C.; Hammock, B.D.
Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase
Bioorg. Med. Chem. Lett.
16
5212-5216
2006
Homo sapiens (P34913), Homo sapiens
brenda
Sura, P.; Sura, R.; Enayetallah, A.E.; Grant, D.F.
Distribution and expression of soluble epoxide hydrolase in human brain
J. Histochem. Cytochem.
56
551-559
2008
Homo sapiens
brenda
Hwang, S.H.; Tsai, H.J.; Liu, J.Y.; Morisseau, C.; Hammock, B.D.
Orally bioavailable potent soluble epoxide hydrolase inhibitors
J. Med. Chem.
50
3825-3840
2007
Canis lupus, Felis catus, Mesocricetus auratus, Mus musculus, Rattus norvegicus, Homo sapiens (P34913), Homo sapiens
brenda
Kim, I.H.; Tsai, H.J.; Nishi, K.; Kasagami, T.; Morisseau, C.; Hammock, B.D.
1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties
J. Med. Chem.
50
5217-5226
2007
Homo sapiens
brenda
Hopmann, K.H.; Himo, F.
Insights into the reaction mechanism of soluble epoxide hydrolase from theoretical active site mutants
J. Phys. Chem. B
110
21299-21310
2006
Homo sapiens (P34913), Homo sapiens
brenda
Ai, D.; Fu, Y.; Guo, D.; Tanaka, H.; Wang, N.; Tang, C.; Hammock, B.D.; Shyy, J.Y.; Zhu, Y.
Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo
Proc. Natl. Acad. Sci. USA
104
9018-9023
2007
Bos taurus, Homo sapiens, Rattus norvegicus
brenda
Decker, M.; Arand, M.; Cronin, A.
Mammalian epoxide hydrolases in xenobiotic metabolism and signalling
Arch. Toxicol.
83
297-318
2009
Homo sapiens, Mus musculus (P34914)
brenda
Anandan, S.K.; Do, Z.N.; Webb, H.K.; Patel, D.V.; Gless, R.D.
Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors
Bioorg. Med. Chem. Lett.
19
1066-1070
2009
Homo sapiens
brenda
Xie, Y.; Liu, Y.; Gong, G.; Smith, D.H.; Yan, F.; Rinderspacher, A.; Feng, Y.; Zhu, Z.; Li, X.; Deng, S.X.; Branden, L.; Vidovi?, D.; Chung, C.; Schuerer, S.; Morisseau, C.; Hammock, B.D.; Landry, D.W.
Discovery of potent non-urea inhibitors of soluble epoxide hydrolase
Bioorg. Med. Chem. Lett.
19
2354-2359
2009
Homo sapiens
brenda
Liu, J.Y.; Tsai, H.J.; Hwang, S.H.; Jones, P.D.; Morisseau, C.; Hammock, B.D.
Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation
Br. J. Pharmacol.
156
284-296
2009
Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Burdon, K.P.; Lehtinen, A.B.; Langefeld, C.D.; Carr, J.J.; Rich, S.S.; Freedman, B.I.; Herrington, D.; Bowden, D.W.
Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study
Diab. Vasc. Dis. Res.
5
128-134
2008
Homo sapiens
brenda
EnayetAllah, A.E.; Luria, A.; Luo, B.; Tsai, H.J.; Sura, P.; Hammock, B.D.; Grant, D.F.
Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase
J. Biol. Chem.
283
36592-36598
2008
Homo sapiens, Mus musculus
brenda
Ulu, A.; Davis, B.B.; Tsai, H.J.; Kim, I.H.; Morisseau, C.; Inceoglu, B.; Fiehn, O.; Hammock, B.D.; Weiss, R.H.
Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model
J. Cardiovasc. Pharmacol.
52
314-323
2008
Homo sapiens, Mus musculus
brenda
Luo, B.; Norris, C.; Bolstad, E.S.; Knecht, D.A.; Grant, D.F.
Protein quaternary structure and expression levels contribute to peroxisomal-targeting-sequence-1-mediated peroxisomal import of human soluble epoxide hydrolase
J. Mol. Biol.
380
31-41
2008
Homo sapiens (P34913), Homo sapiens
brenda
Cronin, A.; Homburg, S.; Duerk, H.; Richter, I.; Adamska, M.; Frere, F.; Arand, M.
Insights into the catalytic mechanism of human sEH phosphatase by site-directed mutagenesis and LC-MS/MS analysis
J. Mol. Biol.
383
627-640
2008
Homo sapiens (P34913), Homo sapiens
brenda
Monti, J.; Fischer, J.; Paskas, S.; Heinig, M.; Schulz, H.; Goesele, C.; Heuser, A.; Fischer, R.; Schmidt, C.; Schirdewan, A.; Gross, V.; Hummel, O.; Maatz, H.; Patone, G.; Saar, K.; Vingron, M.; Weldon, S.M.; Lindpaintner, K.; Hammock, B.D.; Rohde, K.; Dietz, R.; Cook, S.A.; Schunck, W.H.; Luft, F.C.; Hub, H.u.b.n.
Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease
Nat. Genet.
40
529-537
2008
Homo sapiens, Rattus norvegicus
brenda
Morisseau, C.; Hammock, B.D.
Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical
Pest Manag. Sci.
64
594-609
2008
Homo sapiens
brenda
Zhang, L.; Ding, H.; Yan, J.; Hui, R.; Wang, W.; Kissling, G.E.; Zeldin, D.C.; Wang, D.W.
Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population
Pharmacogenet. Genomics
18
45-51
2008
Homo sapiens (P34913), Homo sapiens
brenda
Shi, D.H.; Xu, C.; Guo, B.X.; Wang, X.T.; Chen, Y.X.; Tan, R.X.
Inhibition of soluble epoxide hydrolase by extracts derived from inflammation-treating Chinese medicinal herbs
Phytother. Res.
22
1264-1268
2008
Homo sapiens
brenda
Gschwendtner, A.; Ripke, S.; Freilinger, T.; Lichtner, P.; Mueller-Myhsok, B.; Wichmann, H.E.; Meitinger, T.; Dichgans, M.
Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans
Stroke
39
1593-1596
2008
Homo sapiens
brenda
Lee, S.H.; Lee, J.; Cha, R.; Park, M.H.; Ha, J.W.; Kim, S.; Kim, Y.S.
Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation
Transplant. Proc.
40
1353-1356
2008
Homo sapiens
brenda
Oguro, A.; Sakamoto, K.; Suzuki, S.; Imaoka, S.
Contribution of hydrolase and phosphatase domains in soluble epoxide hydrolase to vascular endothelial growth factor expression and cell growth
Biol. Pharm. Bull.
32
1962-1967
2009
Homo sapiens (P34913), Homo sapiens
brenda
Shen, H.C.; Ding, F.X.; Wang, S.; Xu, S.; Chen, H.S.; Tong, X.; Tong, V.; Mitra, K.; Kumar, S.; Zhang, X.; Chen, Y.; Zhou, G.; Pai, L.Y.; Alonso-Galicia, M.; Chen, X.; Zhang, B.; Tata, J.R.; Berger, J.P.; Colletti, S.L.
Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors
Bioorg. Med. Chem. Lett.
19
3398-3404
2009
Homo sapiens (P34913), Rattus norvegicus (P80299)
brenda
Shen, H.C.; Ding, F.X.; Deng, Q.; Xu, S.; Chen, H.S.; Tong, X.; Tong, V.; Zhang, X.; Chen, Y.; Zhou, G.; Pai, L.Y.; Alonso-Galicia, M.; Zhang, B.; Roy, S.; Tata, J.R.; Berger, J.P.; Colletti, S.L.
Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors
Bioorg. Med. Chem. Lett.
19
5314-5320
2009
Homo sapiens (P34913), Homo sapiens, Rattus norvegicus (P80299)
brenda
Shen, H.C.; Ding, F.X.; Deng, Q.; Xu, S.; Tong, X.; Zhang, X.; Chen, Y.; Zhou, G.; Pai, L.Y.; Alonso-Galicia, M.; Roy, S.; Zhang, B.; Tata, J.R.; Berger, J.P.; Colletti, S.L.
A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors
Bioorg. Med. Chem. Lett.
19
5716-5721
2009
Homo sapiens (P34913), Homo sapiens
brenda
Taylor, S.J.; Soleymanzadeh, F.; Eldrup, A.B.; Farrow, N.A.; Muegge, I.; Kukulka, A.; Kabcenell, A.K.; De Lombaert, S.
Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase
Bioorg. Med. Chem. Lett.
19
5864-5868
2009
Homo sapiens (P34913), Homo sapiens, Rattus norvegicus (P80299)
brenda
Kullmann, S.; Binner, P.; Rackebrandt, K.; Huge, A.; Haltern, G.; Lankisch, M.; Fueth, R.; von Hodenberg, E.; Bestehorn, H.P.; Scheffold, T.
Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention
BMC Cardiovasc. Disord.
9
48
2009
Homo sapiens (P34913), Homo sapiens
brenda
Keserue, B.; Barbosa-Sicard, E.; Schermuly, R.T.; Tanaka, H.; Hammock, B.D.; Weissmann, N.; Fisslthaler, B.; Fleming, I.
Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition
Cardiovasc. Res.
85
232-240
2010
Homo sapiens (P34913), Homo sapiens, Mus musculus (P34914), Mus musculus C57BL/6 (P34914)
brenda
Qiu, H.; Li, N.; Liu, J.Y.; Harris, T.R.; Hammock, B.D.; Chiamvimonvat, N.
Soluble epoxide hydrolase inhibitors and heart failure
Cardiovasc. Ther.
29
99-111
2011
Homo sapiens, Mus musculus (P34914)
brenda
Wang, Y.X.; Ulu, A.; Zhang, L.N.; Hammock, B.
Soluble epoxide hydrolase in atherosclerosis
Curr. Atheroscler. Rep.
12
174-183
2010
Homo sapiens (P34913), Homo sapiens, Mus musculus (P34914), Rattus norvegicus (P80299)
brenda
Oguro, A.; Fujita, N.; Imaoka, S.
Regulation of soluble epoxide hydrolase (sEH) in mice with diabetes: high glucose suppresses sEH expression
Drug Metab. Pharmacokinet.
24
438-445
2009
Homo sapiens, Mus musculus (P34914)
brenda
Tsai, H.J.; Hwang, S.H.; Morisseau, C.; Yang, J.; Jones, P.D.; Kasagami, T.; Kim, I.H.; Hammock, B.D.
Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs
Eur. J. Pharm. Sci.
40
222-238
2010
Canis lupus familiaris, Homo sapiens (P34913)
brenda
Iliff, J.J.; Alkayed, N.J.
Soluble epoxide hydrolase inhibition: targeting multiple mechanisms of ischemic brain injury with a single agent
Future Neurol.
4
179-199
2009
Homo sapiens (P34913), Mus musculus (P34914), Rattus norvegicus (P80299)
brenda
Barbosa-Sicard, E.; Froemel, T.; Keserue, B.; Brandes, R.P.; Morisseau, C.; Hammock, B.D.; Braun, T.; Krueger, M.; Fleming, I.
Inhibition of the soluble epoxide hydrolase by tyrosine nitration
J. Biol. Chem.
284
28156-28163
2009
Homo sapiens (P34913), Homo sapiens, Mus musculus (P34914), Mus musculus, Mus musculus C57BL/6 (P34914)
brenda
Shen, H.; Ding, F.; Wang, S.; Deng, Q.; Zhang, X.; Chen, Y.; Zhou, G.; Xu, S.; Chen, H.; Tong, X.; Tong, V.; Mitra, K.; Kumar, S.; Tsai, C.; Stevenson, A.; Pai, L.; Alonso-Galicia, M.; Chen, X.; Soisson, S.; Roy, S.; Zhang, B.; Tata, J.; Berger, J.; Colle
Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement
J. Med. Chem.
52
5009-5012
2009
Homo sapiens (P34913)
brenda
Falck, J.; Kodela, R.; Manne, R.; Atcha, K.; Puli, N.; Dubasi, N.; Manthati, V.; Capdevila, J.; Yi, X.; Goldman, D.; Morisseau, C.; Hammock, B.; Campbell, W.
14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: Influence upon vascular relaxation and soluble epoxide hydrolase inhibition
J. Med. Chem.
52
5069-5075
2009
Bos taurus, Homo sapiens (P34913)
brenda
Eldrup, A.B.; Soleymanzadeh, F.; Taylor, S.J.; Muegge, I.; Farrow, N.A.; Joseph, D.; McKellop, K.; Man, C.C.; Kukulka, A.; De Lombaert, S.
Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase
J. Med. Chem.
52
5880-5895
2009
Homo sapiens (P34913), Homo sapiens, Rattus norvegicus (P80299)
brenda
Deng, Y.; Theken, K.N.; Lee, C.R.
Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation
J. Mol. Cell. Cardiol.
48
331-341
2010
Homo sapiens (P34913), Mus musculus (P34914)
brenda
Xie, W.; Tang, X.; Lu, Q.; Ames, R.S.; Ratcliffe, S.J.; Li, H.
Development of a high throughput cell-based assay for soluble epoxide hydrolase using BacMam technology
Mol. Biotechnol.
45
207-217
2010
Homo sapiens (P34913)
brenda
Liu, J.Y.; Park, S.H.; Morisseau, C.; Hwang, S.H.; Hammock, B.D.; Weiss, R.H.
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo
Mol. Cancer Ther.
8
2193-2203
2009
Homo sapiens
brenda
Imig, J.D.; Hammock, B.D.
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
Nat. Rev. Drug Discov.
8
794-805
2009
Homo sapiens (P34913)
brenda
Nishi, K.; Kim, I.H.; Ma, S.J.
Expression of the human soluble epoxide hydrolase in Escherichia coli by auto-induction for the study of high-throughput inhibition assays
Protein Expr. Purif.
69
34-38
2010
Homo sapiens (P34913), Homo sapiens
brenda
Zhang, D.; Ai, D.; Tanaka, H.; Hammock, B.D.; Zhu, Y.
DNA methylation of the promoter of soluble epoxide hydrolase silences its expression by an SP-1-dependent mechanism
Biochim. Biophys. Acta
1799
659-667
2010
Homo sapiens
brenda
Cronin, A.; Decker, M.; Arand, M.
Mammalian soluble epoxide hydrolase is identical to liver hepoxilin hydrolase
J. Lipid Res.
52
712-719
2011
Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Xing, L.; McDonald, J.J.; Kolodziej, S.A.; Kurumbail, R.G.; Williams, J.M.; Warren, C.J.; ONeal, J.M.; Skepner, J.E.; Roberds, S.L.
Discovery of potent inhibitors of soluble epoxide hydrolase by combinatorial library design and structure-based virtual screening
J. Med. Chem.
54
1211-1222
2011
Homo sapiens (P34913)
brenda
Kim, I.H.; Park, Y.K.; Hammock, B.D.; Nishi, K.
Structure-activity relationships of cycloalkylamide derivatives as inhibitors of the soluble epoxide hydrolase
J. Med. Chem.
54
1752-1761
2011
Homo sapiens
brenda
Hwang, S.H.; Wagner, K.M.; Morisseau, C.; Liu, J.Y.; Dong, H.; Wecksler, A.T.; Hammock, B.D.
Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase
J. Med. Chem.
54
3037-3050
2011
Mus musculus, Homo sapiens (P34913)
brenda
Wang, Q.; Pang, W.; Cui, Z.; Shi, J.; Liu, Y.; Liu, B.; Zhou, Y.; Guan, Y.; Hammock, B.D.; Wang, Y.; Zhu, Y.
Upregulation of soluble epoxide hydrolase in proximal tubular cells mediated proteinuria-induced renal damage
Am. J. Physiol. Renal Physiol.
304
F168-F176
2013
Homo sapiens
brenda
Pecic, S.; Pakhomova, S.; Newcomer, M.E.; Morisseau, C.; Hammock, B.D.; Zhu, Z.; Rinderspacher, A.; Deng, S.X.
Synthesis and structure-activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors
Bioorg. Med. Chem. Lett.
23
417-421
2013
Homo sapiens
brenda
Burmistrov, V.; Morisseau, C.; Lee, K.S.; Shihadih, D.S.; Harris, T.R.; Butov, G.M.; Hammock, B.D.
Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors
Bioorg. Med. Chem. Lett.
24
2193-2197
2014
Homo sapiens
brenda
Kim, I.H.; Lee, I.H.; Nishiwaki, H.; Hammock, B.D.; Nishi, K.
Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase
Bioorg. Med. Chem.
22
1163-1175
2014
Homo sapiens (P34913), Homo sapiens
brenda
Amano, Y.; Yamaguchi, T.; Tanabe, E.
Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography
Bioorg. Med. Chem.
22
2427-2434
2014
Homo sapiens (P34913)
brenda
Harris, T.R.; Hammock, B.D.
Soluble epoxide hydrolase: gene structure, expression and deletion
Gene
526
61-74
2013
Homo sapiens (P34913), Homo sapiens
brenda
Nelson, J.W.; Subrahmanyan, R.M.; Summers, S.A.; Xiao, X.; Alkayed, N.J.
Soluble epoxide hydrolase dimerization is required for hydrolase activity
J. Biol. Chem.
288
7697-7703
2013
Homo sapiens (P34913), Homo sapiens
brenda
Chen, H.; Zhang, Y.; Ye, C.; Feng, T.T.; Han, J.G.
Insight into the binding modes and inhibition mechanisms of adamantyl-based 1,3-disubstituted urea inhibitors in the active site of the human soluble epoxide hydrolase
J. Biomol. Struct. Dyn.
32
1231-1247
2014
Homo sapiens
brenda
Morisseau, C.; Wecksler, A.T.; Deng, C.; Dong, H.; Yang, J.; Lee, K.S.; Kodani, S.D.; Hammock, B.D.
Effect of soluble epoxide hydrolase polymorphism on substrate and inhibitor selectivity and dimer formation
J. Lipid Res.
55
1131-1138
2014
Homo sapiens (P34913), Homo sapiens
brenda
la Buscato, E.; Bloecher, R.; Lamers, C.; Klingler, F.M.; Hahn, S.; Steinhilber, D.; Schubert-Zsilavecz, M.; Proschak, E.
Design and synthesis of dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors
J. Med. Chem.
55
10771-10775
2012
Homo sapiens
brenda
Lee, K.S.; Liu, J.Y.; Wagner, K.M.; Pakhomova, S.; Dong, H.; Morisseau, C.; Fu, S.H.; Yang, J.; Wang, P.; Ulu, A.; Mate, C.A.; Nguyen, L.V.; Hwang, S.H.; Edin, M.L.; Mara, A.A.; Wulff, H.; Newcomer, M.E.; Zeldin, D.C.; Hammock, B.D.
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy
J. Med. Chem.
57
7016-7030
2014
Rattus norvegicus, Homo sapiens (P34913), Homo sapiens
brenda
Zhang, W.; Davis, C.M.; Edin, M.L.; Lee, C.R.; Zeldin, D.C.; Alkayed, N.J.
Role of endothelial soluble epoxide hydrolase in cerebrovascular function and ischemic injury
PLoS ONE
8
e61244
2013
Homo sapiens
brenda
Lee, K.S.; Henriksen, N.M.; Ng, C.J.; Yang, J.; Jia, W.; Morisseau, C.; Andaya, A.; Gilson, M.K.; Hammock, B.D.
Probing the orientation of inhibitor and epoxy-eicosatrienoic acid binding in the active site of soluble epoxide hydrolase
Arch. Biochem. Biophys.
613
1-11
2017
Homo sapiens (P34913)
brenda
Liu, J.Y.; Tsai, H.J.; Morisseau, C.; Lango, J.; Hwang, S.H.; Watanabe, T.; Kim, I.H.; Hammock, B.D.
In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors
Biochem. Pharmacol.
98
718-731
2015
Homo sapiens (P34913), Homo sapiens, Mus musculus (P34914), Rattus norvegicus (P80299), Mus musculus C57BL/6 (P34914), Rattus norvegicus Sprague Dawley (P80299)
brenda
Burmistrov, V.; Morisseau, C.; Harris, T.R.; Butov, G.; Hammock, B.D.
Effects of adamantane alterations on soluble epoxide hydrolase inhibition potency, physical properties and metabolic stability
Bioorg. Chem.
76
510-527
2018
Homo sapiens (P34913), Homo sapiens, Mus musculus (P34914), Mus musculus, Rattus norvegicus (P80299)
brenda
Amano, Y.; Tanabe, E.; Yamaguchi, T.
Identification of N-ethylmethylamine as a novel scaffold for inhibitors of soluble epoxide hydrolase by crystallographic fragment screening
Bioorg. Med. Chem.
23
2310-2317
2015
Homo sapiens (P34913)
brenda
Takai, K.; Chiyo, N.; Nakajima, T.; Nariai, T.; Ishikawa, C.; Nakatani, S.; Ikeno, A.; Yamamoto, S.; Sone, T.
Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors
Bioorg. Med. Chem. Lett.
25
1705-1708
2015
Homo sapiens (P34913), Homo sapiens, Rattus norvegicus (P80299)
brenda
Gurung, A.B.; Mayengbam, B.; Bhattacharjee, A.
Discovery of novel drug candidates for inhibition of soluble epoxide hydrolase of arachidonic acid cascade pathway implicated in atherosclerosis
Comput. Biol. Chem.
74
1-11
2018
Homo sapiens (P34913)
brenda
Kim, J.H.; Cho, I.S.; Ryu, J.; Lee, J.S.; Kang, J.S.; Kang, S.Y.; Kim, Y.H.
In vitro and in silico investigation of anthocyanin derivatives as soluble epoxide hydrolase inhibitors
Int. J. Biol. Macromol.
112
961-967
2018
Homo sapiens (P34913)
brenda
Liu, Z.B.; Sun, C.P.; Xu, J.X.; Morisseau, C.; Hammock, B.D.; Qiu, F.
Phytochemical constituents from Scutellaria baicalensis in soluble epoxide hydrolase inhibition kinetics and interaction mechanism merged with simulations
Int. J. Biol. Macromol.
133
1187-1193
2019
Homo sapiens (P34913)
brenda
Yamanashi, H.; Boeglin, W.E.; Morisseau, C.; Davis, R.W.; Sulikowski, G.A.; Hammock, B.D.; Brash, A.R.
Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function
J. Lipid Res.
59
684-695
2018
Homo sapiens (P34913), Homo sapiens (Q9H6B9), Homo sapiens, Mus musculus (Q3V1F8), Mus musculus
brenda
Bloecher, R.; Lamers, C.; Wittmann, S.K.; Merk, D.; Hartmann, M.; Weizel, L.; Diehl, O.; Brueggerhoff, A.; Boss, M.; Kaiser, A.; Schader, T.; Goebel, T.; Grundmann, M.; Angioni, C.; Heering, J.; Geisslinger, G.; Wurglics, M.; Kostenis, E.; Bruene, B.; Steinhilber, D.; Schubert-Zsilavecz, M.; Kahn, K.a.h.n.t.
N-Benzylbenzamides a novel merged scaffold for orally available dual soluble epoxide hydrolase/peroxisome proliferator-activated receptor gamma modulators
J. Med. Chem.
59
61-81
2016
Homo sapiens (P34913), Homo sapiens
brenda
Meirer, K.; Glatzel, D.; Kretschmer, S.; Wittmann, S.K.; Hartmann, M.; Bloecher, R.; Angioni, C.; Geisslinger, G.; Steinhilber, D.; Hofmann, B.; Fuerst, R.; Proschak, E.
Design, synthesis and cellular characterization of a dual inhibitor of 5-lipoxygenase and soluble epoxide hydrolase
Molecules
22
45-54
2016
Homo sapiens (P34913)
brenda
Abis, G.; Charles, R.L.; Eaton, P.; Conte, M.R.
Expression, purification, and characterisation of human soluble epoxide hydrolase (hsEH) and of its functional C-terminal domain
Protein Expr. Purif.
153
105-113
2019
Homo sapiens (P34913), Homo sapiens
brenda
Butov, G.; Burmistrov, V.; Danilov, D.
Synthesis and properties of 1-(R-adamant-1-yl)-3-(1-propionylpiperidin-4-yl)ureas and 4-({4-[3-(R-adamant-1-yl)ureido]cyclohexyl}oxy)benzoic acids, efficient target-oriented human soluble epoxide hydrolase inhibitors
Russ. Chem. Bull.
66
1876-1880
2017
Homo sapiens (P34913)
-
brenda
Burmistrov, V.; Butov, G.; Karlov, D.; Palyulin, V.; Zefirov, N.; Morisseau, C.; Hammock, B.
Synthesis and properties of diadamantyl-containing symmetric diureas as target-oriented inhibitors of human soluble epoxide hydrolase
Russ. J. Bioorg. Chem.
42
404-414
2016
Homo sapiens (P34913)
-
brenda
Butov, G.; Burmistrov, V.; D'yachenko, V.
Synthesis and properties of symmetrical N,N-bis(R-adamantan-1-yl)ureas as target-oriented soluble epoxide hydrolase (sEH) inhibitors
Russ. J. Org. Chem.
53
977-980
2017
Homo sapiens (P34913)
-
brenda
Hiesinger, K.; Kramer, J.S.; Beyer, S.; Eckes, T.; Brunst, S.; Flauaus, C.; Wittmann, S.K.; Weizel, L.; Kaiser, A.; Kretschmer, S.B.M.; George, S.; Angioni, C.; Heering, J.; Geisslinger, G.; Schubert-Zsilavecz, M.; Schmidtko, A.; Pogoryelov, D.; Pfeilschifter, J.; Hofmann, B.; Steinhilber, D.; Sch, S.c.h.w.
Design, synthesis, and structure-activity relationship studies of dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase
J. Med. Chem.
63
11498-11521
2020
Homo sapiens
brenda